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“Courage is the most important of all the virtues, because without  















The joint Biomedical Engineering program at Georgia Tech & Emory has 
provided me with many exceptional opportunities to grow as a research scientist and an 
academic professional.   Beyond the rigorous academic program, my true education came 
from the people that I have interacted with during my five years in Atlanta.  The 
dynamic, high energy environment created by the diverse and immensely talented pool of 
professors and graduate students has opened my mind to cultures and concepts that have 
exceeded my wildest imagination.  The completion of this thesis would not have been 
possible without the influence of the many intellectually-gifted people that I have met 
and the lessons that they have explicitly and/or implicitly taught me along the way.   
First and foremost, I want to thank my advisor, Dr. Andrés J. García.  Andrés took 
a risk by allowing this “make-up engineer” to join his lab after a three year stint in 
industry.  And he has continued to offer exceptional guidance and support throughout my 
time at Georgia Tech, giving me complete freedom to pursue my wacky “hair-brained” 
ideas, providing a multitude of opportunities to present my research at conferences, and 
even funding two international excursions.  Andrés believed in me and my potential when 
many others did not, and I am certain that my desire to pursue an academic career is 
largely inspired by his example.  He taught me that science can be serious AND 
silly….rigorous AND creative…and, most importantly, fun!  Science life will likely seem 
dull without his continuous diatribe of highly exaggerated stories (Heckle & Jeckle being 
my personal favorite), unsolicited advice, and “choice vocabulary” en espanõl.  I may 
never draw a biological cartoon again without hearing a booming voice yell 
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“OCKHAM’S RAZOR” over my shoulder with a Spanish-German accent.  Thank you, 
Andrés, for your trust, (sometimes brutal) honesty, and for always believing in me.  
Working with you for the last five years has been a privilege and I am certain that I will 
continue to see the benefits of your mentorship for many years to come.  Now, I am off, 
to start my own Mickey Mouse operation! 
I would also like to thank my committee members for their guidance and support.  
Dr. Robert Guldberg has been a veritable co-advisor to me during my time at Georgia 
Tech.  My first experience in academic research was as a rotation student in his lab and 
he is a co-author on almost all of my papers.  Scientifically, he brought a great deal of 
expertise to the project in the area of in vivo testing and characterization of tissue 
engineered constructs.  Beyond science, Bob has been an exceptional example of a 
person who has achieved the ever-elusive combination of academic excellence and work-
life balance.  Thank you, Bob, for always allowing me to crash the annual Guldberg 
Orthopaedic Research Society lab dinner, and for investing in me like one of your own!   
Dr. Barbara Boyan has brought expertise to the project associated with bone cell biology 
and hormone signaling.  Beyond this knowledge, she has also been a behind-the-scenes 
mentor to me on many science- and non-science-related topics.  Thank you, Dr. Boyan, 
for taking a specific interest in me and my work and for teaching me the importance of 
using rigorous scientific wording which doesn’t over-promise on experiments that under-
deliver.  Dr. Joe Le Doux has brought a great deal of expertise to the Runx2 project in the 
area of gene therapy since its inception ten years ago.  He has patiently endured an open, 
revolving door policy for all of Andrés’ students….offering technical expertise, advice, 
and/or reagents at any time we have run into roadblocks on our projects.  Dr. Todd 
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McDevitt is a relatively new faculty member at Georgia Tech, but in a very short time on 
my committee has offered fresh ideas and a candid perspective which has improved the 
quality of the work. Todd brought expertise to the project in the area of biomaterials and 
signaling gradients and I greatly appreciate the extra time he invested in 
reading/analyzing my thesis work.  Beyond science, watch out for Todd on the golf 
course….he might just take your money.   Dr. Roberto Pacifici is an M.D., Ph.D. and 
chair of the Endocrinology department at Emory. His background has brought both 
extensive expertise in hormone signaling and bone biology as well as a clinical 
perspective to this work.  Dr. Pacifici taught me that there is “nothing new under the sun” 
and stressed the importance of reading the primary literature from orthogonal fields in 
order to find creative solutions to scientific problems.  Overall, each of my committee 
members provide examples of rewarding careers in biomedical research and tangible 
proof that I can enjoy the process along the way.   
I would also like to acknowledge a subset of faculty members who have indirectly 
contributed to the completion of this work.  In particular, Dr. Robert Nerem and Dr. Don 
Giddens, who have committed the majority of their professional careers toward the 
development of the field of Biomedical Engineering as a whole and this specific 
interdisciplinary program in Atlanta.  The extraordinary vision and pioneering leadership 
of these two men has provided opportunities for countless young scientists to pursue their 
dreams.   I would also like to thank Dr. Stephen DeWeerth and Dr. Ajit Yoganathan for 
their leadership and extensive efforts toward developing the joint GT/Emory Biomedical 
Engineering program from scratch into what it is today.   In particular, I would like to 
acknowledge Steve, as well as Dr. Lena Ting, Dr. Bob Lee, Dr. Michelle La Placa, and 
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Dr. Wendy Newstetter for their role in the program’s early curriculum development and 
for patiently humoring my numerous questions and blazing intensity during the first two 
years of graduate school.  Special thanks also goes out to Dr. Nael McCarty for taking an 
interest in my career development and for teaching my favorite class at Georgia Tech.  
Also, I would like to acknowledge Dr. Laura O’Farrell, the veterinary consultant on this 
project, and Aqua Asberry and Tracey Couse for helpful discussions and histological 
assistance.  Finally, a special thank you goes out to Sally Garrish and Beth Bullock 
Spencer for administrative support and ensuring that I completed all of the logistical 
details in a timely fashion.  I appreciate your patience, kindness, fun conversations, and 
gentle reminders about deadlines!   
I would also like to thank past and present members of the García lab for creating 
a challenging, fun, and intellectually stimulating work environment.  First and foremost, I 
want to acknowledge our lab manager, Kellie Burns.  Kellie runs a tight ship and keeps 
all of the members of the García lab humble and on their toes.  She also brings a great 
deal of expertise to our lab in the area of animal work and in vivo testing—an expertise 
that has bailed me out of numerous tumultuous situations over the years!  Behind her 
tough exterior, Kellie is a one-of-a-kind friend with a heart of gold (ahem, transformer-
decorated cake, ahem!).  Who else would be willing to donate her future offspring to 
science?  I daresay I will never again find another fellow scientist who can use rap lyrics 
to describe experimental results, who understands the neurotic drama of an Italian family, 
and who knows from first-hand experience just how cold it really is in upstate NY.  So, 
Kellie, thank you, for your help, comic relief, and friendship.  You are proof that 
everyone does indeed love an Italian girl.   
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On the flip side, our former lab manager, Lindsay Bryant, was my first officially 
“southern” friend.  I will forever be indebted to Lindsay for teaching this rough-around-
the-edges Northerner how to dress appropriately (“do we THINK these two colors go 
together?”) and how to conduct oneself like a lady at a South Carolina plantation.  
Throughout the course of our friendship, I was introduced to palmetto trees, monograms, 
country line dancing, and the dreaded “boat shoe”.  Most importantly, I learned that blue 
eyeliner is NEVER a good idea and that the secret to insulting people is to deliver the 
message with a big smile and a sickeningly sweet voice tone (“bless her heart”).  Thank 
you, LinZ, for your refreshing honesty, tremendous loyalty, and the eye-liner intervention 
which saved my social life.  I look forward to many more years of tomfoolery….the 
black feather boa WILL be mine someday!    
Over the years, many former members of the García lab have also grown to be 
friends whom I respect and admire.  Dr. Nathan Gallant has undoubtedly humbled many 
a giant in his day with his razor sharp wit and remarkable intuition.  Thanks, Nate, for 
your empathetic ear, your no-nonsense honesty, and for being my Peachtree Road Race 
cross-training sidekick.  I am proud to call you my friend!   I would also like to thank Dr. 
Catherine Reyes for our inseparable friendship during my early years of grad school.  
Catherine opened my eyes to the value of good grammar, sophisticated cuisine, reading 
(gasp!) fiction, and overpriced accessories.  Thank you, Cathy, for commiserating with 
me while sliding down black diamonds in Lake Tahoe, tolerating my neurotic animal-
phobias, and always having a camera ready to capture moments of poor judgment on 
film.  I’d also like to give mad props to Dr. Ben Keselowsky and Dr. Jeff Capadona for 
keeping me humble during my first year in the García lab with relentless verbal torture.  
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Thanks Ben, for serving as a fellow rap lyric appreciator (“you got money in da’ bank!”), 
GRC canoeing partner, and for a second shot at friendship.  And thank you, Jeff, for 
enlightening me on the life-changing power of FTIR, a solid poker face, and country 
music lyrics.  I look forward to many more years of Gordon Research conference 
debauchery with team García!   
 Importantly, I’d also like to thank my predecessors on the Runx2 project, Dr. Ben 
Byers and Dr. Charles Gersbach, for the many hours spent training me on gene therapy 
techniques and the numerous rigorous discussions that have improved the quality of this 
work.  The progress that was made in my own project would not have been possible 
without the groundwork that was laid by these two outstanding scientists.  Also, I’d like 
to give a shout-out to Amanda Walls and Abigail Wojtowicz, who worked with me 
during their rotations on the dexamethasone signaling project.  Abbey is a co-author on 
the JCS paper and her experiments played a critical role in the publication of this work.  
Thank you, Abbey, for being an awesome office-mate…one of these days I will get up 
enough nerve to go salsa dancing with you.  And how could I not thank Amanda for 
being my partner-n-crime and roommate at the GRC and for laughing at my neurotic 
tendencies (n=100) through the years.  I admire her grit and courage…who else could 
survive an airplane crash without shedding a single tear or twitching a single facial 
muscle?  Finally, I must give a major shout-out to my gym-buddies, Timothy Petrie and 
David Dumbauld (a.k.a. sweet-tips and cool-tips, respectively).  It was a pleasure 
collaborating with Tim on the human mesenchymal stem cells project. He is a hard 
worker and a creative person who is willing to stay up to all hours of the night to get the 
job done.  Dave is also a hard worker and a terrific problem solver and I greatly 
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appreciate all of the help he offered me on a side project involving molecular cloning. 
Thanks, T&D, for letting me tag along on your male-bonding golf expeditions.  Don’t 
forget to always give the lady a choice……and remember, if your game ain’t tight, you 
gotta call it a night!    Finally, I would like to wish all of the current members of the 
García lab, including the international man of mystery (Sean Coyer) and the new wave 
(Nduka, Ed, Rachel, Brandon, and Asha) the best of luck in finding your path, your 
purpose, and completing your own dissertation work.    
I would be remiss without acknowledging several members of the Guldberg lab 
who have made my time in graduate school fun and meaningful.   Beyond his brilliant 
business sense, Chris Gemmitti is also the best super-bowl-party-thrower and final-four-
bracket-organizer that I know.  Without question, some of my favorite grad school 
memories involve moments when the goose was loose!   Most importantly, I will forever 
be indebted to Chris for offering me his whoppers box on the way to Muir Woods.  
Thank you, Chris, for pretending to enjoy the 1-inch-thick-brownies I made for your 
birthday and for making me laugh every day during our 2+ years in The Fort.   Much  
respect also goes out to Blaise Porter, for showing me the ropes in tissue culture, 
guarding me like a man in basketball, pushing me to run my first Peachtree Road Race, 
and, ultimately, inspiring me to run the Chicago marathon.  Thanks, Blaise, for keeping 
me in line (“you’re so base”), keeping up on the dance floor (“it’s all in the down beat”), 
and, most importantly, for stealing the mashed potatoes AND the foul towel in the same 
night.  For you, I would actually visit our friend Galen in Porkopolis.  And yes, I am still 
waiting on that email reply, G-rob!  Finally, I would like to thank Rhima Coleman for 
showing me the ropes during my rotation in the Guldberg lab and for being a loyal, 
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(sometimes brutally) honest friend.  I look forward to many silly conversations and 
philosophical debates over Thai food in the future.   
I must thank Angela Lin and Dr. Srinidhi Nagaraja for making it fun to come into 
work everyday.  Throughout the many years of helping me with micro-CT image analysis 
and mechanical testing, they have both also become lifelong friends.  Srin, affectionately 
known as Na-ha-rah, is a naturally gifted teacher with a knack for making people smile 
and keeping the atmosphere light.  In retrospect, I realize that the majority of the time he 
made people smile at my expense with his relentless hazing and politically-incorrect 
remarks.  Perhaps the most important lesson that I learned from Srin is that the emotional 
damage from my stern Italian glances can be undone with key lime pie or an 
exceptionally large piece of strawberry shortcake (“Dang, dats a goooood biscuit!”).  
Thank you, Srin, for five years of laughter, theological musings, impromptu 6am waffle 
house trips, ORS abstract all-nighters, Indian buffet information sessions, double-book-
challenges, hijacked myspace pages, and regrettable conference craziness.   Remember, 
“Hell hath no fury like a woman scorned!”.  Perhaps I will indeed visit the Russian 
federation someday.   
Angela Shue-ping Lin, what can I say, except that I am so happy we crossed paths 
in the Lair of Inefficiency!  Over the years, I have grown to highly respect “Jeela” for her 
problem-solving skills, courage, unusual capacity for fairness, and overall world-class-
athlete-ness.  From Angela, I have learned that any person can be beautiful when they are 
just being themselves and the importance of never judging a man until you have walked a 
mile in his shoes.  Nevertheless, it certainly has not been easy to endure five years of 
Jeela flaunting her perfectly straight and shiny hair, while my knappy-Italian-weave 
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turned “frizzled” at the slightest hint of rain.  And, for the record, I never found the whole 
“tape-a-picture-of-Jenn’s-head-in-the-plastic-fish-aquarium” prank to be all that clever.  
Thank you, Angela, for your friendship, for accepting me for who I am, and for eating my 
insane culinary concoctions with a smile.   I look forward to the day when we find out 
after all these years just exactly why the white regions really are so extremely white.  For 
you, I might actually go to the Georgia aquarium.   
 I would also like to quickly acknowledge a handful of teachers whose influence 
during my formative years led me to pursue a career in science.  First, I’d like to thank 
Mrs. Karen O’Connor for sparking my initial interest in math during high school and Mr. 
Bill Stevens for believing in me when no one else did.   I would also like to acknowledge 
my undergraduate advisor, Dr. Richard McCluskey, for encouraging me to pursue higher 
education and opening my eyes to careers in academia.  Also, a special thank you goes 
out to Dr. F. James Boerio at the University of Cincinnati for providing me with a short-
term research opportunity which ultimately convinced me to leave industry and go back 
to graduate school.   Finally, I offer appreciation to my former bosses and colleagues at 
Procter & Gamble for equipping me with skills (critical thinking, writing, public 
speaking) that enabled me to succeed in graduate school.  Thank you, Tim Fowler, Chris 
Irwin, Steve Hicks, Paul Tanner, Rich Farris, Paul Cootes (and many others) for 
graciously letting me off the hook to pursue my dreams.   
I would also like to acknowledge some refreshingly non-science friendships that 
have kept me sane, grounded, and smiling over the years.   First and foremost, I express 
my heartfelt gratitude to my Atlanta partners-n-crime, Greer Howard, Brooke Forsyth, 
Rachel Forrester, Courtney Littlefield, and Elizabeth David.  These women have become 
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like family to me during my time here in Atlanta and I will not even attempt to recount 
the many ways that their friendship has enriched my life.  I will say that, without a doubt, 
the completion of this thesis would feel empty and anticlimactic if I did not have these 
women walking alongside me and sharing in the journey, the struggles, and the 
occasional victorious moments.  Thank you, Greer, Brooke, Rach, Court, and Lizzie, for 
your faithful friendship and for making me a better person by your willingness to speak 
truth into my life.  I’d also like to give a long-distance shout-out to my Clarkson friends, 
Megan Leto, Krista Nielsen, and Erika Parsons, who have stuck by me for over ten years 
despite being scattered throughout the United States.  Together, we have traversed 
through multiple life-stages, dramatic career changes, and numerous city relocations—it 
has been an adventure!  I look forward to many email laughs and weekend reunions in the 
future!   Finally, I would also like to give mad props to Mumta Patel for being a top-
notch marathon-training buddy (“what happens during the Chicago marathon stays at the 
Chicago marathon”) and Rekha Nair for being an exceptional grad school roommate and 
an even better friend.     
I must acknowledge the Patierno family, Steve, Kim, Katie, Nicole, Brendon, and 
Justin, for the numerous ways they have invested into my life over the years.  In 
particular, my uncle, Dr. Steven Patierno, has without a doubt been the most significant 
influence on my decision to pursue a scientific research career.  My initial interest in 
biology was sparked as a child when he brought me to a cadaver museum at the George 
Washington University Medical School.  He then provided many key opportunities for 
me to fan the flames of this spark; most notably, tolerating my insatiable questions during 
a summer undergraduate research project in his lab at GWU.  Throughout my time in 
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grad school, Steve and Kim have been a steady source of guidance, encouragement, and 
perspective on topics ranging far beyond science. What’s more, their children, my 
cousins, have become fabulous friends and bona-fide sisters/brothers over the years.  
Thank you, Patierno family, for opening up your home to me as though I were your very 
own and for filling my life with love and laughter.  Our holiday caravans between D.C. 
and NY and the over-the-top Italian celebratory feasts are the highlight of my year!   
Speaking of Italian feasts, I must take a moment to offer much love, respect, and 
admiration to my NY grandparents, Arlene and Dominick Patierno.  Their little green 
house on Cardiff road has served as a safe-haven for our family throughout their 55+ 
years of marriage.  Thank you, Gram, for showing me that there is no disappointment or 
broken heart that cannot be healed with a good bowl of escarole soup or a 15-layer piece 
of lasagna!  You sure do know a “Fachagalupe” when you see one!  Thank you, Gramp, 
for infusing our holidays with rich Italian traditions…who knew there were so many 
different ways to prepare fish!?!  Words cannot express how much I appreciate the way 
you have tirelessly and selflessly supported me and my crazy ideas/projects over the 
years.  I am proud of my Italian-heritage, but even “prouder” to be your granddaughter!   
I would also like to extend much love and appreciation to my Grandmother 
Phillips, for serving as a role model of hard work and perseverance during my childhood 
summers on her farm in Virginia.  Although I did not realize it at the time, she taught me 
the secret to completing a Ph.D. when I was only five-years-old… 
 
“When a task is once begun 
  Never leave it till it’s done. 
Be the labor great or small, 
Do it well, or not at all.” 
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Thank you, grandmother, for fostering my work ethic, curiosity, and creativity; and for 
your late-night prayers which have undoubtedly bailed me out of many a sticky situation! 
Finally, I would like to express my eternal gratitude to my parents, Charles and 
Linda Phillips.  I cannot fathom the amount of patience that was required to turn this 
strong-willed, type-A, first-born child into someone who would not become a terror and 
menace to society!  I think they both had a panic attack five years ago when I casually 
mentioned that I wanted to quit my industry job and forgo any semblance of financial 
savings/security in order to come back to graduate school.  But, within the hour, they 
called me back and told me that they would support any risk I needed to take to pursue 
my dreams.  I tell this story because it exemplifies the type of people they are…and the 
selfless way they seem to always put not only me, but just about everyone that they come 
into contact with, ahead of themselves.  From a very young age, they prioritized the 
importance of finding my purpose in life, they taught me the secret to finding that 
purpose, and then served as role models for the character traits necessary to pursue that 
purpose with all of my heart, mind, and strength.  Thank you, Mom and Dad, for the 
numerous intangible ways that you have contributed to the completion of this work.  I 
look forward to our future trips to Central America! 
Upon completion of this dissertation, I now realize that the most valuable lesson I 
learned in graduate school is the importance of developing and maintaining a curious, 
teachable mind.  I entered Georgia Tech as an ambitious and overly confident student 
with the naïvely utopian goal of curing a fatal disease with my graduate work.  I leave 
Georgia Tech humbled, with a greater appreciation for the complexities of life, and a 
more realistic sense for just how little control we truly have over certain outcomes.  It 
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seems that the more I learn, the more I realize I don’t know; and that answering one 
question oftentimes gives rise to ten more questions, each harder and more complex than 
the first.  Oddly enough, it was by studying the foundational principals of life that I found 
faith; a faith which is diametrically opposed to man-made religion/ritual/rules.   This faith 
has infused every aspect of my life with a newfound sense of meaning, purpose, and, 
most importantly, peace.  I intend to test this God-hypothesis, and its co-existence with 
science, for the rest of my life.  There is just so much more to learn…  
 
 
“The important thing is not to stop questioning. Curiosity has its own 
reason for existing. One cannot help but be in awe when he contemplates the 
mysteries of eternity, of life, of the marvelous structure of reality.  It is 
enough if one tries merely to comprehend a little of this mystery every day. 





“Ask and it will be given to you; seek and you will find; knock and the door will be 
opened to you.  For everyone who asks receives; he who seeks finds; and to him who 
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Tissue engineering has emerged as a promising alternative to conventional 
orthopaedic grafting therapies.  The general paradigm for this approach, in which 
phenotype-specific cells and/or bioactive growth factors are integrated into polymeric 
matrices, has been successfully applied in recent years toward the development of bone, 
ligament, and cartilage tissues in vitro and in vivo.  Despite these advances, an optimal 
cell source for skeletal tissue repair and regeneration has not been identified.   
Furthermore, the lack of robust, functional orthpaedic tissue interfaces, such as the bone-
ligament enthesis, severely limits the integration and biological performance of 
engineered tissue substitutes.  This works aims to address these limitations by spatially 
controlling the commitment of primary dermal fibroblasts toward an osteoblastic (bone 
cell) lineage within three-dimensional polymeric matrices.  The overall objective of this 
project was to investigate transcription factor-based gene therapy strategies for the 
differentiation of fibroblasts into a mineralizing cell source for orthopaedic tissue 
engineering applications.  Our central hypothesis was that fibroblasts genetically 
engineered to express Runx2 via conventional and biomaterial-mediated ex vivo gene 
transfer approaches will differentiate into a mineralizing osteoblastic phenotype. 
As a first step toward testing this hypothesis, we investigated retroviral gene 
delivery of the osteogenic transcription factor Runx2 as a mineralization induction 
strategy in primary dermal fibroblasts.  We found that a combination of constitutive 
Runx2 overexpression and supplementation with the steroid hormone dexamethasone 
(DEX) synergistically induced osteogenic differentiation, including bone sialoprotein 
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gene expression, alkaline phosphatase activity, and biological mineral deposition in 
primary dermal fibroblast monolayer cultures.  This unexpected result suggested that 
Runx2-engineered fibroblasts have the capacity to create mineralized templates for bone 
repair and may be a potential cell source for bone tissue engineering applications.  
Furthermore, the complete absence of native osteoblastic phenotype in hormone-only 
treated cultures suggested that these cells could be utilized as a robust experimental 
model to study the Runx2-dependent mechanisms of DEX-induced osteogenesis. 
 Further characterization of Runx2-engineered fibroblasts involved investigation 
of the cellular and molecular pathway(s) driving the induction of osteogenesis in this 
non-osteoblastic cellular phenotype.  More specifically, we used these cells as a model 
system to study the effect of DEX on Runx2 serine phosphorylation and the functional 
role of this phosphorylation state during osteoblastic differentiation.  We demonstrated 
that DEX decreased Runx2 phosphoserine levels, particularly on Serine125, in parallel 
with the upregulation of MAPK phosphatase-1 (MKP-1).  Mutation of Ser125 to glutamic 
acid, mimicking constitutive phosphorylation, inhibited Runx2-induced osteogenic 
differentiation, which was not rescued by DEX treatment.  Conversely, mutation of 
Serine125 to glycine, mimicking constitutive dephosphorylation, markedly increased 
osteogenic differentiation, which was enhanced by but did not require additional DEX 
supplementation.  The DEX-induced decrease in Runx2 phosphorylation correlated with 
upregulation of MKP-1 through a glucocorticoid-receptor-dependent mechanism.  
Furthermore, inhibition of MKP-1 abrogated the effect of DEX on Runx2 phosphoserine 
levels.  Collectively, these results demonstrated that DEX induces osteogenesis, at least 
in part, by modulating the phosphorylation state of a negative regulatory serine residue 
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(Ser125) on Runx2 via MKP-1. This work identifies a previously unreported mechanism 
for glucocorticoid-induced osteogenic differentiation and provides insights into the role 
of Runx2 phosphorylation during skeletal development. 
Runx2-expressing fibroblasts were then evaluated within the context of three-
dimensional polymeric matrices for their potential as a mineralizing cell source for bone 
tissue engineering applications.  Genetically modified fibroblasts were cultured in vitro 
on three commercially available scaffolds with highly divergent properties, including: 
fused deposition-modeled polycaprolactone (PCL), gas-foamed polylactide-co-glycolide 
(PLGA), and fibrous collagen disks.  We demonstrated that the mineralization capacity of 
Runx2-engineered fibroblasts is scaffold-dependent, with collagen foams exhibiting ten-
fold higher mineral volume compared to PCL and PLGA scaffolds.  Constructs were 
differentially colonized by genetically modified fibroblasts, but the scaffold-directed 
changes in DNA content did not correlate with trends in mineral deposition.  Sustained 
expression of Runx2 upregulated osteoblastic gene expression relative to unmodified 
control cells and the magnitude of this expression was modulated by scaffold properties.  
Histological analyses revealed that matrix mineralization co-localized with cellular 
distribution, which was confined to the periphery of fibrous collagen and PLGA sponges 
and around the circumference of PCL microfilaments.  Fourier transform infrared 
analysis verified that mineral deposits within Runx2-engineered scaffolds displayed the 
chemical signature characteristic of carbonate-containing, poorly crystalline 
hydroxyapatite, whereas control constructs did not contain biologically-equivalent 
mineral.  Importantly, Runx2-transduced fibroblasts formed mineralized templates in vivo 
after implantation in a subcutaneous, heterotopic site, whereas minimal mineralization 
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was evident in control constructs.  Immunohistochemical analysis revealed that Runx2-
expressing cells co-localized with mineral deposits in vivo, suggesting that mineral was 
primarily produced by transplanted donor cells.  Taken together, these results establish 
Runx2-genetic engineering as a strategy for the conversion of a non-osteogenic cellular 
phenotype into a mineralizing osteoblastic cell source for bone repair.   
Finally, we explored the feasibility of spatially regulating Runx2 expression in 
fibroblasts to engineer heterogeneous bone-soft tissue interfaces.  Toward this end, we 
first demonstrated that biomaterial-mediated retroviral gene transfer is a feasible strategy 
for the genetic modification and differentiation of fibroblasts into a mineralizing 
osteoblastic phenotype.  Viral uptake from these constructs was found to be highly 
dependent on the non-covalent adsorption of retroviral vectors to positively-charged 
poly-L-lysine prior to cell seeding.  This observation was leveraged to create a graded 
distribution of Runx2 retrovirus within tissue engineered constructs.  These 3-D retroviral 
gradients resulted in spatially regulated genetic modification of fibroblasts and, 
consequently, zonal organization of osteoblastic and fibroblastic cellular phenotypes in 
vitro.  Moreover, implantation of heterogeneous constructs into a subcutaneous, ectopic 
site resulted in Runx2-induced spatial patterning of mineral deposition and non-
mineralized fibroblastic extracellular matrix in vivo.  Notably, discrete mineralized 
nodules co-localizing with transduced cell colonies were distributed throughout the 
interior of virus-coated constructs, suggesting that a biomaterial-mediated gene transfer 
approach may circumvent mass transport issues caused by the localization of a dense 
mineralized shell around the scaffold periphery.   Collectively, these results indicate that 
heterogeneous bone-ligament-mimetic tissue interfaces can be developed by a simple, 
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one step seeding of autologous fibroblasts into polymeric scaffolds containing a graded 
distribution of the Runx2 retroviral vector.  The concept of controlling expression of 
tissue-specific transcription factors to create spatial gradients of differential cell function 
within 3-D matrices may be applicable to the development of interfacial zones for a large 
number of tissue engineering applications.  
In summary, this research has established transcription factor-based gene therapy 
strategies for the conversion of a non-osteoblastic cellular phenotype into a mineralizing 
cell source for orthopaedic tissue engineering applications.  This work is significant 
because it leverages these genetically engineered fibroblasts to simultaneously (1) 
elucidate previously unreported molecular pathways involved in bone formation and (2) 
develop mineralized templates for orthopaedic (bone, ligament) tissue repair.  This work 
is innovative because it utilizes novel biomaterial-mediated gene transfer technologies to 
engineer bone-soft tissue interfacial zones.  Overall, these results are significant toward 
our ultimate goal of regenerating complex, higher order tissue structures which mimic the 
cellular and microstructural characteristics of native tissue. Cellular therapies based on 
primary dermal fibroblasts would be particularly beneficial for patients with a 
compromised ability to recruit progenitors to the sight of injury as result of traumatic 









Six million bone fractures are reported each year in the Unites States and roughly 
10% of these require some form of orthopaedic graft 1, 2.  As a result, approximately 
500,000 grafting procedures are performed annually in victims of non-healing defects 
caused by age-related bone deterioration, traumatic injury, tumor resection, or osteolytic 
disease 3.  Conventional skeletal grafting therapies typically involve the implantation of 
autogenic bone harvested from the patient’s iliac crest or allogenic bone from cadaver 
tissue banks.  Although successful in many cases, these grafts remain limited by 
inadequate osseointegration, donor site morbidity, poor mechanical properties, and/or the 
risk of disease transmission.  More recently, formulations based on recombinant human 
bone morphogenetic proteins (BMP-2 and BMP-7) have been approved by the FDA for 
the treatment of severe orthopaedic conditions such as spinal fusion and skeletal 
nonunion 4-6.  However, the doses of recombinant protein required to accelerate healing 
in humans are significantly higher than the levels expressed during normal bone repair, 
likely due to suboptimal delivery vehicles and rapid in vivo protein degradation.  These 
supraphysiologic concentrations are cost-prohibitive to widespread clinical usage and 
may be problematic if the non-selective targeting of neighboring non-osseous tissues 
leads to ectopic bone formation 7, 8.   
Tissue engineering has emerged as a promising alternative to conventional 
skeletal repair strategies 9-12.  The general paradigm for this approach, in which 
phenotype-specific cells and/or bioactive growth factors are integrated into polymeric 
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matrices, has been successfully applied in recent years toward the development of 
skeletal tissues in vitro and in vivo.  Cell-based strategies have shown particular efficacy 
in bone repair applications, as several groups have demonstrated healing of critical-sized 
defects by combining marrow-derived mesenchymal stem cells with three-dimensional 
scaffolds 13-18.  Although results in animal studies are promising, it is still unknown if 
MSC transplantation will induce an osteogenic response robust enough to heal critical-
sized bone defects in humans.  Moreover, these autologous osteogenic precursors remain 
intrinsically limited by their complex and painful cell procurement process and age- and 
passage-dependent decreases in mineralization capacity 16, 19.  These limitations leave a 
pressing need for alternative cell source options for bone repair.   
Non-osteogenic cells, such as skin fibroblasts, are a particularly attractive cell 
source alternative because they are easy to harvest from autologous donors and display a 
high capacity for in vitro expansion.  Ex vivo gene therapy strategies based on soluble, 
osteoinductive factors have been developed for the induction of osteogenesis in 
fibroblastic cell types 20-23.  Notably, dermal fibroblasts genetically engineered to express 
BMP-2 form significant amounts of bone in both ectopic implantation sites and critical 
sized calvarial defects 24, 25.  Despite these advances, complex release kinetics and 
uncontrolled paracrine signaling to neighboring non-osseous tissues may limit the clinical 
success of this approach 26-28.   The present research is fundamentally different from 
growth factor-based gene therapy strategies because it focuses on gene delivery of the 
transcription factor Runx2, a downstream intracellular effector, to primary dermal 
fibroblasts in order to avoid detrimental effects associated with unregulated protein 
secretion.   
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In addition to cell sourcing issues, the regeneration of complex tissue structures 
with graded interfacial tissue zones remains another significant challenge in current tissue 
engineering strategies.   In particular, the lack of robust, functional interfaces between 
bone and soft tissues severely limits the integration and biological performance of 
engineered orthopaedic substitutes.  One such complex structure is found at the insertion 
site between native anterior cruciate ligament (ACL) and bone, where there is a 
heterogeneous interface consisting of four distinct regions, including: ligament, non-
mineralized fibrocartilage, mineralized fibrocartilage, and bone.  ACL graft failure is 
typically localized to this insertion site, suggesting that regeneration of a heterogeneous 
tissue interface would promote graft osseointegration into the surrounding bone tissue 
and, consequently, enhance the long-term mechanical function of tissue engineered ACL 
replacements. 
This work aims to address cell sourcing and osseointegration limitations 
associated with skeletal tissue engineering by spatially controlling the differentiation of 
fibroblasts into an osteoblastic phenotype within three-dimensional polymeric matrices.   
The overall objective of this project was to investigate transcription-factor based gene 
therapy strategies for the differentiation of fibroblasts into a mineralizing cell source for 
orthopaedic tissue engineering applications.  Our central hypothesis was that fibroblasts 
genetically engineered to express Runx2 via conventional and biomaterial-mediated ex 
vivo gene transfer approaches will differentiate into a mineralizing osteoblastic 
phenotype. The overall objective was accomplished by testing our central hypothesis 
according to the following specific aims:  
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Aim1:  Elucidate the molecular mechanism(s) by which Runx2-expressing 
fibroblasts differentiate into a mineralizing osteoblastic phenotype. 
Our working hypothesis was that glucocorticoid hormones induce osteoblastic 
differentiation in fibroblasts by modulating the phosphorylation state of Runx2. We 
tested this hypothesis using Runx2-expressing fibroblasts as a model system.  Site-
directed mutagenesis was used to mutate a specific serine residue (Ser125) within Runx2 
into glycine (mimicking constitutive dephosphosphorylation) or glutamic acid 
(mimicking constitutive phosphorylation).   Primary fibroblasts were transduced with 
wild type Runx2 (Runx2-WT), Runx2-125Gly, or Runx2-125Glu retroviral vectors and 
cultured in osteogenic media supplemented with or without the synthetic glucocorticoid 
hormone dexamethasone.  These experimental conditions were used to investigate the 
effect of dexamethasone on Runx2 serine phosphorylation, the functional role of this 
phosphorylation state during osteoblastic differentiation, and to identify upstream 
signaling molecules which modulate the phosphorylation state of Runx2. 
 
Aim2:  Investigate Runx2-genetically engineered dermal fibroblasts as a 
mineralizing cell source for bone tissue engineering applications. 
Our working hypothesis was that primary fibroblasts genetically modified to 
constitutively express the osteoblastic transcriptional activator Runx2 will create 
mineralized templates in vitro and in vivo.  We tested this hypothesis by integrating 
Runx2-transduced fibroblasts into three commercially available scaffolds with divergent 
properties: fused deposition-modeled polycaprolactone (PCL), gas-foamed polylactide-
co-glycolide (PLGA), and fibrous collagen disks. Tissue-engineered constructs which 
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displayed the highest degree of osteogenic potential in vitro were implanted in vivo into 
an ectopic, subcutaneous site in order to assess the mineralization capacity of these cells 
in the absence of osteoinductive cues and cell-types typically present in orthotopic 
defects. 
 
Aim3:  Engineer a heterogeneous bone-ligament tissue interface by spatially 
regulating Runx2 expression in fibroblasts 
Our working hypothesis was that zonal organization of bone and ligament tissue can be 
engineered by seeding primary fibroblasts onto three-dimensional scaffolds containing a 
spatial distribution of the Runx2 retroviral vector.  We tested this hypothesis by 
transducing fibroblasts with a novel biomaterial-mediated gene transfer approach in 
which Runx2 retrovirus was non-covalently adsorbed to polymeric biomaterials.  
Retroviral gradients were created by partially coating the proximal portion of these 
scaffolds with poly-L-lysine prior to incubation in retroviral supernatant and cell seeding.  
The spatial distribution of bone and ligament markers, mineralization, and mechanical 
properties was characterized after both in vitro culture and in vivo implantation in a 
subcutaneous, ectopic site.     
 
This work is significant because it develops hybrid ex vivo gene therapy/tissue 
engineering strategies to address the cell sourcing and osseointegration issues associated 
with cell-based orthopaedic therapies.  First, it establishes the use of transcription factor-
based genetic engineering strategies for the conversion of a non-osteogenic cell-type into 
a mineralizing cell source for bone tissue engineering applications.  Second, it contributes 
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to the field of orthopaedic biology by elucidating a previously unreported mechanism for 
glucocorticoid-induced osteogenic differentiation.  Third, it validates the feasibility of a 
biomaterial-mediated retroviral gene transfer approach to create heterogenous bone-soft 
tissue interfacial zones.  The proposed research is innovative because it utilizes 
biomaterial-mediated retroviral gene transfer as a novel strategy for spatially-controlled 
genetic modification and transdifferentiation of fibroblasts within 3-D matrices.  Overall, 
cellular therapies based on primary dermal fibroblasts would be particularly beneficial for 
patients with a compromised ability to recruit progenitors to the sight of injury as result 


















Bone Anatomy and Physiology 
Bone is a specialized connective tissue which provides mechanical support and 
protection for the body’s internal organs.  Beyond this structural role, bone tissue also 
serves as a major reservoir for calcium and phosphate ions and contains a population of 
hematopoietic and stromal cell precursors within its marrow cavity.  Thus, despite its 
inert appearance, bone is a metabolically active organ that undergoes continuous 
remodeling throughout life in order to maintain serum homeostasis and the structural 
integrity of the skeleton 29.  This remodeling process involves a complex series of highly 
regulated steps that primarily depend on the interplay of two cell types, the osteoblast and 
the osteoclast.  Osteoblasts promote bone formation by regulating deposition of osteoid 
and mineral nucleation. Osteoclasts are primarily responsible for bone resorption through 
the secretion of hydrogen ions and acid proteases.   Mature osteoblasts (termed 
osteocytes) are embedded within the dense extracellular matrix in lacunae and extend 
microfilament-rich canaliculi processes.  These processes contact canaliculi originating 
from other cells through gap junctions, enabling the propagation of signals to the interior 
of the highly dense bone matrix.     
Bone contains both cortical (compact) and trabecular (spongy) tissue types.   
 
*Modified from 
J.E. Phillips, C.A. Gersbach, and A.J. Garcia, Virus-based gene therapy strategies for bone regeneration. 
Biomaterials, 2007. 28(2):211-229. 
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Although these tissues are structurally and functionally different, they contain the same 
fundamental constituents, including a highly organized extracellular matrix, bone 
resorbing cells (osteoclasts), and bone forming cells at various stages of maturation (e.g. 
osteoprogenitors, osteoblasts, osteocytes, and periosteal lining cells).  The matrix is 
comprised of an inorganic, poorly crystalline hydroxyapatite mineral phase and a mixture 
of collagenous and noncollagenous (e.g. osteocalcin, bone sialoprotein, osteopontin, 
fibronectin) proteins.  Trabecular bone is found within the marrow cavity and throughout 
the ends of long bones and consists of a latticework of reticulated spicules lined with 
osteoblasts and osteoclasts.  Compact bone is located around the circumference of all 
bones and comprises the outer tubular shell surrounding the intramedullary marrow 
cavity in long bones.  It consists of parallel cylindrical units (osteons), which contain a 
Haversian canal surrounded by concentric lamellar rings of osteocytes embedded within 
the calcified matrix.  Blood vessels and nerves run through this canal system to allow for 
transport of nutrients and waste and to innervate osseous tissue.  Finally, eriostemon, a 
thin layer of connective tissue, covers the outer surface of bone and contains progenitor 
cells capable of bone formation.   
 
Bone Development 
Normal skeletal development originates from two main processes:  
intramembranous ossification and endochondral ossification30.  Intramembranous 
ossification primarily occurs during embryonic development of flat bones such as the 
calvarium and mandible.  In this process, mesenchymal precursors within vascularized 
embryonic connective tissue differentiate directly into an osteoblastic phenotype.  
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Endochondral ossification is the primary mode of long bone development during 
embryogenesis, pre-pubescent limb growth, and fracture healing.   This process differs 
from intramembranous bone formation in that it includes a highly complex, intermediate 
cartilaginous phase prior to mineralized matrix deposition.  Briefly, pre-chondrocytes 
within the growth plate proliferate and differentiate into mature hypertrophic 
chondrocytes, which secrete matrix and undergo apoptosis. This avascular, cartilaginous 
matrix is then infiltrated with blood vessels, calcified, and eventually remodeled by 
osteoblasts and osteoclasts to form lamellar trabecular bone.  Details of this complex 
process and the regulatory factors involved are beyond the scope of the current research 
and are discussed elsewhere30, 31. 
 
Bone Regulatory Factors  
Recent advances in bone cell biology have identified a central role for numerous 
signaling molecules during bone development and regeneration.  Differentiation of 
mesenchymal progenitor cells into an osteoblastic phenotype is tightly regulated by a 
complex spatiotemporal cascade of growth and differentiation factors, hormones, 
transcription factors, and extracellular matrix proteins.  Among these, several soluble and 
extracellular matrix proteins bind to transmembrane receptors to initiate signaling 
pathways which converge to activate osteogenic transcription factors.  These factors 
primarily have an intracellular mode of action to coordinate the expression of osteoblastic 
genes regulating the deposition of a mineralized matrix.   A mechanistic understanding of 
these signaling pathways will enable researchers to more effectively develop strategies 
for skeletal gene therapy applications.    
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Osteoinductive growth and differentiation factors 
Osteoinductive factors are typically embedded within the extracellular matrix and 
released during remodeling or injury.  These proteins bind to specific transmembrane 
receptors to initiate signaling cascades which induce osteogenesis through autocrine and 
paracrine signaling.  Among these, bone morphogenetic proteins (BMPs) have been 
identified as potent inducers of osteoblastic differentiation and ectopic and orthotopic 
bone formation8, 32, 33.  Complex expression patterns of multiple BMP isoforms have been 
observed during bone growth, as BMP-2, -4, and -7 are expressed in overlapping patterns 
during bone development34, 35 and BMP-2,-3,-4,-7, and -8 are expressed during fracture 
healing36.  Furthermore, a comparative study of 14 different human isoforms revealed 
that BMP-2, -6, and -9 potently induce osteoblastic differentiation in mesenchymal stem 
cells37.  The canonical mechanism of BMP signaling involves binding of this factor to a 
transmembrane receptor to initiate Smad-dependent and -independent signaling pathways 
that activate a cascade of osteogenic transcription factors, most notably Runx2/Cbfa1 and 
Osterix38-41.  
Insulin-like growth factors (IGF-I and IGF-II) serve as local regulators of bone 
matrix and remodeling.  These factors enhance collagen synthesis, inhibit collagen 
degradation, and stimulate proliferation of cells within the osteoblastic lineage42, 43.  
Systemic injection of IGF-I has a net anabolic effect on bone mass and enhances bone 
healing in vivo44.  However, discrepancies exist in the literature, as some studies report 
negligible effects of IGF on the skeleton45.  
Transforming growth factor-β (TGF-β) is present in high quantities within bone 
matrix and has pleiotropic regulatory effects during skeletal development and fracture 
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healing.   TGF-β stimulates osteoid formation and osteoblast proliferation, but has been 
shown to inhibit mineral deposition and osteocalcin gene expression46, 47.  Indeed, 
Opperman et al. reported that systemic TGF-β injection induces ectopic mineralization in 
vivo only after growth factor administration is discontinued48.  Alternatively, in vivo 
studies in fracture healing animal models have revealed that TGF-β enhances callus 
formation and mechanical strength compared to untreated fracture controls49, 50.  Despite 
these promising results, the use of this factor as an osteoinductive therapeutic agent may 
be significantly limited because the exceptionally large doses required to enhance bone 
repair are often toxic to the host51.   
Fibroblast growth factors (aFGF/FGF-1 and bFGF/FGF-2) function mainly as 
angiogenic agents during limb development, craniofacial bone formation, and the process 
of fracture healing.  Disruption of endogenous FGF signaling via blocking antibodies 
inhibits osteogenesis52, while mutations rendering the FGF transmembrane receptor 
constitutively active lead to enhanced osteoblast activity and premature fusion of 
craniofacial sutures53, 54.  Consistent with these results, administration of exogenous FGF 
enhances migration, proliferation, and differentiation of osteoprogenitors and ultimately 
accelerates fracture healing in long bones55-57.   
 
Osteogenic transcription factors 
Osteoinductive factors, such as BMPs, bind to the extracellular domain of 
transmembrane receptors to initiate signaling cascades which converge to activate a 
program of downstream transcriptional regulators.  Many transcription factors are 
expressed during bone development and fracture healing, including Runx2/Cbfa1, DLX-
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3, DLX-5, MSX-2, AP-1, Osterix 58.  Among these, Runx2/Cbfa1 and Osterix have been 
extensively characterized for their role in regulating the commitment of multipotent 
mesenchymal stem cells into the osteoblastic lineage.   
Runx2 is an essential transcriptional regulator of chondrocyte hypertrophy, 
osteoblast differentiation, and bone formation 59, 60.   Runx2-/- transgenic mice display an 
entirely cartilaginous skeleton with complete arrest of osteoblast activity and 
endochondral ossification 61.  Moreover, Runx2 haploinsufficiency causes the pathogenic 
skeletal phenotype cleidocranial dysplasia in mice and humans, characterized by short 
stature, hypoplastic clavicles, and dental abnormalities 62, 63.  Runx2 functions as a 
transcriptional scaffolding protein which associates with additional co-regulatory proteins 
and binds to the promoter region of skeletal target genes to regulate their expression 64, 65. 
We and others have demonstrated that forced expression of Runx2 upregulates 
osteoblast-specific gene expression and induces mineralization in a cell-type-dependent 
manner 23, 24, 59, 66, 67.  Intriguingly, both postnatal disruption of Runx2 by dominant 
negative expression and overexpression of Runx2 from the pro- (I) collagen promoter 
induces bone fragility and osteopenia in transgenic mice 68, 69.  These studies collectively 
demonstrate that cellular regulation of Runx2 is critical for normal skeletal development 
and bone formation. 
Osterix (OSX) is a zinc-finger-containing transcription factor that acts 
downstream of Runx2 to induce the differentiation of osteoprogenitors into mature 
osteoblasts.  Homozygous deletion of Osterix inhibits osteoblast differentiation and 
activity, while chondrocyte hypertrophy proceeds normally in these transgenic mice70.  
Several reports have suggested that Runx2 directly regulates Osterix, as its expression is 
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completely absent in Runx2-null mice70 and Runx2 binding sites have been identified in 
the Osterix promoter71.  Regulation of these two osteoblastic transcription factors and 
their temporal expression with respect to each other is an active area of research. Notably, 
both Runx2 and Osterix are downstream effectors of BMP-2-activated signaling72-76. 
 
Biological and Synthetic Bone Grafts 
Conventional skeletal grafting therapies typically involve the implantation of 
autogenic bone harvested from the patient’s iliac crest or allogenic bone from cadaver 
tissue banks.  Autograft implantation is considered the gold standard in bone repair, but 
the widespread clinical success of this procedure has been hindered by variable results 
associated with the quality of the bone graft, inadequate tissue supply, and donor site 
morbidity 77.  Allografts offer advantages for off-the-shelf tissue availability, but display 
reduced biological activity and mechanical properties due to tissue processing and carry 
the risk of disease transmission 78, 79.  Synthetic materials such as metals, calcium 
phosphate ceramics, bioactive glasses, and polymers have also been explored for bone 
grafting applications, but generally display insufficient regenerative potential to warrant 
the inflammatory host reaction 80.  More recently, osteogenic devices containing 
recombinant bone morphogenetic protein-2 (BMP-2) or BMP-7 have shown efficacy in 
human clinical trials and have been approved by regulatory agencies for the treatment of 
non-healing fractures and spinal fusion 4-6, 8.  Nevertheless, the wide-spread clinical 
success of this growth-factor based approach continues to be hampered by suboptimal 
delivery vehicles, short biological half-life, and safety issues associated with aphysiologic 
dosage 7, 8.  Although several approaches to augment bone formation are presently 
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available, it is clear that their limitations leave a pressing need for alternative bone 
regeneration strategies. 
 
Gene Therapy Approaches to Bone Grafting 
Gene therapy aims to introduce exogenous nucleic acid sequences into cells in 
order to alter their endogenous protein synthesis or induce the expression of therapeutic 
proteins.  Both in vivo and ex vivo gene therapy strategies have been investigated for bone 
regeneration 20, 81.  Table 2.1 lists examples of in vivo gene delivery of osteogenic factors 
for bone repair.  In vivo strategies involve vector delivery via intravenous injection or 
direct local implantation to a selected anatomic site.  This simple, one-step process would 
promote high surgeon compliance and may be necessary for disorders requiring 
immediate treatment, but involves significant challenges associated with low transduction 
efficiency, inflammatory/immune limitations, and difficulty targeting the cell population 
of interest.  Moreover, this strategy is highly dependent on the presence and 
responsiveness of host cells and may not be effective in patients with compromised 
ability to recruit osteoprogenitors to the site of injury as a result of disease, trauma, 
radiation treatment, or age-related tissue deterioration.   Ex vivo strategies involve the 
harvest of a specific population of cells from the patient, followed by genetic 
modification of these cells under in vitro conditions and their subsequent implantation 
into the site of injury.  Tables 2.2 and 2.3 provide examples of ex vivo strategies using 
osteogenic and non-osteogenic cell sources, respectively.  Ex vivo gene delivery 
approaches allow for expansion of the target cell population prior to genetic modification 
and selection for cells expressing the transgene.  Furthermore, ex vivo gene transfer in a  
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Chen et al., 2003. 
Adenovirus BMP-2 Dorsal osseous 
nasal defect 







Athymic nude rats Jane et al, 2002. 
Adenovirus BMP-2 Intramuscular 
injection 
Immunocompetent 
and athymic nude 
rats 








Li et al., 2003. 
Retrovirus BMP-2/4 Periosteal injection 
adjacent to fracture 
Critical-sized 
femoral defect in 
immunocompetent 
rats 





BMP-6 Ectopic injection Immunocompetent 
and athymic nude 
rats 













New Zealand white 
rabbits 
Baltzer et al., 
2000. 














cell-based delivery vehicle may be safer in a clinical setting than direct injection of viral 
particles in vivo.  Although cells can be screened for tumorigenicity before implantation 
into the host, these initial steps are often labor intensive and would involve significant 
cost and complexity.   
Both in vivo and ex vivo gene therapy strategies have been investigated for bone 
regeneration 20, 81.  In vivo approaches for bone repair have predominantly utilized 
transient adenoviral vectors to avoid risks associated with retroviral-mediated insertional 
mutagenesis.  Direct injection of adenoviral vectors expressing BMP-2 led to increased 
bone formation in critical-sized rat mandibular defects 82 and rabbit femoral segmental 
defects 83.  Importantly, Baltzer et al. reported detection of transgene expression at high 
levels in muscle tissue surrounding femoral defects for at least 6 weeks, suggesting that 
muscle-derived osteoprogenitors contributed to bone formation 84.  In a separate study, 
intramuscular injection of BMP-2-expressing adenovirus induced ectopic bone formation 
in mice, but a more robust osteogenic response was observed in immunodeficient 
compared to immunocompetent animals 85.  This observation corroborated reports from 
several groups that the host immune response induced by first-generation adenoviral 
vectors is strong enough to attenuate the efficacy of adenovirus-based approaches 86-88.  
In an attempt to overcome issues associated with viral immunogenicity, Rundle et al. 
pursued an in vivo strategy based on a retroviral vector encoding a BMP-2/4 fusion 
protein 89.  Although accelerated fracture healing was observed after retroviral injection 
in a rat femoral defect at early time points, both treatment and control fractures 
eventually remodeled to comparable dimensions and mineral levels.  Nevertheless, 
evidence of vector integration into surrounding non-skeletal tissues was not observed, 
 17
suggesting that retroviral-based in vivo gene therapy strategies may be safe for specific 
local tissue repair applications 89. 
Ex vivo approaches based on different cell-types, gene delivery vectors, and target 
genes have been extensively explored for bone repair applications.  One strategy that has 
shown particular promise is the implantation of bone marrow stromal cells (BMSCs) 
genetically engineered to overexpress BMP-2 into critical-sized defects 90-96.  Lieberman 
et al. reported that autologous Ad-BMP-2-expressing BMSCs embedded within a 
demineralized bone matrix carrier significantly healed segmental femoral defects in 
syngeneic rats compared to carrier only and Ad-LacZ-expressing BMSC controls 92.  
Importantly, these investigators directly compared this ex vivo approach to the delivery of 
a clinical dose of rhBMP-2 protein and showed that genetically engineered cells produce 
more robust trabecular architecture than recombinant protein injection.  In an independent 
study, Tsuchida et al. investigated the bone healing capacity of allogenic BMSCs infected 
with a BMP-2 adenoviral vector in a rat femoral segmental defect 97.  BMP-2-expressing 
allogenic cells in combination with the immunosuppressant FK506 induced fracture 
repair in vivo to levels comparable to BMP-2-expressing autologous cells.  Notably, 
investigation into the cellular origin of bone formation suggested that genetically 
engineered cells secrete BMP-2 for paracrine signaling and also directly participate in 
bone formation.  In contrast to studies focused on transient adenoviral gene delivery, an 
ex vivo approach based on constitutive retroviral overexpression of BMP-4 in BMSCs 
was recently investigated by Gysin et al 96.    BMP-4-expressing BMSCs healed critical-
sized calvarial defects in rats, while untransduced BMSCs showed limited bone 
formation. Collectively, these results suggest that ex vivo genetic manipulation of 
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mesenchymal stem cells may provide a more robust strategy for bone formation than the 
direct implantation of these cells alone.   
 
Cell-based Tissue Engineering Approaches to Bone Grafting  
Bone tissue engineering has emerged as a promising alternative to conventional 
grafting strategies.98-100  The general paradigm for this approach involves the integration 
of osteogenic cells and/or bioactive growth factors into three-dimensional scaffolds to 
produce hybrid constructs for skeletal repair.101  The success of bone tissue engineering 
to date has been limited in part by inadequate availability of a mineralizing cell source 
which can be easily obtained in sufficient quantities and maintain osteoblastic phenotype 
during in vitro culture and expansion.   
 
Cell Source 
Traditional cell-based approaches typically involve the use of terminally 
differentiated osteoblasts,102, 103 osteogenic cell lines, 104, 105 unfractionated bone marrow  
stroma,106, 107 or purified mesenchymal stem cells 108-110.   Primary osteoblasts are 
difficult to isolate in sufficient quantities from calvarial or trabecular bone and display a 
limited capacity for proliferation.  Immortalized osteogenic cell-lines are clonally-derived 
and well-characterized, but exhibit abnormal regulatory mechanisms that may lead to 
tumorigenic growth in vivo.  Because of these limitations, a large number of cell 
transplantation strategies are based on primary bone marrow stromal cells (BMSCs) 14, 
108, 109, 111-113.  These cells contain a subpopulation of osteoprogenitors and mesenchymal 
stem cells (MSCs) which have shown significant mineralization capacity in vitro and in 
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Table 2.2.  Selected examples of ex vivo gene therapy approaches for bone repair in 














Adenovirus BMP-9 Human 
mesenchymal stem 
cells 
Ectopic intramuscular site 
in athymic nude rats 
Dayoub et 
al., 2003. 
Adenovirus Runx2 Primary bone 
marrow stromal cells 
Ectopic subcutaneous site 
in immunocompetent mice 
Zhao et al., 
2005. 
Retrovirus Runx2 Primary bone 
marrow stromal cells 
Ectopic subcutaneous site 




Byers et al., 
2004. 




BMP-2 Primary bone 




Park et al., 
2003. 
Retrovirus BMP-7 Primary periosteal 
cells 
Critical-sized cranial 




Retrovirus BMP-4 Primary bone 
marrow stromal cells 
Critical-sized calvarial 
defect in syngeneic rats 
Gysin et al., 
2002. 
Lentivirus BMP-2 Primary bone 
marrow stromal cells 
Ectopic intramuscular site 
in SCID mice 
Sugiyama 




BMP-2 Primary bone 
marrow stromal cells 
Critical-sized calvarial 
defects in rats 
 





BMP-2 Primary bone 
marrow stromal cells 
Critical-sized femoral 




et al., 1999 
Adenovirus BMP-2 Bone marrow 
stromal cell line 
Ectopic intramuscular site 
in SCID mice and critical-
sized femoral segmental 
defect in athymic rats 
Lieberman 
et al., 1998. 



































BMP-2 Muscle-derived stem 
cells 
Critical-sized calvarial 
defect in SCID mice 
Lee et al., 2002. 
Adenovirus LMP-1 Peripheral blood-
derived buffy coat 
cells 
Spine fusion in 
immunocompetent rabbits 
Viggeswarapu 
et al., 2001. 




Ectopic intramuscular site 
and critical-sized calvarial 
defect in immunocompetent 
mice 
Peng et al., 
2002. 
Adenovirus BMP-4 Muscle-derived stem 
cells 
Critical-sized calvarial 
defect in immunocompetent 
rats 
Wright et al., 
2002. 
Adenovirus BMP-4 Muscle-derived stem 
cells and primary 
bone marrow stromal 
cells 
Critical-sized femoral defect 
in immunocompetent rats 
Rose et al., 
2003. 
Adenovirus BMP-7 Rat dermal fibroblasts Ectopic subcutaneous site 
and critical-sized calvarial 
defect in 
immunocompromised mice 
Krebsbach et al., 
2000. 





fibroblast cell line 
Ectopic subcutaneous site in 
immunocompetent mice 
Zhao et al., 
2005. 
Retrovirus Runx2 Primary dermal 
fibroblasts 
Ectopic subcutaneous site in 
immunocompetent 
syngeneic rats 
Phillips et al., 
2006. 
Retrovirus Runx2 Skeletal myoblasts Ectopic intramuscular site 
in immunocompetent 
syngeneic mice 
Gersbach et al., 
2006.  




C3H10T1/2 cell line Ectopic subcutaneous site in 
immunodeficient mice 






Ectopic subcutaneous site 
and critical-sized calvarial 
defect in immunocompetent 
mice 
Hirata et al., 
2003. 
Adenovirus BMP-2 Human diploid fetal 
lung cell-line and 
primary bone marrow 
stromal cells and 
primary dermal 
fibroblasts 
Ectopic intramuscular site in 
SCID mice 
Gugala et al., 
2003. 
Adenovirus BMP-2 Adipose-derived stem 
cells 
Ectopic intramuscular site in 
SCID mice 
Dragoo et al., 
2003. 
Adenovirus BMP-2 Adipose-derived stem 
cells 
Critical-sized femoral defect 
in athymic rats 
Peterson et al., 
2005. 
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vivo 13, 14, 17, 18, 114.  Although results in animal studies are promising, it is still unknown if 
BMSC transplantation will induce an osteogenic response robust enough to heal critical-
sized bone defects in humans.   
Ex vivo gene therapy strategies, such as the ones discussed above, have further 
enhanced the bone healing capacity of bone marrow-derived osteogenic cells (see Table 
2.2 for representative examples).  Yet, the clinical use of these precursors is still hindered 
by their complex and painful cell procurement process 115, potential for dedifferentiation 
during in vitro expansion, low frequency in healthy marrow 111, 116, and reduced 
mineralization capacity associated with increased age and disease-state of the donor 16, 19.  
These limitations leave a pressing need for alternative cell source options for bone 
regeneration.   
Genetic engineering strategies have been employed for the differentiation of non-
osteogenic cells, such as fibroblasts and skeletal myoblasts, into a mineralizing 
osteoblastic phenotype (see Table 2.3 for selected examples).  Rat dermal fibroblasts 
transduced with adenoviral vectors encoding for either BMP-2 or BMP-7 form significant 
amounts of bone in both ectopic implantation sites and critical sized defects 21, 24, 25.  
Furthermore, Ad-BMP-7-expressing human gingival fibroblasts induced osteogenic 
differentiation in vivo after subcutaneous implantation in immunocompromised animals 
25. Importantly, an assessment of fibroblast fate after implantation revealed that 
genetically engineered fibroblasts directly differentiate into osteoblast-like cells and 
secrete osteoinductive factors which stimulate mineral deposition by host cells.  In a 
separate study, skeletal myoblasts engineered to overexpress BMP-2 with a retroviral 
vector deposited significant amounts of ectopic mineralization after intramuscular 
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implantation into the hind limbs of immunocompetent syngeneic mice 117.  Finally, an ex 
vivo strategy based on buffy coat cells derived from peripheral blood has successfully 
induced spinal fusion in animal studies 118.  This particular approach is attractive for 
therapeutic use because cells are harvested, transected, and re-implanted during the same 
operation.  Overall, non-osteogenic cell sources have promising clinical relevance 
because they are easily obtained in large quantities by minimally invasive biopsy from 
autologous donors. 
More recently, osteocompetent stem cell populations have been isolated from 
muscle tissue and human liposuction aspirates 119-123.  Huard and colleagues showed that 
muscle-derived stem cells (MDSCs) transduced with a BMP-4 retroviral vector induce 
orthotopic bone formation in rat critical-sized calvarial and femoral defects 124, 125.  
Importantly, robust mineral production by these allogenic MDSCs was observed in 
immunocompetent animal models despite the presence of CD4+ and CD8+ lymphocytes.  
Moreover, an analysis of cell fate suggested that genetically engineered MDSCs 
differentiate down the osteogenic lineage to directly contribute to bone repair and secrete 
osteoinductive factors which promote mineral deposition by host cells.  In a separate 
approach, adipose-derived mesenchymal progenitors transduced with a BMP-2 
adenovirus formed bone in vivo after implantation into the hind limb of SCID mice 126.  
Moreover, these BMP-2-expressing cells also healed critical sized defects in 
immunodeficient rats, while unmodified liposuction aspirate control cells did not 
mineralize 127.  Adipose-derived stem cells are particularly advantageous because a large 
amount of autologous tissue can be harvested from various anatomic locations with 
minimal donor site morbidity and negligible loss of some critical function to the host.   
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The optimal cell source for gene therapy-based bone repair strategies has not been 
determined.  A comparative study conducted by Gugala et al. suggested that bone healing 
efficacy is independent of cell type 128.  In this report, no significant difference in ectopic 
in vivo mineralization capacity was observed between BMSCs, primary dermal 
fibroblasts, and a human diploid fetal lung cell line transduced with a BMP-2-expressing 
adenoviral vector.  However, these investigators did observe a marked difference in bone 
formation due to the type of viral delivery vector and the subsequent amount of the 
osteoinductive factor produced 128.  In contrast, Rose et al. reported that BMP-4-
expressing muscle-derived stem cells form significantly more bone in critical-sized 
femoral defects compared to BMP-4-expressing BMSCs  129.  It is clear from these 
conflicting results that additional comparative studies will be necessary to determine the 
relative potency of these osteoblastic and nonosteoblastic cell-types for bone 
regeneration.  Nevertheless, beyond requirements for osteoinductive potency, the ideal 
cell source for ex vivo gene therapy strategies would be easily harvested with minimal 
donor site morbidity, available in large quantities, and susceptible to genetic 
manipulation by gene transfer vectors.  In general, autologous cells would be preferred in 
order to minimize potential host immune response. Studies characterizing cell fate after 
implantation and the cellular origin of bone formation will become increasingly 
important in the clinical application of these strategies to human bone defects.   
 
Target Genes 
As evidenced by the above discussion, gene therapy strategies based on soluble 
growth factors, such as BMP-2, BMP-4, and BMP-7, have been successfully applied to 
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augment bone formation in preclinical animal models.  Despite promising results, the 
clinical feasibility of these growth factor-based gene therapy approaches may be 
hampered by complex release kinetics and unregulated, ectopic bone formation caused by 
paracrine signaling to neighboring non-osseous tissues.  The delivery of downstream 
transcriptional activators has been extensively explored to address these limitations.  In 
particular, overexpression of genes encoding LIM mineralization protein-1 (LMP-1), 
Runx2/Cbfa1, and Osterix have been explored in various cell-types for their bone 
regenerative potential 67, 118, 130, 131, 131, 132.  
 In contrast to growth factor-based therapies, which have been administered as 
recombinant proteins or genetic sequences, most attempts to utilize transcription factors 
with an intracellular mode of action have involved the use of a genetic engineering 
approach.  LMP-1 is an intracellular protein which has been shown to induce secretion of 
soluble factors such as BMP-2, BMP-4, BMP-6, and BMP-7 133.  Adenoviral 
overexpression of LMP-1 in buffy coat cells successfully induced spinal fusion in rodents 
and rabbits 118, 134.  In a different approach, we and others have demonstrated that Runx2 
overexpression directs the differentiation of a wide range of osteogenic and non-
osteogenic cell-types toward an osteoblastic lineage in vitro 59, 66, 67, 135, 136.  Both transient 
and long-term expression of Runx2 in primary BMSCs enhances in vivo mineral 
deposition compared to unmodified BMSCs 137-139.  More recently, we have demonstrated 
that primary dermal fibroblasts transduced with a Runx2 retroviral vector create 
mineralized templates in vivo after implantation in a subcutaneous, heterotopic site 131.  In 
this report, Runx2-expressing fibroblasts co-localized with mineral deposits in vivo, 
suggesting that bone formation primarily originated from transplanted donor cells.   
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Finally, Tu et al. recently observed that retroviral gene delivery of Osterix enhances the 
mineralization capacity of primary bone marrow stromal cells in vitro, suggesting that 
this strategy may lead to stimulation of bone formation in vivo 140.   
In order to more closely mimic the signaling pathways involved in natural bone 
formation, several investigators have pursued strategies based on simultaneous delivery 
of multiple regenerative molecules.  Franceschi and colleagues investigated a 
combinatorial gene therapy approach based on the overexpression of multiple genes 
encoding osteoinductive growth factors.  Co-infection of murine embryonic fibroblasts 
with BMP-2/BMP-7 adenoviral vectors synergistically enhanced in vivo bone formation 
compared to overexpression of individual molecules alone 22.  Peng et al. investigated the 
ability of an angiogenic factor to promote blood vessel infiltration and cartilage formation 
during BMP-induced endochondral ossification 141.  Genetic modification of muscle-
derived stem cells with a combination of BMP-4 and vascular endothelial growth factor 
(VEGF) synergistically enhanced ectopic and orthotopic bone formation compared to 
BMP-4-expressing or VEGF-expressing cells alone.  Finally, the osteogenic potential of a 
combinatorial strategy based on co-expression of a soluble factor with a transcription 
factor has been recently evaluated.  Yang et al. reported that the C3H10T1/2 fibroblastic 
cell-line expressing Ad-BMP-2 and Ad-Runx2 synergistically induced subcutaneous 
bone formation compared to BMP-2-expressing or Runx2-expressing cells alone 23.  
Taken together, these results highlight the potential of combinatorial factor delivery as a 
strategy to enhance in vivo bone formation. 
Preliminary evidence suggests that BMP-2-based genetic engineering strategies 
may have a more potent osteoinductive effect in vivo than those based on Runx2 23, 24.  
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This heightened osteogenic response is likely due to paracrine signaling by BMP-2 cells, 
which may be absent or attenuated in Runx2-expressing cells.  As these strategies move 
forward, further characterization of the protein release profile and the threshold of factor 
delivery necessary to achieve efficacy in each scenario will be necessary.  In general, it is 
unlikely that one single target gene will be universally appropriate for the treatment of the 
numerous orthopaedic conditions requiring bone grafting.   
 
Rationale for Genetic and Tissue Engineering Strategies 
It is evident from the preceding discussion that the natural processes of skeletal 
development and fracture healing involve a complex spatiotemporal cascade of local and 
systemic factors.  These highly regulated signaling pathways result in an intricately 
designed osseous tissue containing multiple cell-types and extracellular matrix proteins 
woven together into a precise three-dimensional structure.  It is not currently well 
understood whether the optimal bone regenerative strategy must perfectly mimic the 
precise architecture and biochemical properties of native bone.  Indeed, it is likely that 
the degree of native tissue recapitulation will be dependent on the anatomic location of 
the defect and the level of damage to vasculature and progenitor cell populations within 
the host tissue bed surrounding the repair site.  For example, one could postulate that 
healing could be induced in certain applications by transplants which serve only as 
bridging scaffolds to support mechanical function temporarily, to initiate the endogenous 
healing response, and then be eventually remodeled and replaced by endogenous bone.  
Nevertheless, it is likely that the complex biomolecular organization of endogenous 
skeletal tissue cannot be achieved by the delivery of a single dose of recombinant protein 
to the repair site in a poorly-controlled manner.  Even after the development of an 
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optimal protein delivery vehicle has been realized, recombinant growth factor-based 
approaches may still be insufficient to induce an adequate osteogenic response in patients 
with compromised tissue beds because they require the presence of an endogenous cell 
population capable of osteogenic differentiation.  Gene transfer technologies may enable 
the design of therapies which result in bone tissue that more closely mimics the complex 
spatial and temporal cascade of proteins involved in bone formation.  In theory, the 
temporally-regulated delivery of genetic sequences encoding a combinatorial group of 
osteoinductive factors would be capable of an enhanced osteogenic response compared to 
a single bioactive factor or cell-based approach alone. Furthermore, combinatorial gene 
therapy strategies would have advantages over combinatorial protein delivery strategies 
because they may avoid issues such as high cost, toxic protein doses, short factor half-
life, and suboptimal delivery vehicles.  Finally, it is important to note that the biomaterial 
delivery vehicle or matrix supporting cell delivery/activity plays an important role in 
modulating the efficacy of these genetic engineering approaches and providing a 
structural role in the healing response.  A thorough discussion of these biomaterial-
related considerations is beyond the scope of the present literature review.    
 
Biological and Synthetic Ligament Grafts  
Ligaments are densely organized, fibrous connective tissues that are primarily 
responsible for the attachment of two or more bones across a joint.  The ligaments which 
connect the femur to the tibia stabilize the knee against abnormal translational and 
rotational motion and are particularly susceptible to sports-related traumatic injury 142.  
Partial tears or full rupture of the anterior cruciate ligament (ACL) and/or the medial 
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collateral (MCL) ligament account for over 90% of all knee ligament injuries 143.  The 
MCL has a propensity for spontaneous repair due to its high vascularity 144, 145.  However, 
the biochemical composition and extracellular matrix organization of this healing tissue 
is significantly different than native MCL, resulting in suboptimal mechanical properties 
for up to 2 years after injury 146, 147.  In contrast, surgical intervention is typically required 
to restore ACL function, which has limited healing capacity because it is poorly 
vascularized and surrounded by synovial fluid 148.   
Over 100,000 ACL reconstructions are performed each year in the United States 
with an estimated cost totaling over $5 billion dollars 149, 150.  Autologous hamstring 
tendon or patellar tendon grafts with bony attachments on the proximal and distal ends 
represent the most common reconstruction materials.   Procedures based on these 
autografts are considered the gold standard in ligament repair, but are associated with 
side effects such as donor site morbidity, pain, tendonitis, arthritis, and the formation of 
restrictive scar tissue 151.  Allogenic tissue derived from the achilles tendon has shown a 
comparable clinical outcome to autogenic tendon in some cases, but has disadvantages 
for the risk of disease transmission, limited tissue supply, and inadequate mechanical 
properties 152.  Finally, approaches based on engineered synthetic grafts (e.g. Leeds-Keio 
polyethylene terephthalate, polypropylene-based Kennedy ligament augmentation device 
(LAD), polyester (Dacron), polytetrafluoroethylene (Gore-Tex), and multifilament or 
braided collagen fibers have also been explored 149, 153.  Many of these synthetic grafts 
have shown a high rate of mechanical failure when used for primary ACL repair.  This 
tissue failure has been attributed to multiple factors, including suboptimal tissue 
anchorage to bone, inability to support tissue ingrowth and remodeling, and generation of 
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particulate matter due to prostheses abrasion and wear 144.   Beyond the selection of a 
grafting template, even reconstructions which fully restore tissue function involve an 
extensive rehabilitation process that can take from 4 months up to 3 years 142, 154. 
 
Ligament Anatomy and Biochemistry 
Human ligaments display complex time- and history-dependent viscoelastic 
behavior that is highly dependent on the biochemical composition and microstructure of 
the extracellular matrix.  Most ligament tissues consist of 65-80% water and 20-35% 
solids such as collagen, decorin, elastin, and fibronectin 148.  The majority of collagen 
within this matrix is the type I isoform, but types II, III, V, IX, X, XI, and XII have also 
been detected depending on the species, age, and disease state of the animal model 155.  
Collagen fibrils are densely packed into a crimped pattern within fasicular subunits, 
which are arranged in parallel to the long axis of the ligament into a higher order 
structure of functional bands.  Heterogeneous zones of ligament, fibrocartilage, 
mineralized fibrocartilage, and bone are found at the transitionary region between bone 
and soft tissue.  The collagen structure shifts toward a more helical and/or non-parallel 
orientation in this bone-ligament interface in order to avoid the formation of stress 
concentrations that may lead to failure during loading.  Populations of fibroblasts are 
interspersed throughout the matrix and function in tissue remodeling, adaptation, and 
healing.  Ultimately, the structural arrangement of these biochemical constituents gives 
the human ACL an average tensile strength of 1730 N, an average linear stiffness of 182 
N/mm, and an average energy absorbed at failure of 12.8 N-m.  It is the inability of most 
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grafting templates to mimic the complex geometry and stress-strain behavior of native 
ligament tissue that eventually leads to mechanical failure 149.   
 
Growth and Differentiation Factors in Ligament Repair 
Specific growth factors, including platelet derived growth factor (PDGF), 
epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), transforming 
growth factor beta (TGF-β), and insulin-like growth factor (IGF-I), have altered 
expression levels following ligament injury 156-158.  Furthermore, in vitro studies have 
demonstrated that many of these proteins specifically modulate migration, proliferation, 
and/or matrix deposition by ligament fibroblasts 159.  In particular, fibroblast proliferation 
is stimulated by EGF, IGF-I, bFGF, or PDGF-BB, while TGF-β regulates collagen 
deposition by these cells 160-162.  Additionally, both PDGF-BB and TGF-β are 
chemoattractants which stimulate fibroblast migration through ligament tissue 163.  Direct 
administration of recombinant PDGF has been reported to significantly improve the 
mechanical properties of healing ligament tissue 164.  In contrast, conflicting reports exist 
regarding local delivery of TGF-β, which has shown isoform- and concentration-
dependent enhancement in the healing of rabbit MCL tissue 165-167.  More recently, 
combinatorial delivery of both TGF-β1 and EGF has been shown to improve MCL 
healing in canines 168.  Despite promising results in preclinical animal models, these 
recombinant protein-based therapies are limited by suboptimal delivery vehicles, rapid in 
vivo protein degradation, and cost-prohibitive supraphysiologic concentrations.  Because 
of these complications, gene therapy and tissue engineering strategies have been pursued 
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as an alternative strategy for the sustained delivery of therapeutic proteins to the 
compromised tissue site 155, 169. 
 
Gene Therapy Approaches to Ligament Repair 
Reporter Gene Delivery to Ligament and Tendon 
The feasibility of both in vivo and ex vivo gene transfer to ligament and/or tendon 
tissue has been investigated in a variety of animal models 170.  Because the signaling 
pathways involved in ligament healing are poorly understood, the majority of these 
approaches have focused on proof-of-principle studies involving delivery of a reporter 
gene.  Gerich et al. isolated fibroblasts from ACL, PCL, MCL, patellar tendon and 
semitendinosus tendon tissue harvested from New Zealand white rabbits 171, 172.  All five 
cell types were reported to be susceptible to transduction in vitro with both a first 
generation adenoviral vector and a retroviral vector encoding for the β-galactosidase 
(LacZ) gene.  In vivo gene delivery of this LacZ adenovirus via direct injection into the 
patellar tendon of New Zealand white rabbits resulted in a limited level of LacZ 
expression adjacent to the site of delivery 171, 173.  In a separate approach, Huard and 
colleagues genetically engineered an autologous semitendinosus tendon graft with 
adenovirus-LacZ or adenovirus-luciferase in vitro 174.  Reporter genes were detected 
around the periphery of this tissue for 6 weeks in vitro, suggesting that fibroblasts could 
be genetically modified in situ within the native three-dimensional environment 175.   
Finally, Lou et al. found that in vivo transduction efficiency after injection into chicken 
tendon and tendon sheath was highly dependent on the titer of LacZ adenovirus 176.  
Positive staining was observed for up to 75 days in vivo, suggesting that the host immune 
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response against adenoviral vectors may not be as robust in certain connective tissues 
compared to most highly vascularized tissues.  Moreover, the observed confinement of 
the virus to the tissue periphery suggested that the collagenous composition and structure 
may serve as a barrier against plasmid penetration into the center of certain connective 
tissues 177.   
An ex vivo approach was explored by Gerich et al. in which allogenic primary 
tendon fibroblasts were genetically engineered with a LacZ retroviral vector and 
implanted directly into the patellar tendon of healthy New Zealand White rabbits171.  
Notably, a significantly higher number of LacZ-expressing fibroblasts were detected after 
6 weeks in vivo with this cell-based approach compared to direct injection of virus 171.  
These results were corroborated by a study by Menetrey et al. where myoblasts and ACL-
derived fibroblasts were infected with an adenoviral vector encoding LacZ and 
transplanted into healthy ACLs of adult rabbits.  Transgene expression was detected for 
up to 21 days with this ex vivo approach, while direct injection of adenoviral particles 
resulted in marker gene expression through 42 days 178.  In order to determine if this 
strategy would be technically feasible for the healing of injured ligaments, Woo and 
colleagues implanted allogenic LacZ-expressing fibroblasts into a ruptured MCL in 
skeletally mature rabbits, while the contralateral controls received saline injections 179.  
Importantly, LacZ expression was upregulated at comparable levels in both ruptured and 
unruptured MCL tissue compared to control tissue, suggesting that transduction is 
independent of the injury state of the ligament.  Results from this study indicate that 
natural ligament healing process may not disrupt expression of an exogenously delivered 
transgene. 
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 In Vivo Gene Therapy for Ligament and Tendon Repair 
The studies discussed above demonstrated that in vivo and ex vivo techniques can 
be used to maintain expression of an exogenous transgene for up to 8 weeks in preclinical 
animal models.   Techniques optimized in these proof-of-concept studies have been 
utilized by some investigators to study the effects of therapeutic molecules gene delivery 
on ligament and/or tendon healing 180.  Lou et al. used an in vivo gene transfer strategy 
based on direct injection of adenoviral vectors encoding for sense and antisense focal 
adhesion kinase (FAK) into the tendon and tendon sheath of White Leghorn chickens.  
Tendons overexpressing FAK showed an increase in adhesion formation compared to 
unmodified and antisense FAK-expressing controls, suggesting that this molecule may 
have a critical role in regulating the formation of restrictive tendon adhesions during 
tissue healing 181.   More recently, Manske and colleagues reported that adenovirus-
mediated gene delivery of BMP-12 into primary chicken tendon cells increased type I 
collagen synthesis in vitro 182.  Ad-BMP-12 was directly injected into a completely 
lacerated toe tendon in White Leghorn chickens.  Tendons expressing BMP-12 displayed 
a two-fold increase in tensile strength and stiffness compared to controls expressing a 
reporter gene, suggesting that BMP-12 enhances mechanical properties of healing 
tendons in vivo 183.  Finally, Nakamura et al. investigated the direct injection of 
hemagglutinating virus of Japan (HVJ)-conjugated liposomes containing PDGF-BB 
cDNA into injured patellar ligament in Wistar rats 184.  PDGF expression was detected 
around the wound for up to 4 weeks after injection.   Overexpression of this protein 
enhanced angiogenesis at early time points (7 days) and stimulated collagen I matrix 
deposition and organization at late time points (28 days) compared to control ligaments 
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expressing HVJ-liposomes without DNA 185.  Taken together, these studies suggest that 
in vivo gene transfer of a therapeutic molecule may be a promising strategy for the 
functional repair of injured ligament tissue.   
 
Ex Vivo Gene Therapy for Tendon Repair 
The use of ex vivo genetic engineering techniques for the delivery of therapeutic 
transgenes to ligament tissue has not been reported to the best of the authors’ knowledge.  
However, advances have been made in the application of ex vivo gene therapy strategies 
toward tendon repair.  Gazit and colleagues have recently reported a novel approach 
based on transient transfection of the mesenchymal progenitor C3H10T1/2 cell line in 
vitro with cDNA encoding the Smad8 transcription factor 186.  Notably, co-expression of 
Smad8 and BMP-2 inhibited osteogenesis and promoted differentiation toward a 
tenocyte-like phenotype in vitro compared to BMP-2- or Smad8-engineered cells alone.  
Importantly, in vivo implantation of these Smad8/BMP-2-expressing C3H10T1/2 
progenitor cells resulted in the formation of ectopic tendon tissue in mice and the 
induction of tissue repair in an Achilles tendon partial defect in rats 187.  This landmark 
study highlights the potential of ex vivo gene therapy for repair of tendon/ligament 
connective tissue.  Future advances in the understanding of the signaling pathways 
involved in this healing process will likely drive the identification of novel therapeutic 
targets for ligament regeneration.   
 
 Antisense Gene Therapy for Connective Tissue Repair 
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Previous research has demonstrated that healing ligaments often develop scar 
tissue with different biochemical constituents and inferior mechanical properties to native 
tissue.  More specifically, scar tissue has been reported to have elevated content of the 
proteoglycan decorin, enhanced fibronectin and type III collagen expression, decreased 
type I collagen levels, decreased collagen fibril diameter, and abnormal collagen 
organization and cross-linking compared to native tissue 188-192.  The presence of this scar 
tissue increases the probability of ligament re-injury and/or the development of arthritis 
within the knee joint.  Notably, reports have shown that the diameter of collagen fibrils is 
directly proportional to ligament tissue mechanical properties and may be negatively 
regulated by decorin and type V collagen 193, 194.  Nakamura et al. developed an in vivo 
gene therapy method based on HVJ-liposome-mediated delivery of inhibitory antisense 
oligodeoxynucleotides (ODNs) against decorin to specifically block mRNA and protein 
expression of this proteoglycan in a rabbit MCL gap injury model 195-197.  Overexpression 
of decorin antisense increased the mechanical properties and collagen fibril diameter of 
MCL scar tissue compared to sense and empty HVJ-liposome treated ligaments.  In 
addition, Woo and colleagues investigated a similar approach for reducing scar tissue 
formation based on antisense ODNs against type III collagen and the type V procollagen 
alpha1 chain 198, 199.  These investigators identified sequences which would efficiently 
suppress types III or V collagen in human patellar tendon fibroblasts in vitro and have 
proposed experiments to test these sequences in vivo 200.  Taken together, these 
preliminary studies indicate that antisense gene therapy may improve the biochemical 
and mechanical properties of healing ligament tissue.   
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Tissue Engineering Approaches for Ligament Repair 
          Tissue engineering has recently emerged as a promising alternative strategy to 
address the limitations associated with conventional ACL reconstruction procedures.  In 
this approach, cells and/or bioactive growth factors are combined with polymeric 
scaffolds to produce ligament grafting templates. Because the ligament serves as a 
structural tissue, research efforts to date have focused heavily on the development and 
optimization of scaffolds based on collagen, silk, synthetic polymers, and/or a composite 
blend 149, 201-204.  More recently, investigators have discovered that the cellular phenotype 
and extracellular matrix organization also play an essential role in mimicking the 
complex structure-function relationship of native tissue.  For this reason, cellular 
therapies based on bone marrow-derived mesenchymal stem cells (MSCs) have also been 
investigated for their ligament healing capacity in preclinical animal models 15, 149, 159, 205-
210.  Mechanical loading regimes and tissue bioreactors have also been developed for the 
manipulation of matrix organization in vitro211-214.   
 
Genetic and Tissue Engineering for Enhanced Soft Tissue Graft Osseointegration 
        Investigators have also pursued gene therapy and tissue engineering strategies to 
improve the integration of autologous tendon grafts into the surrounding bone at the 
bone-tendon interface.  Huard and colleagues reported an ex vivo approach based 
replacement of the ACL in New Zealand white rabbits with an autologous double-bundle 
semitendinosus tendon graft 215.  These grafts were explanted and genetically engineered 
in vitro with adenoviral vectors encoding BMP-2, luciferase, or LacZ before in vivo 
implantation.  Histological analysis of Ad-BMP-2-transduced grafts revealed evidence of 
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mineral, mineralized cartilage, and nonmineralized fibrocartilage tissue at the tendon-
bone interface, while control grafts (unmodified, LacZ-expressing, luciferase-expressing) 
deposited a dense matrix resembling Sharpey fibers.  BMP-2-expressing grafts also 
displayed enhanced mechanical properties compared to control tendons 216.  This study 
demonstrated that gene delivery of BMP-2 can enhance osseointegration of tendon grafts 
used for ACL reconstruction.  More recently, alternative strategies based on the design of 
multi-phase scaffolds or the integration of multiple cell types (i.e. osteoblasts, fibroblasts, 
chondrocytes) into a single scaffold have been explored for the generation of interfacial 
bone-soft tissue zones 217-219.     Overall, the tissue engineered ligament grafts which are 
currently available continue to be limited by failure at the bone-tendon insertion site and 
inadequate mechanical properties, suggesting that genetic engineering techniques could 




RUNX2-GENE THERAPY IN COMBINATION WITH 
DEXAMETHASONE TREATMENT SYNERGISTICALLY INDUCES 




It is well documented that adenoviral and retroviral gene delivery of Runx2 
upregulates osteogenic gene expression in osteoblastic and non-osteoblastic cell types 59, 
66, 67, 137.   However, we and others have reported that forced Runx2 expression induces 
matrix mineralization in a cell type-dependent manner and is insufficient to direct 
significant in vitro nodule formation in NIH3T3 and IMR-90 fibroblasts, primary murine 
fibroblasts, and the C3H10T1/2 pluripotent fibroblastic cell line 23, 24, 66.  These results 
suggested that Runx2-mediated mineralization requires additional cofactors, which may 
not be endogenously expressed in certain nonosteoblastic cells.    In this study, primary 
dermal fibroblasts were genetically engineered to constitutively express the Runx2 type II 
isoform and cultured in differentiation media supplemented with and without 10 nM 
DEX.  We hypothesized that the putative signaling pathways necessary for mineralization 
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Materials and Methods  
Cell Culture and Reagents 
Primary fibroblasts were harvested from 8- to 16-week-old male Wistar rats by  
enzymatic digestion of the dermal skin layer 220.  Cells were expanded in growth media 
consisting of DMEM, 10% fetal bovine serum, and 1% penicillin-streptomycin.  
Antibiotics and cell culture media were obtained from Invitrogen (Carlsbad, CA), fetal 
bovine serum was purchased from Hyclone (Logan, UT), and all other cell culture 
supplements and reagents were acquired from Sigma Chemical Company (St. Louis, 
MO).   
 
Retroviral Transduction 
The Runx2 retroviral vector utilizes the promoter activity of a 5’ long terminal 
repeat to express a single, bicistronic mRNA encoding the murine cDNA for the type II 
MASNSLF Runx2 isoform, followed by an internal ribosomal entry site and a Zeocin 
resistance-enhanced green fluorescent fusion protein.  Plasmid DNA was purified from 
transformed E. coli using Megaprep kits from Qiagen (Valencia, CA).  Retroviruses were 
packaged by transient transfection of helper-virus free ΦNX amphotropic producer cells 
with plasmid DNA as described elsewhere 66.  ΦNX cells were cultured in growth media 
(DMEM, 10% fetal bovine serum, 100 U/ml penicillin G sodium, 100 µg/ml 
streptomycin sulfate) in a humidified 5% CO2 atmosphere at 37 °C and plated 9 x 104 
cells/cm2 24 h prior to transfection. Cells were transfected with 0.5 µg/cm2 of plasmid 
DNA, either Runx2 or empty vector (no Runx2 insert), using calcium phosphate 
coprecipitation and 25 µM chloroquine for 8-12 h prior to refeeding with fresh growth 
media. Twenty-four hours after the start of the transfection, media was replaced with 
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fresh growth media and dishes were transferred to a humidified 5% CO2 atmosphere at 
32 °C for enhanced stability of retroviral particles.  Retroviral supernatants were 
collected at 48, 60, and 72 h post-transfection, filtered through a 0.45 µm cellulose 
acetate filter, aliquoted, snap frozen, and stored at -80 °C until use.  
Passage four primary fibroblasts were plated on 6-well tissue culture polystyrene 
plates coated with 0.1% type I collagen (Vitrogen, Palo Alto, CA).  Cells at 50-70% 
confluence were transduced with retroviral stocks and maintained in differentiation media 
consisting of DMEM, 10% fetal bovine serum, 100 U/ml penicillin G sodium, 100 µg/ml 
streptomycin sulfate, 50 µg/ml L-ascorbic acid, 2.1 mM sodium β-glycerophosphate, and 
with or without 10 nM DEX 66.   Tissue culture media was changed every 2 days until 
end-point assay.  No differences were observed between empty vector retrovirus 
(negative control) and unmodified cells in all experiments.  Runx2-transduced cells were 
analyzed for transduction efficiency by quantification of eGFP expression via flow 
cytometry.  High levels of eGFP were detected in ≥ 65% of primary dermal fibroblasts at 
72 hours post-transduction.   
 
Real Time RT-PCR 
Total RNA was isolated at 1, 3, and 7 days post transduction using the RNeasy 
RNA isolation kit (Qiagen). cDNA synthesis was performed on DNaseI-treated (27 
Kunitz units/sample) total RNA (1 µg) by oligo(dT) priming using the Superscript™ First 
Strand Synthesis System for RT-PCR (Invitrogen). Real-time PCR using SYBR Green 
intercalating dye was performed with the ABI Prism 7700 Sequence Detection System 
(Applied Biosystems, Foster City, CA, 40 cycles, melting: 15 sec at 95ºC, annealing and 
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extension: 60 sec at 60ºC)24. Real-time PCR oligonucleotide primers (Table 3.1) were 
designed using ABI Primer Express software and purchased from IDTDNA (Coralville, 
IA). Primer specificity was confirmed by agarose gel electrophoresis and ABI Prism 
7700 Dissociation Curve Software. Standards for each gene were amplified from cDNA 
using real-time oligonucleotides (Table 3.1), purified using a Qiagen PCR Purification 
kit, and diluted over a functional range of concentrations. Transcript concentration in 
template cDNA solutions was quantified from a linear standard curve, normalized to 1 µg 
of total RNA, and expressed as femtomoles of transcripts per µg of total RNA. Detection 
limits for each gene were determined by reactions without cDNA and were at least an 
order of magnitude below the most dilute sample. 
 
Western Blotting 
Cells were washed with PBS and lysed in cold radioimmunoprecipitation assay 
(RIPA) buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 
150 mM Tris-HCl pH 7.2, 350 µg/ml phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 
10 µg/ml aprotinin, and 1 mM sodium orthovanadate) for 20 min.  Lysates were pipetted 
up and down ~25 times to shear the DNA and then clarified by centrifugation at 10,000g 
for 10 min.  Protein concentration was then determined using a Micro BCA protein assay 
kit (Pierce, Rockford, IL).  Equal amounts of protein (25 µg) were boiled in Laemmli 
sample buffer (2% SDS, 10% glycerol, 100 mM DTT, 60 mM Tris-HCl pH 6.8, and 
0.001% bromophenol blue) for 10 min and separated by SDS-PAGE.  Proteins were 
transferred by electrophoresis onto nitrocellulose membranes and blocked with Blotto 
(5% non-fat dry milk, 0.02% sodium azide, 0.2% Tween 20 in PBS w/o Ca2+/Mg2+) 
 42
overnight at 4ºC.  Membranes were then incubated with 1 µg/ml anti-AML3 (Oncogene, 
San Diego, CA) or 9 µg/ml anti-GAPDH (Chemicon, Temecula, CA) in Blotto for 1 h at 
room temperature under gentle rocking.  Membranes were washed in TBS-Tween (20 
mM Tris HCl pH 7.6, 137 mM NaCl, 0.1% Tween 20) for 30 min and incubated in 
secondary antibody (biotin-conjugated anti-rabbit/mouse IgG, 1:20,000 dilution in Blotto, 
Jackson ImmunoResearch, West Grove, PA) for 1 h at room temperature.  Membranes 
were washed again in TBS-Tween for 30 min and incubated in tertiary antibody (alkaline 
phosphatase-conjugated anti-biotin IgG, 1:10,000 dilution in Blotto, Sigma) for 1 h at 
room temperature. After antibody incubation, membranes were washed in TBS-Tween 
for 30 min and immunoreactivity was detected using ECF fluorescent substrate 
(Amersham Bioscience, Piscataway, NJ) and a Fuji Image Analyzer. 
 
Alkaline Phosphatase Biochemical Activity 
As a marker of osteoblastic enzyme activity, alkaline phosphatase (ALP) activity 
was quantified at 7 days post-transduction as previously described24. Cells were rinsed 
and scraped into ice-cold 50 mM Tris·HCl, pH 7.4. Following sonication and 
centrifugation, total soluble protein concentration was quantified using the MicroBCA 
Protein Assay Kit. Equal amounts of protein (2.5 µg) were added to 60 µg/mL 4-
methylumbelliferyl-phosphate fluorescent substrate in diethanolamine buffer (pH 9.5).  
Following incubation for 60 min at room temperature, the fluorescence was read at 360 
nm excitation/465 nm emission on an HTS 7000 Plus BioAssay Reader (Perkin Elmer, 
Norwalk, CT). Enzymatic activity was standardized using purified calf intestinal alkaline 
phosphatase (Sigma) and normalized to total protein concentration. 
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von Kossa Histochemical Analysis 
Cultures were fixed in 70% ethanol at 14 and 21 days and examined 
histochemically for mineralized matrix by von Kossa staining for phosphate deposits.  
Plates were stained with 5% AgNO3 under uniform light exposure for 30 min, fixed in 
5% Na2SO3 for 2 min, and air-dried. Mineralized surface area was quantified by 
automated capturing and averaging of twenty-four representative 2X images using Image 
Pro analysis software. 
 
FTIR Spectroscopy 
Cell culture samples at 21 days post-transduction were fixed in 100% ethanol, 
craped from the culture dish, and dried at 50ºC overnight. Bone samples were scraped 
from a lyophilized rat cranium. Bulk samples were mixed with KBr (Sigma) and pressed 
into pellets. Samples were analyzed with a Nicolet Nexus 470 FTIR spectrometer 
ThermoNicolet, Madison, WI) equipped with a DTGS detector. 64 scans were acquired at 
4 cm-1 resolution under N2 purge. 
 
Data Analysis 
Unless otherwise stated, experiments were performed at least three times in 
triplicate, each with unique Runx2 retroviral supernatant preparations, and two 
independent fibroblast isolates.  No differences were observed between unmodified and 
empty vector transduced cells in all assays.  Data are reported as mean ± standard error of 
the mean (SEM), and statistical comparisons using SYSTAT 8.0 were based on an 
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analysis of variance (ANOVA) and Tukey’s test for pairwise comparisons within 
timepoints, with a p-value < 0.05 considered significant.  In order to make the variance 
independent of the mean, statistical analysis of real-time PCR data was performed 
following logarithmic transformation of the raw data 66. 
 
Results 
Dex enhances Runx2-induced osteoblastic gene expression 
In order to assess the effects of DEX on Runx2-mediated osteogenesis in the 
absence of native osteoblastic signals, primary dermal fibroblasts were genetically 
engineered to constitutively express the Runx2 type II isoform and cultured in 
differentiation media supplemented with and without 10 nM DEX.  We hypothesized that 
a combination of forced Runx2-expression and DEX supplementation would induce 
osteoblastic differentiation in primary dermal fibroblasts.  Skeletal gene expression was 
investigated at 1, 3, and 7 days post-transduction by quantitative RT-PCR (Fig. 3.1).  
Runx2 mRNA levels were upregulated by 2 orders-of-magnitude in transduced cultures 
compared to control cells at day 3, and this relative difference decreased to one order-of-
magnitude as cells reached confluence at day 7.  eGFP transgene expression was 
detectable by flow cytometry through 21 days, demonstrating integrated and sustained 
expression of the Runx2 transgene.  Runx2 primers utilized in this study 137 were 
designed to detect both type I and type II Runx2 isoforms 221, 222.  Thus, the absence of 
Runx2 mRNA transcripts in untransduced cultures indicates that the Runx2 type II 
isoform is the predominant isoform expressed in transduced cultures.  Osteocalcin (OCN) 

















Figure 3.1.  DEX enhances Runx2-induced osteoblastic gene expression.   Primary 
dermal fibroblasts were transduced with Runx2 or empty vector retrovirus and cultured in 
osteogenic media with and without 10 nM DEX.  mRNA expression was investigated by 
quantitative RT-PCR at 1, 3, and 7 days post-transduction (Mean + SEM, n=16; 
ANOVA: p<1E-11; * different from empty vector control, ** different from empty 
vector and DEX controls, and †different from Runx2 (p< 0.05)).  Relative gene 
expression is expressed on a logarithmic scale.  Detection limits for each gene were 
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of mature osteoblasts 223.  Bone sialoprotein (BSP) and osteopontin (OPN) are 
extracellular matrix glycoproteins implicated in the regulation of mineralized nodule  
nucleation 224.  BSP mRNA levels were upregulated by 3 orders-of-magnitude in Runx2-
transduced cells, while OCN and OPN demonstrated a 10-fold increase at 7 days post-
transduction compared to control cultures.  Notably, addition of DEX to Runx2- 
expressing cultures resulted in significant enhancements in OCN, BSP, and OPN mRNA 
levels at days 3 and 7 compared to untreated Runx2-expressing cultures.  DEX 
supplementation alone significantly increased OPN mRNA compared to untreated 
controls, but had no effect on Runx2, OCN and BSP mRNA levels.  These results 
demonstrate that sustained expression of Runx2 upregulates osteoblastic gene expression 
and treatment with DEX enhances this effect.     
 
Runx2 and DEX synergistically induce osteoblastic differentiation 
 Alkaline phosphatase (ALP) is a membrane-bound enzyme that hydrolyzes 
phosphate esters, thereby making inorganic phosphate available for incorporation into 
mineral deposits 224.  The activity of this enzyme was examined at 7 days post-
transduction (Fig. 3.2A).  Runx2-overexpression stimulated a 15-fold increase in ALP 
activity compared to control cultures.  Moreover, addition of DEX to Runx2-transduced 
cultures resulted in a synergistic increase in ALP activity.  Matrix mineralization was 
assessed at 14 and 21 days post-transduction by von Kossa staining and image analysis 
(Fig. 3.2B,C).  Notably, co-treatment with Runx2 and DEX synergistically induced 
matrix mineralization in primary dermal fibroblasts, while Runx2-expressing cultures 
alone displayed minimal staining and sparse nodule formation.  No mineral was detected 
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in empty vector or DEX-treated control cultures.  FTIR spectroscopy was utilized to 
analyze the chemical composition of the mineral phase because osteogenic culture 
conditions can lead to non-biological calcium phosphate precipitation 225, 226.  (Fig. 3.2D).  
Runx2 and cranial bone samples displayed amide I and II peaks indicative of 
extracellular matrix proteins, an enhanced phosphate peak at 1100 cm-1, a doublet split 
phosphate peak at 560 and 605 cm-1, and a carbonate peak at 870 cm-1, which represent 
the characteristic bands of a carbonate-containing, poorly crystalline hydroxyapatite 227.  
These bands were absent in empty vector and DEX-only control cultures.  Collectively, 
these results demonstrate that a combination of constitutive Runx2 overexpression and 
DEX supplementation synergistically induces osteoblastic differentiation in primary 
dermal fibroblasts.   
 
Discussion 
Forced expression of Runx2 upregulates osteogenic gene expression in a variety 
of osteoblastic and non-osteoblastic cell types 59, 66, 67.  However, we and others have 
demonstrated that Runx2 overexpression induces matrix mineralization in a cell type-
dependent manner and is insufficient to produce significant levels of nodule formation in 
primary murine fibroblasts and fibroblastic cell-lines 66.  This suggests that Runx2-
mediated mineralization requires additional cofactors, which may not be endogenously 
expressed in non-osteoblastic cells.  In this study, dermal fibroblasts were analyzed for 
their osteogenic potential following retroviral gene delivery of Runx2.  We hypothesized 
that the putative signaling pathways necessary for mineralization in this non-osteogenic 
cell source can be activated by DEX.  We demonstrate that sustained expression of 
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Runx2 was necessary but not sufficient to promote terminal osteogenic differentiation in 
primary dermal fibroblasts and that DEX is required for robust matrix mineralization in 
this model system.  DEX synergistically enhanced BSP gene expression, ALP activity, 
and mineralization in Runx2-expressing cells, while hormone-only treated cultures 
exhibited minimal expression of these markers.  The absence of osteogenic phenotype 
expression in DEX-only treated cultures makes it unlikely that distinct subpopulations of 
DEX-responsive and Runx2-responsive cells cause the synergistic effect of DEX 
supplementation and Runx2-overexpression.  Overall, this data suggests that DEX 
induces osteogenesis by a Runx2-dependent molecular mechanism, but does not rule out 
the possibility of a Runx2-independent mode of action in this model system.     
Overall, these results demonstrate that a combination of constitutive retroviral 
Runx2-expression and treatment with the steroid hormone dexamethasone synergistically 
induces osteogenic differentiation in primary dermal fibroblasts cultured in monolayer.  
This surprising result suggests that Runx2-engineered primary dermal fibroblasts have 
the capacity to create mineralized templates for bone repair and may still have potential 
as a cell source for bone tissue engineering applications if exposed to the appropriate 
osteogenic cues.  Furthermore, the absence of osteoblastic phenotype in hormone-only 
treated cultures suggests that Runx2-transduced fibroblasts may represent a robust 
experimental model system for the investigation of Runx2-dependent molecular 
















Figure 3.2.  DEX and Runx2 synergistically induce osteoblastic differentiation.  
Primary dermal fibroblasts were transduced with Runx2 or empty vector retrovirus and 
cultured in osteogenic media with and without 10 nM DEX.   (A) ALP activity was 
examined by a biochemical assay at 7 days post-transduction (Mean ± SEM, n=12; 
ANOVA: p<1E-8; ** different from empty vector and DEX controls, and †different from 
Runx2 (p< 0.05)).  (B) Mineralized matrix deposition was assessed via von Kossa 
staining for phosphate-positive regions and (C) quantified by image analysis at 14 and 21 
days post-transduction (Mean ± SEM, n=12; ANOVA: p<1E-9, ** different from empty 
vector and DEX controls, and †different from Runx2 (p< 0.05)).  Scale bar 2 cm.  (D) 
Chemical composition of the mineral phase was analyzed by Fourier transform infrared 
spectroscopy.  Bone samples scraped from a lyophilized rat cranium served as a positive 
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GLUCOCORTICOID-INDUCED OSTEOGENESIS IS NEGATIVELY 
REGULATED BY RUNX2/CBFA1 SERINE PHOSPHORYLATION* 
 
Introduction 
Glucocorticoids (GCs) are steroid hormones secreted by the adrenal cortex that 
play a pivotal role in the regulation of a variety of developmental, metabolic, and immune 
functions.  The classic mechanism of GC action is primarily at the level of transcription, 
where the hormone forms a transcriptionally active complex with its cognate intracellular 
receptor.  This complex can either enhance or attenuate gene expression by binding to 
GC response elements in the promoter region of target genes or by non-covalently 
associating with additional co-regulatory proteins 228. 
Synthetic GC derivatives, such as dexamethasone (DEX), have complex 
stimulatory and inhibitory effects on skeletal metabolism and bone formation 229.  DEX is 
widely utilized at pharmacological doses for the treatment of inflammatory and 
autoimmune diseases.  However, long-term administration of this hormone has adverse 
side effects on the skeleton, inducing osteoporosis by impairing osteoblast activity 230.  
The mechanism(s) by which pharmacological doses of DEX induce bone loss include:  
(a) attenuated osteoblast proliferation 231, 232, (b) impaired collagen synthesis 233, (c) 
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and (e) downregulation of osteogenic gene expression 237.  In contrast to these catabolic 
effects, physiologic levels (10 nM) of DEX promote osteoblastic differentiation in vitro 
238, 239.  Furthermore, it has been recently demonstrated that GC signaling is required for 
normal bone volume and architecture in transgenic models, suggesting that endogenously 
expressed GCs may have an anabolic effect on skeletal metabolism and bone formation 
in vivo 240.  The mechanism(s) by which DEX promotes osteogenesis remain poorly 
understood, largely due to conflicting results associated with the various species and 
differentiation states of the model systems used to study this hormone in vitro 228, 241-246.   
Runx2/Cbfa1 (Osf2/AML3/PEBP2αA) is an essential transcriptional regulator of 
osteoblast differentiation and bone formation.  Homozygous deletion of Runx2 arrests 
osteoblast maturation, resulting in the absence of endochondral and intramembranous 
ossification 247.  Moreover, Runx2 haploinsufficiency causes the pathogenic skeletal 
phenotype cleidocranial dysplasia in mice and humans, characterized by short stature, 
hypoplastic clavicles, and dental abnormalities 62, 63.  Runx2 directs osteogenic 
differentiation by binding to OSE2 cis-acting elements in the promoter region of skeletal 
target genes and regulating their expression 59.  We and others have demonstrated that 
forced expression of Runx2 upregulates osteoblast-specific genes expression and induces 
mineralization in a cell type-dependent manner 24, 59, 66, 248.  Intriguingly, both postnatal 
disruption of Runx2 by dominant negative expression and overexpression of Runx2 from 
the pro-α (I) collagen promoter induces bone fragility and osteopenia in transgenic mice 
68, 69.  These studies collectively demonstrate that cellular regulation of Runx2 is critical 
for normal skeletal development and bone formation. 
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Runx2 is regulated at multiple levels by a complex spatiotemporal cascade of 
growth factors, hormones, transcription factors, and cell-matrix interactions 65, 221, 249, 250.  
In particular, DEX has differential effects on Runx2 mRNA transcript expression, protein 
levels, and DNA-binding activity depending on the species, osteogenic cell type, and 
culture conditions used to study this hormone in vitro 237, 243, 244.  These conflicting results 
suggest that DEX may regulate Runx2 by modulating its post-translational modification.  
The mitogen activated protein kinase (MAPK) pathway has been shown to phosphorylate 
Runx2 on residues within the C-terminal proline-serine-threonine-rich (PST) domain 64, 
251.  This increase in phosphorylation strongly correlates with enhanced Runx2 
transactivation and is stimulated by signaling via extracellular matrix, fibroblast growth 
factor-2, and mechanical loading 252-254.   In contrast, Wee and colleagues have reported 
that the activity of the human Runx2 type I isoform is negatively regulated by 
phosphorylation of two serine residues, Ser104 and Ser451 (corresponding to Ser125 and 
Ser472 in the murine type II Runx2 isoform) 255.  The putative signaling cascades or 
effector molecules that regulate these inhibitory phosphorylation events, as well as the 
functional significance of these residues, remain poorly understood.   
In the present study, we investigated the effect of DEX on Runx2 serine 
phosphorylation and the functional role of this phosphorylation state during osteoblastic 
differentiation.  Runx2-transduced primary dermal fibroblasts were utilized as the 
experimental model in order to investigate the Runx2-dependent molecular pathway(s) 
involved in DEX-mediated osteogenesis. This reconstituted model system allowed for the 
direct examination of DEX and Runx2 interactions in the absence of native osteoblastic 
components, such as endogenous Runx2 isoforms or Runx2-independent signaling 
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pathways, which may confound the analysis. We show that DEX induces osteogenesis, at 
least in part, by modulating the phosphorylation state of a negative regulatory serine 
residue (Ser125) on the Runx2 type II isoform.  We demonstrate that the phosphorylation 
state of this specific serine residue plays a critical role in both early osteoblastic 
differentiation and late stage mineralization induction.  Interestingly, the mutation of 
Ser125 to arginine, which possibly mimics the steric hindrance caused by phosphorylation 
of this residue, has been identified in a human patient with cleidocranial dysplasia 256.  
Thus, this work assists in elucidating a mechanism of GC-mediated osteogenesis and 
provides insights into the functional importance of Runx2 phosphorylation during 
skeletal pathogenesis.    
 
Materials and Methods 
Cell Culture and Reagents 
Primary fibroblasts were harvested from 8- to 16-week-old male Wistar rats by 
enzymatic digestion of the dermal skin layer 220.  Primary bone marrow stromal cells 
(BMSC) were harvested from the femora of 8- to 16-week-old Wistar rats as described 
previously 137.    Cells were expanded in growth media consisting of DMEM (fibroblasts) 
or α-MEM (BMSC), 10% fetal bovine serum, and 1% penicillin-streptomycin.  
Antibiotics and cell culture media were obtained from Invitrogen (Carlsbad, CA), fetal 
bovine serum was purchased from Hyclone (Logan, UT), and all other cell culture 




The Runx2 retroviral vector utilizes the promoter activity of a 5’ long terminal 
repeat to express a single, bicistronic mRNA encoding the murine cDNA for the type II 
MASNSLF Runx2 isoform, followed by an internal ribosomal entry site and a Zeocin 
resistance-enhanced green fluorescent fusion protein 66.  Plasmid DNA was purified from 
transformed E. coli using Megaprep kits from Qiagen (Valencia, CA).  Retroviruses were 
packaged by transient transfection of helper-virus free ΦNX amphotropic producer cells 
with plasmid DNA as described elsewhere 66.  
Passage four primary fibroblasts and passage two BMSC were plated on 6-well 
tissue culture polystyrene plates coated with 0.1% type I collagen (Vitrogen, Palo Alto, 
CA).  Cells at 50-70% confluence were transduced with retroviral stocks and maintained 
in differentiation media consisting of DMEM (fibroblasts) or α-MEM (BMSC), 10% 
fetal bovine serum, 100 U/ml penicillin G sodium, 100 µg/ml streptomycin sulfate, 50 
µg/ml L-ascorbic acid, 2.1 mM sodium β-glycerophosphate, and with or without 10 nM 
DEX.   Culture media was changed every 2 days until end-point assay.  No differences 
were observed between empty vector retrovirus (negative control) and unmodified cells 
in all experiments.  Runx2-transduced cells were analyzed for transduction efficiency by 
quantification of eGFP expression via flow cytometry.  High levels of eGFP were 
detected in ≥ 65% of primary dermal fibroblasts and ≥ 45% BMSC at 72 hours post-
transduction.   
 
Site-Directed Mutagenesis  
Single amino acid mutations were performed on the Runx2 plasmid with the 
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA).  The codon, AGT, 
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encoding Ser125 of the Runx2 Type II isoform was mutated to glycine and glutamic acid.  
The codon, TCT, encoding Ser472 of the Runx2 Type II isoform was mutated to alanine 
and a glutamic acid.  The forward primer 5’-CCGCACCGACGGTCCCAACTTCCTG-3’ 
(mutation underlined) and reverse primer 5’-CAGGAAGTTGGGACCGTCGGTGCGG-
3’ were used to mutate Ser125 to Gly125, while the forward primer 5’-
TGGTCCGCACCGACGAGCCCAACTTCCTGTGCT-3’ and reverse primer 5’-
AGCACAGGAAGTTGGGCTCGTCGGTGCGGACCA-3’ were used to mutate Ser125 to 
Glu125.  The forward primer 5’-GGGGGAGACCGGGCACCTTCCAGGATGGT-3’ and 
reverse primer 5’-ACCATCCTGGAAGGTGCCCGGTCTCCCCC-3’ were used to 
mutate Ser472 to Ala472, while the forward primer 5’-
CGGGGGAGACCGGGAGCCTTCCAGGATGGTC-3’ and reverse primer 5’-
GACCATCCTGGAAGGCTCCCGGTCTCCCCCG-3’ were used to mutate Ser472 to 
Glu472.  The Runx2 gene was sequenced to verify the presence of the desired mutation 
(Seqwright, Houston, TX). 
 
Osteoblastic Differentiation Assays  
Osteoblastic differentiation assays were performed as described previously 66, 67.  
Gene expression was investigated at 1, 3, and/or 7 days post-transduction by quantitative 
RT-PCR using rat-specific primers 137.  Primers used for the analysis of MKP-1 
(NM_053769) were 5’-AGTTTCACGTGCCACCGG-3’ (forward) and 5’- 
GTTATTGCATTGCTCCTCCCA -3’ (reverse).  Alkaline phosphatase (ALP) activity 
was quantified at 7 days post-transduction using 4-methyl-umbelliferyl-phosphate 
substrate and normalized to total protein.  Matrix mineralization was assessed at 14 and 
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21 days post-transduction by von Kossa histochemical staining for phosphate deposits.  
Mineralized surface area was quantified by automated image analysis of twenty-four 
representative 2X images.  FTIR spectroscopy was performed on ethanol-fixed cultures 
pressed into KBr pellets using a Nexus 470 FTIR spectrometer (ThermoNicolet, 
Madison, WI).   
 
Immunoprecipitation and Western Blot Analysis   
Cells were lysed in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% (v/v) NP-40, 
350 µg/ml PMSF, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 1 mM Na3VO4, and 50 mM 
NaF after 7 days in culture.  Whole cell extracts (150 µg protein) were 
immunoprecipitated with 5 µl of anti-Runx2 antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA) and 20 µl protein A agarose beads.  Immune complexes were resolved on 12% 
SDS-PAGE gels, transferred to nitrocellulose, and blotted with anti-AML3 (Oncogene, 
San Diego, CA) and anti-phosphoserine (ab9335, Abcam, Cambridge, MA or 7F12, 
Biomol, Plymouth Meeting, PA), followed by sequential incubation in biotin-conjugated 
anti-IgG and alkaline phosphatase-conjugated anti-biotin antibodies.  Immunoreactivity 
was detected using ECF substrate (Amersham Bioscience, Piscataway, NJ) and a Fuji 
Image Analyzer.  Similar trends were observed for both phosphoserine antibodies.  
Western blot analysis of whole cell lysates was performed with anti-AML3, anti-ERK 
(Santa Cruz Biotechnology, Santa Cruz, CA), anti-phosphoERK (Cell Signaling 
Technology, Beverly, MA), anti-MKP-3 (C-20: Santa Cruz Biotechnology), anti-MKP-1 
(M-18 or C-19: Santa Cruz Biotechnology), and anti-GAPDH (Chemicon, Temecula, 
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CA) antibodies.  Adobe Photoshop image analysis software was used to quantify the 
intensity of the Western blot bands.   
 
Data Analysis  
Experiments were performed at least three times in triplicate, each with unique 
Runx2 retroviral supernatant preparations, and two independent fibroblast isolates.  No 
differences were observed between unmodified and empty vector-transduced cells in all 
assays.  Data are reported as mean ± standard error of the mean, and statistical 
comparisons using SYSTAT 8.0 were based on an analysis of variance and Tukey’s test 
for pairwise comparisons within timepoints, with a p-value < 0.05 considered significant.  
In order to make the variance independent of the mean, statistical analysis of real-time 
PCR data was performed following logarithmic transformation of the raw data 66. 
 
Results  
DEX decreases Runx2 serine phosphorylation 
Because DEX treatment did not alter Runx2 gene expression, we examined the 
effects of this hormone on Runx2 total protein and phosphoserine levels by 
immunoprecipitation and Western blot analysis.  Significant amounts of Runx2 protein 
were detected in Runx2-transduced samples compared to unmodified control cells (Fig. 
4.1A,B).  Surprisingly, addition of DEX to Runx2-transduced cells significantly 
decreased Runx2 serine phosphorylation, while total Runx2 protein levels remained 
unchanged (Fig. 4.1C,D).  Omission of immunoprecipitation antibody or cell lysates in 
negative controls demonstrated the stringency and specificity of the immunoprecipitation 
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procedure.  These findings indicate that DEX regulates Runx2 phosphorylation, with no 
net effect on Runx2 mRNA or protein levels.  This DEX-mediated decrease in Runx2 
serine phosphorylation correlates with and may be functionally linked to DEX-mediated 
synergistic induction of osteoblastic differentiation.   
 
Mutation of Ser125 decreases Runx2 serine phosphorylation 
Several serine phosphorylation sites have been identified on the Runx2/Cbfa1 
type I isoform;  however, Ser104 (corresponding to Ser125 on Runx2 type II) was the only 
residue that exhibited changes in phosphorylation during BMP-2 induced osteogenesis in 
C2C12 cells 255.  Furthermore, phosphorylation of this serine negatively regulated the 
transcriptional activity of Runx2.    In order to assess whether Ser125 is involved in the 
observed net decrease in Runx2 serine phosphorylation following DEX-treatment, site-
directed mutagenesis was performed on this residue in the full-length Runx2 construct 
(Fig. 4.2A).  Mutation of Ser125 to glutamic acid (125Glu) mimics constitutive 
phosphorylation of this residue by placing a bulky, negatively charged group at the site in 
the same manner as the presence of phosphoserine 257.  Mutation of Ser125 to glycine 
(125Gly) leads to constitutive dephosphosphorylation by preventing post-translational 
modification of this residue.  Primary dermal fibroblasts were transduced with wild-type 
Runx2 (Runx2-WT), Runx2-125Gly, or Runx2-125Glu retrovirus and cultured in 
osteogenic media with or without DEX.  Retroviral transduction efficiency was 
approximately 65% for all retroviral stocks (Fig. 4.2B).  Runx2 mRNA expression was 
upregulated by 2 orders-of-magnitude at 3 days post-transduction with Runx2-WT, 














Figure 4.1.  DEX decreases Runx2 serine phosphorylation.  Primary dermal 
fibroblasts were transduced with Runx2 or left unmodified for controls and cultured in 
osteogenic media with and without 10 nM DEX.  (A) Runx2 protein levels were 
examined at 7 days post-transduction by Western blotting of whole cell lysates with a 
polyclonal antibody against Runx2.  GAPDH was used as a loading control.  (B) 
Quantification of Runx2 band intensities (Mean + SEM, n=9; ANOVA: p<0.05; ** 
different from unmodified and DEX only controls (p< 0.05)).  (C) Runx2 phosphoserine 
levels were assessed by immunoprecipitation of whole cell lysates with an antibody 
against Runx2 and Western blotting with antibodies against Runx2 and phosphoserine.  
(D)  Quantification of Runx2 phosphoserine band intensities (Mean ± SEM, n=9; 









A Control         Runx2




















Control          Runx2


























































































Figure 4.2.  Site directed mutagenesis of the Runx2 retroviral vector.  (A) Schematic 
diagram of the Runx2 retroviral expression vector and its mutated derivatives, including 
(a) Runx2-WT control, (b) Runx2-125Gly (mimicking constitutively dephosphorylation), 
and (c) Runx2-125Glu (mimicking constitutively phosphorylation). Primary dermal 
fibroblasts were transduced with Runx2-WT, Runx2-125Gly, or Runx2-125Glu 
retrovirus and cultured in osteogenic media with (+) and without (-) 10 nM DEX.   (B) 
Retroviral transduction efficiency was determined at 3 days post-transduction by flow 
cytometry detection of eGFP expression.  Unmodified cells were used to detect 
autoflourescence.  (C) Runx2 mRNA expression was assessed by quantitative RT-PCR at 
3 days post-transduction and expressed on a logarithmic scale (Mean + SEM, n=12; 
ANOVA: p<1E-11; ** different from unmodified and DEX only controls (p< 0.05)). 
Detection limit was determined by reactions without cDNA is shown as a dotted line.  
(D) Runx2 protein levels were examined at 7 days post-transduction by Western blotting 
of whole cell lysates with a polyclonal antibody against Runx2.  GAPDH was used as a 
loading control.  Blot is representative of data from two separate experiments in 
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4.2C).  Moreover, equivalent levels of Runx2-WT, Runx2-125Gly, and Runx2-125Glu 
protein were detected at 7 days post-transduction (Fig. 4.2D).  Overall, there were no 
differences in Runx2 mRNA or protein levels between transduced samples, excluding the  
possibility that experimental results obtained with these retroviral vectors were skewed 
by differences in Runx2 protein levels and/or transduction efficiencies.    
The effect of Ser125 on Runx2 phosphoserine levels was investigated at 7 days 
post-transduction by immunoprecipitation and Western blotting (Fig. 4.3).   Mutation of 
Ser125 to glycine significantly reduced total Runx2 serine phosphorylation in the absence 
of DEX, suggesting that this serine residue is a major phosphorylation site on 
exogenously-expressed Runx2 in primary dermal fibroblasts.  Furthermore, no apparent 
net change in Runx2-125Gly serine phosphorylation was observed upon addition of 
DEX, while the hormone significantly reduced phosphoserine levels in Runx2-WT.  
Mutation of Ser125 to glutamic acid had similar effects on Runx2 phosphoserine levels as 
those observed upon mutation of this residue to glycine (unpublished data).    These 
results indicate that Runx2 is phosphorylated at a basal level in untreated cultures, 
particularly on Ser125, and suggest that DEX modulates the phosphorylation state of 
Runx2 Ser125 in parallel with the stimulation of osteogenesis.   
Runx2-Ser125 phosphorylation regulates DEX-induced osteoblastic differentiation 
Phosphorylation of Ser125 has been reported to negatively regulate Runx2 
transactivation in NIH3T3 cells transfected with an OCN promoter-driven reporter gene 
255.  However, the direct effects of wild-type Runx2 and its mutated derivatives on 





























Figure 4.3.  Mutation of Ser125 decreases Runx2 serine phosphorylation.  Primary 
dermal fibroblasts were transduced with Runx2-WT or Runx2-125Gly retrovirus and 
cultured in osteogenic media with (+) and without (-) 10 nM DEX.  (A) Runx2 
phosphoserine levels were assessed by immunoprecipitation of whole cell lysates with an 
antibody against Runx2 and Western blotting with antibodies against Runx2 and 
phosphoserine.  (B)  Quantification of normalized Runx2 phosphoserine band intensities 
(Mean ± SEM, n=3; ANOVA: p<0.05; ‡ different from Runx2 + DEX, ¥ different from 
125Gly - DEX, and ## different from 125Gly + DEX (p< 0.05); representative data from 
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phosphorylation state of Runx2-Ser125 plays a critical role in DEX-induced osteogenesis.   
Primary dermal fibroblasts were transduced with Runx2-WT, Runx2-125Gly, or Runx2-
125Glu retrovirus and cultured in osteogenic media supplemented with or without 10 nM 
DEX.  Mutation of Ser125 to glycine, mimicking constitutive dephosphorylation, 
significantly upregulated OCN, BSP, and OPN mRNA transcript expression compared to 
Runx2-WT in the absence of DEX (Fig. 4.4).  Treatment of Runx2-125Gly-expressing 
cultures with DEX had no significant effect on OCN gene expression, but enhanced BSP 
and OPN gene expression.  In contrast, mutation of Serine125 to glutamic acid, mimicking 
constitutive phosphorylation, inhibited Runx2 transactivation of all three osteoblastic 
genes, while DEX partially recovered the effect of Runx2-125Glu on OCN and BSP gene 
expression only.  These results corroborate the observations of Wee et al. that Ser125 
phosphorylation inhibits Runx2 transactivation of an OCN-driven reporter gene.   
Consistent with alterations in osteoblastic gene expression, mutation of Ser125 to 
glycine stimulated ALP activity to levels significantly higher than Runx2-WT cultures 
and comparable to Runx2-WT + DEX treated cultures (Fig. 4.5A).  DEX had no 
additional effect on ALP activity in Runx2-125Gly-expressing cultures.  Mutation of 
Ser125 to glutamic acid diminished ALP activity to levels comparable to unmodified 
control cultures and DEX treatment partially recovered this activity.  Furthermore, 
mutation of Ser125 to glycine also significantly enhanced matrix mineralization compared 
to Runx2-WT-expressing cultures in the absence of DEX (Fig. 4.5B,C).  DEX treatment 
synergistically enhanced mineralization in both Runx2-WT and Runx2-125Gly 
expressing cells.  Conversely, mutation of Ser125 to glutamic acid completely blocked 















Figure 4.4.  Constitutive Ser125 phosphorylation negatively regulates Runx2-
mediated expression of osteoblastic genes.  Primary dermal fibroblasts were transduced 
with Runx2-WT, Runx2-125Gly, or Runx2-125Glu retrovirus and cultured in osteogenic 
media with (+) and without (-) 10 nM DEX.  mRNA levels were investigated by 
quantitative RT-PCR at 7 days post-transduction (Mean + SEM, n=6; ANOVA: p<1E-6;  
† different from Runx2 - DEX, ¥ different from 125Gly - DEX, § different from 125Glu - 
DEX and 125Glu + DEX, and £ different from 125Glu - DEX (p< 0.05)).   Relative gene 
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in Runx2-WT and Runx2-125Gly cultures displayed FTIR spectrograms similar to those 
shown in Fig. 3.2D with the characteristic bands of a carbonate-containing, poorly 
crystalline hydroxyapatite (data not shown).   
Finally, these experiments were repeated in primary bone marrow stromal cells 
(BMSCs) in order to ensure that results were not an artifact of the non-osteogenic cell 
source used in this study (Fig. 4.6A,B).  DEX treatment alone stimulated osteoblastic 
differentiation in BMSCs, including ALP activity and matrix mineralization, compared to 
untransduced controls.  Moreover, co-treatment with Runx2-WT and DEX enhanced 
osteogenic differentiation in BMSCs compared to Runx2-WT overexpression or DEX 
treatment alone.  Mutation of Ser125 to glycine stimulated ALP activity and mineralized 
nodule formation to levels significantly higher than Runx2-WT cultures and equivalent to 
Runx2-WT + DEX treated cultures.  DEX treatment showed no additional effect on 
osteogenesis in Runx2-125Gly-expressing cultures.   Mutation of Ser125 to glutamic acid 
antagonized ALP activity and mineralization to similar levels as untransduced BMSC 
controls with or without DEX.  Overall, these results demonstrate equivalent functional 
effects of Runx2-Ser125 during DEX-induced osteogenesis in primary BMSCs and 
Runx2-engineered primary dermal fibroblasts.  We speculate that the low levels of ALP 
activity and mineralization observed in untransduced and Runx2-125Glu-expressing 
BMSCs may be due to interactions between DEX and endogenously-expressed Runx2 or 






















Figure 4.5.  Constitutive phosphorylation of Runx2 Ser125 inhibits osteoblastic 
differentiation.  Cells were transduced with Runx2-WT, Runx2-125Gly, or Runx2-
125Glu retrovirus and cultured in osteogenic media with (+) and without (-) 10 nM DEX.  
(A) ALP activity was examined by a biochemical assay at 7 days post-transduction 
(Mean ± SEM, n=6; ANOVA: p<1E-11; ** different from unmodified and DEX only 
controls, † different from Runx2 - DEX, Φ different from 125Gly - DEX, § different 
from 125Glu - DEX and 125Glu + DEX, and Ω different from 125Glu (p< 0.05)).  (B) 
Mineralized matrix deposition was assessed by von Kossa staining for phosphate-positive 
regions and (C) quantified by image analysis at 14 days post-transduction (Mean ± SEM, 
n=6; ANOVA: p<1E-11, ** different from unmodified and DEX only controls, † 
different from Runx2 - DEX, ¥ different from 125Gly - DEX, § different from 125Glu - 






































































































































Figure 4.6.  Runx2 phosphorylation regulates osteoblastic differentiation in primary 
bone marrow stromal cells.  BMSC were transduced with Runx2-WT, Runx2-125Gly, 
or Runx2-125Glu retrovirus and cultured in osteogenic media with (+) and without (-) 10 
nM DEX.  (A) ALP activity was examined by a biochemical assay at 7 days post-
transduction (Mean ± SEM, n=3; ANOVA: p<1E-4; * different from unmodified cell 
control, ** different from unmodified and DEX only controls, † different from Runx2 - 
DEX, and £ different from 125Glu - DEX (p< 0.05)).  (B) Mineralized matrix deposition 
was assessed by von Kossa staining for phosphate-positive regions and image analysis at 
14 days post-transduction.  Image represents data from two separate experiments in 
































































DEX upregulates MKP-1 through a GC receptor-mediated transcriptional mechanism 
As a first step toward elucidating the DEX-mediated mechanism(s) involved in 
the regulation of Runx2 phosphorylation, we examined the ability of DEX to activate 
components of the mitogen-activated protein kinase (MAPK) signaling pathway.  In 
particular, MAPK phosphatase-1 (MKP-1) is a dual specificity phosphatase that 
dephosphorylates and inactivates MAPKs such as extracellular signal-regulated kinase 
(ERK1/2), c-Jun N-terminal kinase (JNK), and p38 protein kinase 258-261.  
Pharmacological doses of DEX (≥ 100 nM) have been shown to upregulate MKP-1 in a 
variety of cell types 261-264.  We postulated that MKP-1 may be stimulated by physiologic 
concentrations of DEX during osteoblastic differentiation in our experimental model.  
Primary fibroblasts transduced with Runx2 retrovirus or left unmodified as controls were 
cultured in osteogenic media supplemented with or without DEX.  MKP-1 mRNA and 
protein levels were evaluated at 1, 3, and 7 days post-transduction by quantitative RT-
PCR and Western blot analysis, respectively.  DEX treatment stimulated MKP-1 gene 
(Fig. 4.7A) and protein (Fig. 4.7B) expression in unmodified and Runx2-expressing 
cultures relative to untreated controls.  MKP-1 was upregulated after 3 days and remained 
elevated through 7 days in culture, which correlates with the decrease in Runx2 serine 
phosphorylation observed after treatment with DEX for 7 days.  Overexpression of 
Runx2 significantly inhibited MKP-1 mRNA and protein levels at 3 and 7 days post-
transduction compared to unmodified controls and addition of DEX to Runx2-transduced 
cultures restored MKP-1 to basal expression levels.  Moreover, the induction of MKP-1 
mRNA by DEX was abrogated by treatment with the partial GC receptor-















Figure 4.7.  DEX upregulates MKP-1 through a GC receptor-mediated 
transcriptional mechanism. Primary dermal fibroblasts were transduced with Runx2 
retrovirus or left unmodified for controls and cultured in osteogenic media with (+) and 
without (-) 10 nM DEX.   (A) MKP-1 mRNA expression was investigated by quantitative 
RT-PCR at 1, 3, and 7 days post-transduction and expressed on a logarithmic scale (Mean 
+ SEM, n=12; ANOVA: p<1E-11; * different from unmodified cell control, † different 
from Runx2, and ‡ different from Runx2+DEX (p< 0.05)). (B) MKP-1 protein levels 
were examined at 1, 3, and 7 days post-transduction by Western blot analysis.  GAPDH 
was used as a loading control.  Blots are representative of data from three separate 
experiments in triplicate.   (C)  MKP-1 mRNA expression was investigated by 
quantitative RT-PCR at 3 days post-Runx2 transduction after treatment with vehicle 
(ethanol), DEX (10 nM) or concomitant DEX/RU486 (100 nM) for 72 hours.  Fold 
induction is shown relative to control samples without (-) DEX treatment (Mean + SEM, 
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remained unchanged for all treatment groups in this experiment.  Finally, no differences 
in p38 MAPK, protein phosphatase 5, and protein tyrosine phosphatase type D expression 
were observed among experimental groups, suggesting that the observed shifts in 
expression were specific for MKP-1.  Taken together, this data demonstrates that DEX 
induces MKP-1 in Runx2-expressing fibroblasts through a GC receptor-mediated 
mechanism.   
 
Inhibition of MKP-1 attenuates the DEX-mediated decrease in Runx2 serine 
phosphorylation 
Sanguinarine has recently been identified as a potent and selective inhibitor of 
MKP-1 activity, exhibiting at least a 3-fold selectivity for MKP-1 over dual specificity 
phosphatases such as MKP-3, VH-1-related phosphatase, Cdc25B, and protein-tyrosine 
phosphatase 1B 265.   We utilized this inhibitor to assess the role of MKP-1 during the 
DEX-mediated modulation of Runx2 serine phosphorylation.  Primary dermal fibroblasts 
were transduced with Runx2 retrovirus or left unmodified for controls and cultured in 
osteogenic media with (+) and without (-) 10 nM DEX.  After 7 days in culture, cells 
were treated with vehicle (ethanol), vehicle+DEX (10 nM), sanguinarine (50 µM), or 
sanguinarine (50 µM) + DEX (10 nM) for 30 minutes.  Protein expression for MKP-1, 
MKP-3, phospho-ERK, ERK, and GAPDH was assessed by Western blotting (Fig. 4.8A).  
MKP-1 protein levels were markedly decreased by sanguinarine in unmodified and 
Runx2-expressing fibroblasts.  Consequently, the decrease in ERK phosphorylation 
caused by DEX-induction of MKP-1 was reversed upon treatment with sanguinarine.  
ERK and GAPDH total protein levels remained unchanged for all experimental 
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conditions.  Notably, MKP-3 protein levels were not significantly altered by 
sanguinarine, suggesting that the inhibitor was selective for MKP-1 over this closely 
related dual specificity phosphatase.  Runx2 phosphoserine levels were then examined by 
immunoprecipitation and Western blot analysis (Fig. 4.8B).  Sanguinarine treatment 
blocked the DEX-mediated decrease in Runx2 serine phosphorylation, suggesting that 
DEX modulates the inhibitory phosphorylation of Runx2 via MKP-1.   
 
Discussion 
We demonstrate that a combination of DEX supplementation and constitutive 
Runx2 overexpression synergistically induced osteoblastic differentiation in primary 
dermal fibroblasts, as characterized by enhanced OCN and BSP gene expression, alkaline 
phosphatase activity, and biological mineral deposition.  DEX treatment decreased Runx2 
phosphoserine levels, particularly on Serine125. Mutation of Ser125 to glutamic acid, 
mimicking constitutive phosphorylation, inhibited Runx2-induced osteogenic 
differentiation, which was not rescued by DEX treatment.  Conversely, mutation of Ser125 
to glycine, mimicking constitutive dephosphorylation, markedly increased osteogenic 
differentiation, which was enhanced by but did not require additional DEX 
supplementation.  The DEX-induced decrease in Runx2 phosphorylation correlated with 
upregulation of MKP-1 through a GC-receptor-dependent mechanism.  Furthermore, 
inhibition of MKP-1 abrogated the effect of DEX on Runx2 phosphoserine levels.  To 
our knowledge, this is the first time that DEX-activated MKP-1 expression has been 
implicated in the regulation of Runx2 phosphorylation.  Collectively, these results 
















Figure 4.8.  Inhibition of MKP-1 attenuates the DEX-mediated decrease in Runx2 
serine phosphorylation.  Primary dermal fibroblasts were transduced with Runx2 
retrovirus or left unmodified for controls and cultured in osteogenic media with (+) and 
without (-) 10 nM DEX.  After 7 days in culture, cells were treated with vehicle 
(ethanol), vehicle+DEX (10 nM), sanguinarine (50 µM), and sanguinarine (50 µM) + 
DEX (10 nM) for 30 minutes.  (A) Western blot analysis of whole cell lysates after 7 
days in culture was conducted with antibodies against MKP-1, MKP-3, pERK, and ERK.  
GAPDH was used as a loading control.  Blot is representative of data from three separate 
experiments in triplicate.  (B) Runx2 phosphoserine levels were assessed by 
immunoprecipitation of whole cell lysates with an antibody against Runx2 and Western 
blotting with antibodies against Runx2 and phosphoserine. Blot is representative of data 
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negative regulatory serine residue (Ser125) on Runx2/Cbfa1 via MKP-1.  This work offers 
important insights into the role of Runx2 during hormone-regulated skeletal development 
and maintenance.    
Primary dermal fibroblasts engineered to express elevated and sustained levels of 
Runx2 were utilized for the investigation of the effects of DEX on osteoblastic 
differentiation.  A major advantage of this model system is that it allows for direct 
analysis of the Runx2 type II isoform and its mutants during GC-induced osteogenesis in 
the absence of endogenous Runx2 and DEX-responsive, osteoblast-specific pathways.  
Notably, DEX stimulation of Runx2-expressing fibroblasts induced several important 
components of the osteoblastic differentiation program, including osteocalcin and bone 
sialoprotein gene expression, ALP activity, and matrix mineralization, whereas DEX 
treatment alone did not significantly influence any of these osteoblastic markers.  This 
enhancement in osteogenesis is consistent with the effects of DEX on several osteoblastic 
systems, including rat calvarial cells, rat and human bone marrow stromal cells, and chick 
periosteal cells 137, 238, 239, 241, 242, 266.  While these model systems have been instrumental 
in the elucidation of numerous DEX-responsive signaling pathways, they are limited 
because they prevent the isolation of Runx2-dependent from Runx2-independent 
pathways.  Finally, in order to ensure that these results were not an artifact of the non-
osteogenic cell source, we analyzed the effects of Runx2-WT and Runx2-Ser125 mutants 
during DEX-induced osteoblastic differentiation in primary bone marrow stromal cells.  
This osteoblastic model exhibited equivalent functional responses during DEX-induced 
osteoblastic differentiation compared to Runx2-engineered fibroblasts.  Based on these 
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results, we hypothesized that the anabolic effects of GCs in vitro occur through a Runx2-
dependent mechanism involving the post-translational modification of Runx2.   
We demonstrate that DEX decreases Runx2 phosphoserine levels, particularly on 
Serine125, in parallel with osteoblastic differentiation.  In contrast, Shui et al. reported that 
phosphorylation of Runx2 on tyrosine, threonine, and serine residues increases during 
DEX-induced osteoblastic differentiation in human bone marrow stromal cells 246.    
However, this report did not include a “No DEX” condition to isolate the effects of DEX 
from alternative pathways activated during the onset of osteogenesis.  Thus, beyond this 
correlative evidence, a direct link between DEX and Runx2 phosphorylation has not been 
established prior to this work.  Previous analyses have also shown that collagen, 
fibroblast growth factor-2, and mechanical loading enhance Runx2 transcriptional 
activity via the MAPK pathway 252-254.  Moreover, protein kinase A (PKA) also 
phosphorylates Runx2, and parathyroid hormone enhances Runx2 transactivation of the 
collagenase-3 promoter through a PKA-dependent pathway 267, 268.  These pathways 
stimulate Runx2 phosphorylation on putative residues within the C-terminal PST domain 
251, 268, but the specific residues targeted have not been identified.  Interestingly, while 
these stimulatory phosphorylation sites were found in the PST domain, Ser125 is located 
within the N-terminal runt domain, suggesting that phosphorylation at different regions 
within the Runx2 protein may play different functional roles in osteoblastic 
differentiation.  Finally, it is important to note that our results do not rule out the 
possibility that additional Runx2 phosphorylation sites are altered during DEX-induced 
osteogenesis.   
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The mutagenesis analysis conducted in this study demonstrates that the 
phosphorylation state of Runx2-Ser125 plays a critical role during DEX-induced 
osteoblastic differentiation.  These results offer important insights into skeletal 
pathogenesis, as mutation of this residue to arginine has been documented in one patient 
with cleidocranial dysplasia 256.   Ito and colleagues recently identified Ser14, Ser104, 
Ser451, Ser485, and Ser489 as potential phosphorylation sites on the human Runx2/Cbfa1 
type I isoform.  Of these residues, Ser104 and Ser451 were implicated in the negative 
regulation of Runx2 transcriptional activity.  Mutation of Ser104, corresponding to Ser125 
on the murine Runx2 type II isoform, to both glycine and glutamic acid inhibited Runx2 
transactivation of an OCN promoter-driven reporter gene 255.  These results are consistent 
with our observations for Runx2-mediated differentiation, but contradict reports that 
mutation of Runx1/AML1c Ser94, analogous to RUNX2 Ser125, had no effect on 
transcriptional activity 269.  Wee and colleagues also reported that the phosphorylation 
state of Ser451, corresponding to Ser472 on the murine Runx2 type II isoform, has a critical 
role in the transcriptional activity of Runx2  255.  However, the phosphorylation state of 
Ser472 had no apparent effect on Runx2-induced osteogenic gene expression, alkaline 
phosphatase activity, or mineralization in the present study (unpublished data).  Similarly, 
mutation of Runx1/AML1c Ser424, corresponding to Runx2 type II Ser472, did not alter 
transcriptional activity of this runt domain protein family member 269.    Overall, it is 
evident that disparities exist in the phosphorylation pattern of Runx protein family 
members, suggesting that the phosphorylation state of Ser125 and Ser472 may be isoform-
specific, cell type-specific, or regulated by independent signaling pathways.   
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       The present analysis supports a mechanism by which DEX induces 
osteoblastic differentiation by modulating the phosphorylation state of a negative 
regulatory serine on Runx2.  The ability of DEX to partially recover osteogenic gene 
expression and ALP activity in cultures expressing Runx2-125Glu suggests that the 
hormone may also have auxiliary modes of regulating Runx2 beyond the mechanism 
detailed in this study.  Indeed, GCs may also mediate osteogenesis by a Runx2-
dependent mechanism involving the physical association of the transcription factor 
with co-regulatory proteins.  Recent evidence suggests that Runx2 serves as a 
molecular scaffold, which facilitates the assembly of co-regulatory proteins and 
accessory transcription factors into a macromolecular transcriptional regulatory 
complex 65.  Runx2 contains specific functional regions that physically interact with a 
number of accessory factors 270.  In particular, the runt domain is a 128 amino acid 
conserved region, which is essential for DNA binding and heterodimerization with 
transcription factors such as Cbfβ/PEBP2β 271, 272, LEF-1 273, and c-Fos/c-Jun 267, 274, 
275.  The C-terminal PST domain contains a nuclear localization signal, a 
transcriptional activation region, and a repressor region, and has been shown to co-
localize with SMADs 276, 277, CCAAT/Enhancer-binding proteins (C/EBPβ and δ) 278, 
HES-1, and Groucho/TLE proteins 279.  Osteogenic agents, such as PTH and BMP, 
regulate the association of Runx2 with several of these factors, but the role of DEX in 
these protein-protein interactions is poorly understood.  Interestingly, Wee et al. 
found that the mutation of Ser104 to glutamic acid, which decreased Runx2 
transcriptional activity, also appeared to destabilize the protein and inhibit the 
heterodimerization of Runx2 with CBF-β.  Thus, it is possible that the DEX-mediated 
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regulation of Runx2 phosphorylation alters the interaction of this transcription factor 
with accessory proteins, which may have downstream effects on Runx2 
transcriptional activity.  Finally, these results do not rule out the possibility GCs may 
mediate osteogenesis by Runx2-independent signaling pathway(s), which may 
cooperatively act with Runx2-stimulated gene products to synergistically induce 
matrix mineralization.   
     In summary, we have demonstrated that DEX induces osteogenesis, at least in 
part, by modulating the phosphorylation state of a negative regulatory serine residue 
(Ser125) on Runx2 through an MKP-1 dependent mechanism. While this particular 
mechanism is likely not the sole signaling pathway activated by DEX during 
osteogenic differentiation, it provides significant insights toward the role of Runx2 
phosphorylation during GC-regulated skeletal development. 
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CHAPTER 5 
DERMAL FIBROBLASTS GENETICALLY MODIFIED TO 
EXPRESS RUNX2 AS A MINERALIZING CELL SOURCE FOR 
BONE TISSUE ENGINEERING* 
 
Introduction 
Over 600,000 bone grafting procedures are performed annually in the United 
States to treat non-healing skeletal defects caused by traumatic injury, osteodegenerative 
diseases, and cancer.3, 80  Autograft implantation is considered the gold standard in bone 
repair, but is limited by donor site morbidity, pain, and inadequate supply of tissue.77 
Because of these complications, allogenic bone and synthetic materials have been 
increasingly utilized as bone graft substitutes.80  However, allografts suffer from reduced 
bioactivity and poor mechanical properties due to tissue processing, while synthetic 
materials typically incite an inflammatory response in the host.78, 79  Synthetic materials 
such as metals, calcium phosphate ceramics, bioactive glasses, and polymers have also 
been explored for bone grafting applications, but generally display insufficient 
regenerative potential to warrant the inflammatory host reaction 80.  More recently, 
osteogenic devices containing recombinant bone morphogenetic protein-2 (BMP-2) or 
BMP-7 have shown efficacy in human clinical trials and have been approved by 
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Nevertheless, the clinical success of this growth-factor based approach continues to be 
hampered by suboptimal delivery vehicles, short biological half-life, and safety issues 
associated with aphysiologic dosage.7, 8  
Bone tissue engineering has emerged as a promising alternative to conventional 
grafting strategies.99, 280, 281  In this approach, osteogenic cells and/or bioactive growth 
factors are integrated into three-dimensional scaffolds to produce hybrid constructs for 
skeletal repair.101  The success of bone tissue engineering to date has been limited in part 
by inadequate availability of a mineralizing cell source which can be easily obtained in 
sufficient quantities and maintain osteoblastic phenotype during in vitro culture and 
expansion.  Traditional cell-based approaches typically involve the use of terminally 
differentiated osteoblasts,102, 103 osteogenic cell lines,105, 282 unfractionated bone marrow 
stroma,106, 107 or purified mesenchymal stem cells.108, 109, 283  Marrow-derived progenitors, 
in particular, have been successfully utilized to repair orthotopic bone defects in animal 
models.13, 14, 17, 18, 114  However, the widespread use of these precursors remains limited by 
their low frequency in healthy marrow,116 complex and painful cell procurement 
process,284 and reduced mineralization capacity associated with the age and disease-state 
of the donor.16, 19   Overall, the identification of a sustained, autologous mineralizing cell 
source would be significant toward development of mechanically robust bone grafts 
which genetically match the patient and are capable of healing large, critical sized 
defects.      
Non-osteogenic cells, such as skin fibroblasts, are a particularly attractive cell 
source alternative because they are easy to harvest from autologous donors and display a 
high capacity for in vitro expansion.  Genetic engineering strategies focusing on soluble 
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osteoinductive factors have been effectively applied to promote osteoblastic 
differentiation in fibroblastic cell types.20-23  Notably, dermal fibroblasts transduced with 
adenoviral vectors encoding for either BMP-2 or BMP-7 form significant amounts of 
bone in both ectopic implantation sites and critical-sized calvarial defects.24, 25  Despite 
these advances, complex release kinetics and uncontrolled paracrine signaling to 
neighboring non-osseous tissues may limit the clinical success of this approach.285  
The present work is fundamentally different from BMP-based gene therapy 
strategies because it focuses on retroviral gene delivery of the osteogenic transcription 
factor Runx2/Cbfa1 and may avoid detrimental side effects associated with unregulated 
growth factor secretion.  Runx2 is an essential transcriptional regulator of osteoblast 
differentiation and bone formation.59, 60  It functions as a transcriptional scaffolding 
protein which binds to the promoter region of skeletal target genes and regulates their 
expression.64, 65    Homozygous deletion of this transcription factor arrests osteoblast 
maturation, resulting in total absence of endochondral and intramembranous 
ossification.61  We and others have established that viral overexpression of Runx2 
upregulates osteogenic gene expression in a wide range of cell types, including the 
MC3T3-E1 osteoblastic cell line,66 primary BMSCs,137, 286, 287 and primary skeletal 
myoblasts.117, 135  In contrast, mineral deposition is induced by Runx2 gene delivery in a 
cell type-dependent manner and has been reported by several groups as insufficient to 
induce significant nodule formation in primary dermal fibroblasts and fibroblastic cell 
lines both in vitro and in vivo.23, 24, 66   However, we have recently demonstrated that a 
combination of constitutive retroviral Runx2-expression and treatment with the steroid 
hormone dexamethasone synergistically induces matrix mineralization in primary dermal 
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fibroblasts cultured in monolayer.136  This surprising result suggested that Runx2-
engineered primary dermal fibroblasts have the capacity to create mineralized templates 
for bone repair and may still have potential as a cell source for bone tissue engineering 
applications if exposed to the appropriate osteogenic cues.   
In the present study, we describe a hybrid ex vivo gene therapy/tissue engineering 
strategy based on retroviral gene delivery of the osteogenic transcription factor Runx2 to 
non-osteoblastic primary dermal fibroblasts.  We demonstrate that sustained expression 
of Runx2 induces osteoblastic differentiation and biological mineral deposition in 
primary dermal fibroblasts cultured on fibrous collagen scaffolds in vitro and in vivo.  
These results establish Runx2-genetic engineering as a strategy for the conversion of a 
non-osteogenic cellular phenotype into a mineralizing cell source for bone tissue 
engineering applications.  
 
Materials and Methods   
Cell Culture and Reagents 
Primary fibroblasts were harvested from 8- to 16-week-old male Wistar rats by 
enzymatic digestion of the dermal skin layer.220  Cells were expanded in growth media 
consisting of DMEM, 10% fetal bovine serum, and 1% penicillin-streptomycin.  
Antibiotics and cell culture media were obtained from Invitrogen (Carlsbad, CA), fetal 
bovine serum was purchased from Hyclone (Logan, UT), and all other cell culture 




The Runx2 retroviral vector utilizes the promoter activity of a 5’ long terminal 
repeat to express a single, bicistronic mRNA encoding the murine cDNA for the type II 
MASNSLF Runx2 isoform,221, 222 followed by an internal ribosomal entry site and a 
Zeocin resistance-enhanced green fluorescent fusion protein (eGFP).66  Empty vector 
control vector lacked the Runx2 insert.  Plasmid DNA was purified from transformed E. 
coli using Megaprep kits from Qiagen (Valencia, CA).  Retroviruses were packaged by 
transient transfection of helper-virus free ΦNX amphotropic producer cells with plasmid 
DNA as described elsewhere.66  
Passage four primary fibroblasts were plated on tissue culture-grade polystyrene 
coated with 1 mg/ml type I collagen (Cohesion, Palo Alto, CA).  Cells at 40-60% 
confluence were transduced with Runx2 or empty vector retroviral stocks and maintained 
in osteogenic growth media consisting of DMEM, 10% fetal bovine serum, 100 U/ml 
penicillin G sodium, and 100 µg/ml streptomycin sulfate.   Runx2-transduced cells were 
analyzed for transduction efficiency by quantification of eGFP expression via flow 
cytometry with a Vantage SE cell sorter (Becton-Dickinson, San Jose, CA).  High levels 
of eGFP were detected in ≥ 65% of primary dermal fibroblasts at 72 hours post-
transduction.  Transgene expression was still detectable at 21 days post-transduction (data 
not shown), demonstrating sustained and integrated expression of the target gene by the 
retroviral vector.  Selection of Runx2/eGFP-positive cells was not performed.   
 
Scaffold Seeding  
Fibrous collagen disks (8 mm diameter x 2 mm thick, average pore size 61.7 µm, 
93.7% pore volume, Kensey Nash, Exton, PA) were coated with 20 µg/ml fibronectin in 
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order to promote initial cell adhesion.  At sixty hours post-infection, Runx2-transduced, 
empty vector-infected, and unmodified cells were trypsinized and seeded at 5x105 
cells/scaffold in osteogenic growth media.  Constructs were transferred twenty-four hours 
post-seeding to osteogenic differentiation media consisting of DMEM, 10% fetal bovine 
serum, 100 U/ml penicillin G sodium, 100 µg/ml streptomycin sulfate, 50 µg/ml L-
ascorbic acid, 2.1 mM sodium β-glycerophosphate, and 10 nM dexamethasone.  Culture 
media was changed every 2 days until end-point assay.  No differences were observed 
between empty vector retrovirus (negative control) and unmodified cells in all 
experiments.   
 
Cell Viability  
 Scaffolds were harvested at 1, 21, and 42 days post-seeding, rinsed in complete 
Dulbecco’s phosphate buffered saline (PBS), and incubated in 4 µM calcein-AM and 4 
µM ethidium homodimer-1 (Molecular Probes, Eugene, OR) in PBS for 30 minutes under 
gentle agitation. Constructs were then rinsed (3 x 10 minutes) in PBS and analyzed with a 
Zeiss LSM 510 Confocal Microscope using Ar and HeNe lasers and a 5x objective lens.   
 
Cell Seeding Efficiency 
 Samples were harvested 24-hours post-seeding, rinsed with PBS, and frozen at -
80°C.  Scaffolds and serially diluted cell standards were thawed, lyophilized, and 
digested at 55°C in 500 µl of 0.25 mg/ml proteinase K (Fisher Scientific, Pittsburgh, PA) 
in 100 mM ammonium acetate (pH 7.0) for 24 hours.  Digested samples were assessed 
for DNA content via the PicoGreen dsDNA Quantitation Kit (Molecular Probes, Eugene, 
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OR).  Raw DNA data was converted to cell numbers using a linear standard curve and 
normalized by original seeding density (500,000 cells/scaffold) to determine cell seeding 
efficiency.      
 
Real time RT-PCR 
 Total RNA was isolated at 7 and 21 days post-seeding using the RNeasy RNA 
isolation kit with RNAlater stabilization reagent (Qiagen).  cDNA synthesis was 
performed on DNaseI-treated (27 Kunitz units/sample) total RNA (0.25 µg) by oligo(dT) 
priming using the Superscript™ First Strand Synthesis System for RT-PCR (Invitrogen, 
Carlsbad, CA).  Gene expression was assessed by quantitative RT-PCR using SYBR 
Green intercalating dye (Molecular Probes) and rat-specific primers as previously 
described.66, 137  Primer specificity was confirmed by ABI Prism 7700 Dissociation Curve 
Software. Standards for each gene were amplified from cDNA using real-time 
oligonucleotides, purified using a Qiagen PCR Purification kit, and diluted over a 
functional range of concentrations.  Transcript concentration in template cDNA solutions 
was quantified from a linear standard curve, normalized to 0.25 µg of total RNA, and 
expressed as nanomoles of transcripts per µg of total RNA.  Detection limits for each 
gene were determined by reactions without cDNA and fall below the y-axis minimum. 
 
Microcomputed Tomography 
 High resolution X-ray microcomputed tomography (micro-CT) with a Scanco 
µCT Medical CT 40 imaging system (Bassersdorf, Switzerland) was used to quantify in 
vitro and in vivo mineralization of 3-D scaffolds.  Formalin-fixed specimens were 
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scanned in 70% ethanol at 16 µm voxel resolution and evaluated at a threshold 
corresponding to a linear attenuation of 0.96 cm-1, filter width of 1.2, and filter support of 
2.0.  Reconstructed and thresholded images were evaluated using direct distance 
transformation methods to calculate mineralized matrix volume within each construct.288   
 
FTIR Spectroscopy  
 Scaffolds at 42 days post-seeding were fixed in 100% ethanol and dried at 50ºC 
overnight.  Bone samples were scraped from a lyophilized rat cranium and used as a 
positive control.  Bulk samples were mixed with KBr (Sigma) and pressed into pellets 
with a custom built apparatus.  Samples were analyzed with a Nicolet Nexus 470 FTIR 
spectrometer (ThermoNicolet, Madison, WI) equipped with a DTGS detector.  Sixty-four 
scans were acquired at 4 cm-1 resolution under N2 purge.  
 
Subcutaneous Implantation 
 Cell-seeded constructs were subcutaneously implanted into the backs of 7-week-
old syngeneic rats after 24 hours pre-culture in non-osteogenic growth media.  Two 
implants were placed in each animal, one on each side of a midline incision into 
subcutaneous pockets made by blunt dissection.  Four groups (n = 6 samples for each 
group) of constructs were implanted: (i) Runx2-engineered cells, (ii) empty vector-
infected control cells, (iii) unmodified control cells, and (iv) empty (cell-free) scaffolds.  
Constructs were explanted after 4 weeks of implantation following euthanasia by CO2 
inhalation.  All procedures were carried out according to an IACUC-approved protocol as 
previously described.138   
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Histology and Immunohistochemistry 
 Formalin-fixed constructs were paraffin embedded and sectioned at 5 µm 
thickness.  Sections were stained with hematoxylin-eosin and von Kossa to observe 
cellular distribution and matrix mineralization within 3-D constructs, respectively.  eGFP 
and Runx2 protein expression was observed by immunostaining using a colorimetric 
avidin-biotin kit (Vector Labs, Burlingame, CA).  Sections were deparaffinized, 
rehydrated, and then pretreated using heat-induced antigen retrieval in 10 mM citrate 
buffer (pH 6.0).  After pretreatment, slides were incubated in rabbit polyclonal primary 
antibodies against eGFP (Molecular Probes) or Runx2/AML3 (Oncogene, San Diego, 
CA), followed by sequential incubation in biotinylated anti-rabbit secondary antibody 
and avidin-biotin linked alkaline phosphatase.  Slides were then incubated in Vector Red 
substrate and counterstained with hematoxylin. 
 
Data Analysis 
All in vitro experiments were performed three times in triplicate, each with 
unique Runx2 retroviral supernatant preparations, and two independent isolates of 
primary dermal fibroblasts.  Data are reported as mean ± standard error of the mean 
(SEM), and statistical comparisons using SYSTAT 8.0 were based on an analysis of 
variance (ANOVA) and Tukey’s test for pairwise comparisons, with a p-value < 0.05 
considered significant.  In order to make the variance independent of the mean, statistical 
analysis of real-time PCR data was performed following logarithmic transformation of 
the raw data.66   
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Results 
Fibroblasts remain viable and colonize fibrous collagen disks in vitro 
Runx2-expressing and unmodified fibroblasts were seeded on fibrous collagen 
disks at a density of 500,000 cells/scaffold and cultured statically in vitro in osteogenic 
differentiation media.  Scaffold seeding efficiency was evaluated by quantification of 
DNA content at 1 day post-seeding (Fig. 5.1A).   Approximately 200,000 cells were 
present on both Runx2-expressing and unmodified cell-seeded scaffolds, corresponding 
to cell seeding efficiencies of 43.9 ± 6.5% and 39.6 ± 2.5%, respectively.  Scaffold 
colonization and cellular viability were assessed at 1, 21, and 42 days post-seeding by 
confocal microscopy and Live (green)/Dead (red) fluorescence staining (Fig. 5.1B).   No 
differences were observed in cell viability between Runx2-expressing and unmodified 
control cells at any time point.  After 1 day in culture, cells were evenly distributed 
throughout collagen scaffolds, with spread morphology and minimal cell-cell contact.  
Cells remained viable for the entire 42 day culture period, with confluent cell populations 
localized to the construct periphery.  Isolated necrotic regions were detected at all time 
points, but minimal cell death (<5%) was observed in the dense cellular layer at the 
construct surface.   
 
Runx2 induces osteoblastic gene expression in fibroblasts cultured on collagen scaffolds 
in vitro 
Gene expression of osteoblastic markers, including Runx2, alkaline phosphatase 
(ALP), osteocalcin (OCN), and bone sialoprotein (BSP), was investigated at 7 and 21 













Figure 5.1.  Primary dermal fibroblasts remain viable and populate collagen 
scaffolds in vitro.   Fibroblasts were transduced with Runx2 retrovirus or left unmodified 
for controls, seeded on fibrous collagen disks, and cultured in vitro with osteogenic 
media.  (A) Cell seeding efficiency was determined by quantification of DNA content 
and cell number present in scaffolds at 1 day post-seeding (Mean + SEM, n=6; ANOVA: 
p<0.05).  (B) Cellular viability was assessed at 1, 21, and 42 days post-seeding by 
confocal microscopy and Live (green)/Dead (red) fluorescence staining.  Scale bar 


































































Figure 5.2.  Runx2 upregulates osteoblastic gene expression in fibroblasts seeded on 
collagen scaffolds in vitro.   mRNA transcript levels were investigated by quantitative 
RT-PCR at 7 and 21 days post-seeding (Mean + SEM, n=3; ANOVA: p<0.05; * different 
from day 7 control, ** different from both day 7 and day 21 controls, and † different 

























































































enzyme that hydrolyzes phosphate esters, thereby making inorganic phosphate available 
for incorporation into mineral deposits.224  OCN is the most abundant non-collagenous 
extracellular matrix protein in bone and a marker of mature osteoblasts,223 while BSP is 
an extracellular matrix glycoprotein implicated in the regulation of mineralized nodule 
nucleation.224  Runx2 mRNA levels were upregulated by 5 orders-of-magnitude in 
Runx2-transduced cultures compared to control cells at day 7, and this relative difference 
decreased to 2.5 orders-of-magnitude at day 21.  The temporal decrease in Runx2 
expression may be a result of the non-transduced fibroblastic population proliferating 
faster than Runx2-expressing cells or cell necrosis within the inner core of constructs due 
to mass transport limitations.  Sustained expression of Runx2 significantly upregulated 
ALP, OCN, and BSP mRNA expression compared to control fibroblasts at 7 days post-
seeding.   After 21 days, OCN mRNA levels were reduced in Runx2-expressing cells to 
levels comparable to control cultures.  ALP and BSP gene expression remained elevated 
in Runx2-expressing cells through 21 days in culture.  Moreover, an unexpected increase 
in the expression of these two osteoblastic markers was also observed in unmodified cells 
at day 21 compared to day 7.  
 
Runx2-transduced fibroblasts deposit biological matrix mineralization on collagen 
scaffolds in vitro 
Mineral deposition on fibrous collagen disks was quantified at 28 and 42 days 
post-seeding by micro-CT imaging (Fig. 5.3A+B).  Runx2-expressing fibroblasts 
deposited significantly higher amounts of mineral on collagen scaffolds cultured in vitro 



















Figure 5.3.  Runx2-transduced fibroblasts deposit mineral within collagen scaffolds 
in vitro.   (A) Representative micro-CT images of Runx2-expressing and unmodified 
fibroblasts seeded on collagen scaffolds and cultured in osteogenic media for 28 and 42 
days.  Scale bar indicates 1 mm. (B) Quantification of bone volume by micro-CT image 
analysis of constructs after 28 and 42 days in vitro culture in osteogenic media (Mean + 
SEM, n=6; ANOVA: p<0.00005; * different from day 28 control, ** different from both 




















































edges of these Runx2-engineered constructs after 21 days in culture, but spread to the 
upper face of disks as the magnitude of mineral increased through 42 days.  Notably, 
scaffolds seeded with unmodified cells showed a low level of radiopaque material at 28 
and 42 days.  These radiopaque regions remained confined to the construct periphery and 
appeared to have an arbitrary, disordered distribution which did not significantly increase 
with time in culture.  Furthermore, the presence of these deposits was highly dependent 
on the lot of serum (data not shown), suggesting that the in vitro culture conditions 
utilized in this study lead to precipitation of non-biological mineral.  These results are 
consistent with reports that high levels of sodium β-glycerophosphate or unidentified 
components from specific serum lots may lead to von Kossa-positive mineral deposits 
which do not resemble the chemical composition of bone mineral.225, 289    
The chemical composition of the mineral phase deposited on Runx2-engineered 
and control constructs was analyzed by Fourier Transform Infrared spectroscopy (FTIR) 
(Fig. 5.4).  Runx2-engineered mineral displayed amide I and II peaks indicative of 
proteins, an enhanced phosphate peak at 1100 cm-1, a doublet split phosphate peak at 560 
and 605 cm-1, and a carbonate peak at 870 cm-1.  This chemical signature represents the 
characteristic bands of a carbonate-containing, poorly crystalline hydroxyapatite and is 
equivalent to that of the cranial bone positive control.227  Notably, the carbonate and 
phosphate doublet peaks were absent in control samples, indicating that the radiopaque 
regions observed on these scaffolds corresponded to non-biological mineral deposits.289 
 Cellular distribution within collagen scaffolds after 42 days in vitro culture was 
visualized by hematoxylin-eosin (H&E) staining of histological sections (Fig. 5.5A).  

















Figure 5.4.  Runx2-engineered constructs display FTIR bands characteristic of 
carbonate-containing, poorly crystalline hydroxyapatite.  Chemical composition of 
the mineral phase was analyzed by Fourier transform infrared spectroscopy (FTIR) at 42 
days post-seeding.  Runx2 and cranial bone samples displayed amide I and II peaks 
indicative of proteins, an enhanced phosphate peak at 1100 cm-1, a doublet split 
phosphate peak at 560 and 605 cm-1, and a carbonate peak at 870 cm-1, which represent 
the characteristic bands of a carbonate-containing, poorly crystalline hydroxyapatite.  
Carbonate and phosphate doublet peaks were absent in control samples, indicating that 





































colonization, with confluent cell populations localized to the outer 100-250 µm of the 
scaffold periphery.  Minimal cell growth was observed within the construct interior, 
likely due to mass transport limitations associated with static culture.290, 291  The presence 
of mineralized matrix within Runx2-engineered constructs was confirmed by von Kossa 
staining of histological sections (Fig. 5.5B).  Phosphate-positive regions were detected 
adjacent to Runx2-expressing fibroblasts and were confined to the outer 400-600 µm of 
the scaffold periphery.  von Kossa positive staining was also observed on the side borders 
of control scaffolds, likely due to detection of artifactual phosphate precipitates.  
Histological analyses were corroborated by cross-sectional micro-CT images (Fig. 5.5C).  
Mineral deposition by Runx2-transduced cells was observed on the sides and upper face 
of the scaffold circumference, co-localizing with cellular distribution.  Conversely, 
radiopaque regions detected in control samples remained confined to the side borders of 
each construct despite the presence of dense cell populations throughout the construct 
periphery.   
  
Runx2-transduced dermal fibroblasts form mineralized templates in vivo  
 
Tissue-engineered constructs were implanted into an ectopic, subcutaneous site in 
order to assess the mineralization capacity of these cells in the absence of osteoinductive 
cues and cell-types typically present in orthotopic defects.  Importantly, collagen 
scaffolds seeded with Runx2-expressing cells displayed a significant increase in mineral 
volume after 28 days in vivo, while controls (unmodified cells, empty vector cells, empty 

















Figure 5.5.  Fibroblasts and mineral deposits co-localize to construct periphery in 
vitro. Histological and micro-CT analyses were conducted on cell-seeded scaffolds after 
42 days in vitro culture.  (A)  Cellular distribution within collagen disks was visualized 
by hematoxylin-eosin (H&E) staining of histological sections.  Scale bar indicates 1 mm.  
(B)  Matrix mineralization within collagen disks was assessed by von Kossa staining of 
histological sections for phosphate deposits typically present within mineralized nodules 
(M = mineral and S = scaffold).  Scale bar indicates 250 µm.  (C) Cross-sectional micro-
CT images depicting the distribution of mineralized matrix on collagen scaffolds seeded 




































Figure 5.6.  Runx2-transduced primary dermal fibroblasts mineralize collagen 
scaffolds in vivo.  Primary dermal fibroblasts were transduced with Runx2 retrovirus, 
empty vector retrovirus, or left unmodified for controls, seeded on fibrous collagen disks, 
and transplanted into a subcutaneous, heterotopic site for 28 days. (A) Representative 
micro-CT images of explanted constructs after 28 days subcutaneous implantation.  Scale 
bar indicates 1 mm. (B) Quantification of bone volume by micro-CT image analysis of 
constructs. (Mean + SEM, n=6; ANOVA: p<0.01; * different from unmodified 


















































Histological analysis was conducted on explanted constructs after subcutaneous 
implantation for 28 days (Fig. 5.7).  Significant remodeling/degradation of collagen 
scaffolds was apparent after 4 weeks in vivo; however, no marked difference in host 
inflammatory response was detected between cell-seeded and cell-free scaffolds.  
Hematoxylin-eosin staining revealed residual collagen fibers (S) and uniform distribution 
of infiltrating host cells throughout all constructs.  After 4 weeks in vivo, punctate 
mineralized nodules (M) were detected by von Kossa staining only within Runx2-
engineered constructs.  Cells with osteoblast-like morphology were found adjacent to and 
embedded within mineralized matrix.   
 
Genetically-engineered donor fibroblasts co-localize with mineralized matrix in vivo 
Immunostaining for Runx2 and eGFP expression was performed on serial 
histological sections in order to assess the spatial distribution of Runx2-expressing 
fibroblasts and infiltrating host cells within collagen scaffolds in vivo (Fig. 5.8).  
Significant staining for both Runx2 and eGFP was visualized within the cytoplasm of 
cells adjacent to the newly formed mineral deposits.  Minimal background staining for 
both proteins was observed in unmodified cell-seeded and cell-free scaffolds (data not 
shown).   Interestingly, specific localized regions of Runx2-positive cells and mineralized 
matrix were detected which did not exhibit an eGFP-positive signal.  Collectively, these 
results suggest that mineral deposition within collagen scaffolds in vivo is primarily of 
donor cell origin, but do not rule out contributions from recipient cells.  Notably, Runx2 





















Figure 5.7.  Donor fibroblasts, host cells, and matrix mineralization are uniformly 
distributed throughout Runx2-engineered constructs in vivo. Histological sections 
were stained with hematoxylin-eosin and von Kossa to observe cellular distribution and 
mineralization throughout cell-seeded and cell-free collagen scaffolds after 28 days in 
vivo (M = mineral and S = scaffold).  (A) 4x micrographs. Scale bar indicates 1 mm.  (B) 
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period, ruling out the possibility that exogenous transgene expression was inactivated in 
vivo.     
 
Discussion 
In the present study, we describe a hybrid ex vivo gene therapy/tissue engineering 
approach based on retroviral gene delivery of the osteogenic transcription factor Runx2 to 
primary dermal fibroblasts.  Sustained expression of Runx2 induced osteogenic gene 
expression and mineralized matrix deposition in fibroblasts cultured on 3-D fibrous 
collagen disks in vitro.  Scaffolds seeded with unmodified control cells showed an 
unexpected low level of radiopaque, von-Kossa positive material, as assessed by micro-
CT imaging and histological analyses, respectively.  However, analysis of the chemical 
composition of the mineral phase with FTIR spectroscopy revealed that Runx2-
engineered scaffolds displayed bands characteristic of a biologically-equivalent, poorly 
crystalline, carbonate-containing hydroxyapatite, whereas this chemical signature was 
absent in control samples.  Importantly, Runx2-transduced fibroblasts produced 
significant levels of matrix mineralization in vivo after 28 days implantation in a 
subcutaneous, heterotopic site, while negligible mineral deposits were evident in control 
constructs.  Furthermore, immunohistochemical analysis revealed that Runx2-expressing 
cells co-localized with mineral deposits in vivo, suggesting that bone formation was 
primarily originated by transplanted donor cells. These results are significant toward the 
identification of a sustained mineralizing cell source for cell-based skeletal regeneration 
therapies.   
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Primary dermal fibroblasts have considerable potential as an autologous cell 
source for ex vivo gene therapy and bone tissue engineering applications, as they are 
easily obtained through minimally invasive skin biopsy and display a high capacity for in 
vitro expansion.    Conventional cell-based approaches typically involve the use of 
terminally differentiated osteoblasts,102, 103 osteogenic cell lines,105 unfractionated bone 
marrow stroma,106, 107 or purified mesenchymal stem cells.14  Immortalized osteogenic 
cell-lines are clonally-derived and well-characterized, but exhibit abnormal regulatory 
mechanisms that may lead to tumorigenic growth in vivo.  Primary osteoblasts are 
difficult to isolate in sufficient quantities from trabecular bone and display a limited 
capacity for proliferation.  Bone marrow-derived osteoprogenitors and purified MSCs 
show significant mineralization capacity in vitro and in vivo.13, 17, 18  However, the 
widespread clinical success of these precursors remains limited by their complex and 
painful cell procurement process, potential for dedifferentiation during in vitro expansion, 
and reduced mineralization capacity associated with the age and disease-state of the 
donor.292   Because of these limitations, non-osteoblastic cell-types such as dermal 
fibroblasts, gingival fibroblasts, and skeletal myoblasts have been considered for their 
clinical relevance to bone repair applications.    
Several growth and differentiation factor-based genetic engineering strategies 
have been employed for the induction of sustained osteogenesis in non-osteoblastic 
fibroblasts.   Adenoviral-transduction of dermal fibroblasts with genes encoding BMP-2 
or BMP-7 induces significant bone formation in both ectopic implantation sites and 
critical sized calvarial defects.21, 24  BMP-7-expressing human gingival fibroblasts also 














Figure 5.8. Genetically-engineered donor fibroblasts co-localize with mineralized 
matrix in vivo.  The spatial localization of Runx2-expressing fibroblasts and mineral 
deposits within collagen scaffolds after 28 days subcutaneous implantation was 
investigated by immunohistochemical staining of serial histological sections for eGFP 
and Runx2 expression.  (A) 10x micrographs. Scale bar indicates 500 µm.  (B) 20x 














combinatorial gene therapy approach based on co-transduction of BMP-2/BMP-7 in 
murine embryonic fibroblasts synergistically enhanced in vivo bone formation compared 
to transduction of individual molecules alone.22    Despite these advances, it is unlikely 
that one single strategy will be universally appropriate for the treatment of the numerous 
orthopedic conditions requiring bone grafting procedures.   Indeed, the potential for 
ectopic bone formation as a result of paracrine signaling to neighboring non-osseous 
tissues may limit the clinical application of growth factor-based approaches.293, 294   In the 
present study, we describe retroviral gene delivery of the osteogenic transcription factor 
Runx2 as a robust strategy for the conversion of primary dermal fibroblasts into a 
mineralizing osteoblastic phenotype.  Runx2 is regulated at multiple levels by a complex 
cascade of soluble factors, hormones, and cell-matrix interactions and is a known 
downstream effector of BMP-2-activated signaling.64, 221  Thus, the use of a genetic 
engineering strategy which focuses on controlling expression of downstream 
transcriptional activator may avoid aberrant effects associated with unregulated secretion 
of soluble, osteoinductive factors.   
It is well documented that adenoviral and retroviral gene delivery of Runx2 
upregulates osteogenic gene expression in osteoblastic and non-osteoblastic cell types.59, 
66, 67, 137   However, we and others have reported that forced Runx2 expression induces 
matrix mineralization in a cell type-dependent manner and is insufficient to direct 
significant in vitro nodule formation in NIH3T3 and IMR-90 fibroblasts, primary murine 
fibroblasts, and the C3H10T1/2 pluripotent fibroblastic cell-line.23, 24, 66  These results 
suggest that Runx2-mediated mineralization requires additional cofactors, which may not 
be endogenously expressed in certain nonosteoblastic cell-types.  Indeed, we have 
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recently reported that dexamethasone treatment is required for matrix mineralization in 
Runx2-expressing fibroblasts cultured in monolayer.136  We applied these observations in 
the present work to demonstrate that primary dermal fibroblasts engineered to 
constitutively express Runx2 create mineralized templates in vitro when cultured on 
collagen scaffolds in osteogenic media supplemented with dexamethasone.  Moreover, 
we also show that Runx2-expressing fibroblasts produced mineralized templates in vivo 
after implantation in a subcutaneous, heterotopic site.   This finding is in contrast to 
previous reports indicating that transient adenoviral Runx2 expression is insufficient to 
produce significant levels of mineralization in vivo23, 24 and suggests that sustained 
expression of this transcription factor is necessary for ectopic mineral deposition by 
transplanted fibroblastic cell-types.  Notably, these results also indicate that in vitro pre-
culture in osteogenic media supplemented with dexamethasone prior to implantation138 is 
not necessary for the formation of robust mineralized templates by Runx2-expressing 
fibroblasts in vivo.     
Bone formation within collagen scaffolds in vivo may be a result of several 
different mechanisms, including: (1) the direct deposition of mineralized matrix by 
Runx2-genetically engineered fibroblasts, (2) the secretion of soluble osteoinductive 
factors by Runx2-genetically engineered fibroblasts, which initiate osteogenic 
differentiation in recipient cells via paracrine signaling, and/or (3) the conversion of a 
specific population of recipient cells into a mineralizing osteoblast-like phenotype 
through the osteoinductive surface of collagen disks.  Immunohistochemical analyses 
were performed to investigate the spatial distribution of Runx2-expressing fibroblasts and 
infiltrating host cells relative to mineral deposits within collagen scaffolds in vivo.  
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GFP+/Runx2+ cells co-localized with von Kossa-positive regions, suggesting that 
mineral formation primarily originates from genetically engineered donor fibroblasts.   
Interestingly, the presence of isolated mineralized nodules which spatially align with 
Runx2-expressing cells in the absence of GFP+ signal suggests that infiltrating host cells 
which endogenously express Runx2 may also contribute to in vivo mineral formation.  
Histological analyses revealed cells with osteoblast-like morphology adjacent to and 
embedded within mineralized matrix after 4 weeks in vivo.  In contrast to previous 
reports,23, 25 tissue morphology indicative of bone marrow, cortical bone, and/or cartilage 
was not observed, potentially because temporal changes in cellular differentiation 
throughout the implantation period (28 days) were not monitored in this work.   
In the present study, unmodified control fibroblasts seeded on fibrous collagen 
disks displayed an unexpected upregulation of ALP and BSP gene expression and 
deposition of von Kossa-positive, radiodense plaques after 21-28 days in vitro culture in 
osteogenic media.  Our observations are consistent with a recent report from Hee et al. 
demonstrating that scaffold architecture and chemical composition markedly influences 
osteoblastic gene expression in human dermal fibroblasts.295  At first glance, these results 
suggest that the conversion of a non-osteoblastic cell source into a differentiated 
osteoblastic phenotype may be partially induced by scaffold-dependent effects.  
However, it has been well documented that in vitro culture conditions can lead to non-
biologic mineral precipitation.225, 289, 296, 297  Indeed, further investigation of the chemical 
composition of the mineral phase within control constructs by FTIR spectroscopy 
revealed the absence of the chemical signature characteristic of carbonate-containing, 
poorly crystalline hydroxyapatite.227  Importantly, radiodense regions were not detected 
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on unmodified fibroblast-seeded control constructs implanted in vivo, confirming that the 
presence of non-biological mineral was an artifact of in vitro culture conditions.   Finally, 
histological analyses showed that Runx2-expressing fibroblasts and mineral deposits 
were uniformly distributed throughout constructs implanted in vivo, but remained 
preferentially localized to the periphery of constructs cultured in vitro.  Indeed, mass 
transport limitations associated with static culture are known to cause cell necrosis within 
the inner core of tissue engineered constructs135, 138 and several groups have developed 
perfusion bioreactors to mimic the dynamic environment experienced by cells in vivo.290, 
291, 298  Collectively, these results highlight the limitations of in vitro pre-culture for tissue 
engineering applications and underscore the importance of rigorous characterization of in 
vitro mineral deposits,  particularly because the chemical composition of the 
hydroxyapatite mineral phase modulates osseointegration in vivo.299-302       
In summary, we have demonstrated that sustained expression of Runx2 induces 
osteoblastic differentiation and biological mineral deposition in primary dermal 
fibroblasts cultured on fibrous collagen scaffolds in vitro and in vivo.  The conversion of 
non-osteoblastic dermal fibroblasts into a sustained mineralizing cell source is significant 
toward the development of mechanically robust bone grafts which genetically match the 




MINERALIZATION CAPACITY OF RUNX2-GENETICALLY 
ENGINEERED FIBROBLASTS IS SCAFFOLD DEPENDENT* 
 
Introduction 
Conventional orthopaedic grafting templates based on autogenic bone, allogenic 
bone, or synthetic materials are widely utilized for the clinical treatment of non-healing 
skeletal defects.  Although successful in many cases, these grafts remain limited by 
inadequate osseo-integration, donor site morbidity, poor mechanical properties, and/or 
the risk of disease transmission 3, 77-80, 303.  Bone tissue engineering has emerged as a 
promising strategy to overcome complications associated with these traditional skeletal 
repair therapies 9-12.  Tissue-engineered bone substitutes have been successfully 
developed through the integration of osteoinductive growth factors and/or osteogenic 
cells into an osteoconductive scaffolding matrix.  Notably, several groups have 
demonstrated in vitro and in vivo mineralization and repair of bone defects by combining 
marrow-derived mesenchymal stem cells with three-dimensional scaffolds 13-18.  Despite 
these advances, the development of mechanically robust skeletal grafts which are 
immunoaccepted by the host and are capable of healing large, critical sized defects has 
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Development of tissue-engineered constructs for skeletal regeneration of large 
critical-sized defects requires the identification of a sustained mineralizing cell source 
and careful optimization of scaffold architecture and surface properties.  We have 
recently reported that Runx2-genetically engineered primary dermal fibroblasts express a 
mineralizing phenotype in monolayer culture, highlighting their potential as an 
autologous osteoblastic cell source which can be easily obtained in large quantities.  One 
significant barrier toward the clinical application of tissue engineered bone grafts is the 
inadequate availability of a sustained mineralizing cell source.  In order to address this 
limitation, genetic engineering strategies have been developed for the induction of 
osteoblastic differentiation in nonosteogenic cells  20-22, 67.  In particular, gene delivery of 
soluble factors, such as BMP-2 and BMP-7, or osteogenic transcription factors, such as 
Runx2/Cbfa1, has been investigated for the conversion of fibroblastic cell lines into an 
osteoblastic phenotype 23-25, 304.  We have recently demonstrated that retroviral Runx2 
overexpression induces significant levels of mineral deposition by primary dermal 
fibroblasts cultured in monolayer 305.  These genetically modified fibroblasts have 
considerable potential as a cell source for bone tissue engineering applications because 
they are easily obtained from autologous donors through minimally invasive skin biopsy 
and have a high capacity for in vitro expansion.  
  In addition to the identification of an autologous mineralizing cell source, the 
successful development of bone grafting templates requires careful optimization of 
scaffold architecture and surface properties.  Biomaterial scaffolds typically function as a 
three-dimensional structural support which promotes cell attachment, proliferation, and 
differentiation into functional osteoblasts and facilitates functional integration into the 
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defect site.  Various classes of materials have been considered for skeletal grafting 
applications, including ceramics, natural and synthetic polymers, and their composites 306.  
Among these, scaffolds based on naturally-derived collagen and synthetic 
polycaprolactone (PCL) and polylactide-co-glycolide (PLGA) polymers were selected for 
investigation in this study because of their widespread use in tissue engineering 
applications, well-documented biodegradation profile, FDA-approval, and commercial 
availability 307-310.  These scaffolds present a broad range of architectural and surface 
properties (e.g. topography, surface chemistry, roughness) that may potentially influence 
the biological response of seeded cells 311.  The objective of the present work is to 
evaluate the ability of three commonly utilized, commercially available scaffolds to 
support in vitro matrix mineralization when seeded with Runx2-expressing fibroblasts.   
 
Materials and Methods 
Cells and Culture Reagents 
Primary fibroblasts were harvested from 8- to 16-week-old male Wistar rats by 
enzymatic digestion of the dermal skin layer 220.  Cells were expanded in growth media 
consisting of DMEM, 10% fetal bovine serum, and 1% penicillin-streptomycin.  
Antibiotics and cell culture media were obtained from Invitrogen (Carlsbad, CA), fetal 
bovine serum was purchased from Hyclone (Logan, UT), and all other cell culture 




The Runx2 retroviral vector utilizes the promoter activity of a 5’ long terminal 
repeat to express a single, bicistronic mRNA encoding the murine cDNA for the type II 
MASNSLF Runx2 isoform 221, 222, followed by an internal ribosomal entry site and a 
Zeocin resistance-enhanced green fluorescent fusion protein (eGFP)66.  Empty vector 
control vector lacked the Runx2 insert.  Plasmid DNA was purified from transformed E. 
coli using Megaprep kits from Qiagen (Valencia, CA).  Retroviruses were packaged by 
transient transfection of helper-virus free ΦNX amphotropic producer cells with plasmid 
DNA as described elsewhere 66, 135.  
Passage four primary fibroblasts were plated on tissue culture-grade polystyrene 
coated with 1 mg/ml type I collagen (Cohesion, Palo Alto, CA).  Cells at 40-60% 
confluence were transduced with Runx2 or empty vector retroviral stocks and maintained 
in osteogenic growth media consisting of DMEM, 10% fetal bovine serum, 100 U/ml 
penicillin G sodium, and 100 µg/ml streptomycin sulfate.   Runx2-transduced cells were 
analyzed for transduction efficiency by quantification of eGFP expression via flow 
cytometry with a Vantage SE cell sorter (Becton-Dickinson, San Jose, CA).  High levels 
of eGFP were detected in ≥ 65% of primary dermal fibroblasts at 72 hours post-
transduction.  Transgene expression was still detectable at 21 days post-transduction (data 
not shown), demonstrating sustained and integrated expression of the target gene by the 
retroviral vector.  Selection of Runx2/eGFP-positive cells was not performed.   
 
Scaffold Seeding  
The scaffolds investigated in this study were: (i) 75/25 PLGA (REGEN Biotech 
Inc., Korea, 8 mm diameter × 2 mm thick, 100-200 µm pore size, 85% porosity), (ii) 
 110
fused deposition-modeled PCL (8 mm diameter × 2 mm thick, 300-500 µm pore size, 
66% porosity) 312, and (iii) and fibrous collagen disks (Kensey Nash, Exton, PA, 8 mm 
diameter x 2 mm thick, average pore size 61.7 µm, 93.7% pore volume).  Scaffolds were 
coated with 20 µg/ml fibronectin in order to promote initial cell adhesion.  At sixty hours 
post-infection, Runx2-transduced, empty vector-infected, and unmodified cells were 
trypsinized and seeded at 5x105 cells/scaffold in DMEM supplemented with 10% fetal 
bovine serum, 100 U/ml penicillin G sodium, and 100 µg/ml streptomycin sulfate.  
Constructs were transferred twenty-four hours post-seeding to osteogenic differentiation 
media consisting of DMEM, 10% fetal bovine serum, 100 U/ml penicillin G sodium, 100 
µg/ml streptomycin sulfate, 50 µg/ml L-ascorbic acid, 2.1 mM sodium β-
glycerophosphate, and 10 nM dexamethasone.  Culture media was changed every 2 days 
until end-point assay.  No differences were observed between empty vector retrovirus 
(negative control) and unmodified cells in all experiments.   
 
Cell Viability  
 Scaffolds were harvested at 1, 21, and 42 days post-seeding, rinsed in complete 
Dulbecco’s phosphate buffered saline (PBS), and incubated in 4 µM calcein-AM and 4 
µM ethidium homodimer-1 (Molecular Probes, Eugene, OR) in PBS for 30 minutes under 
gentle agitation. Constructs were then rinsed (3 x 10 minutes) in PBS and analyzed with a 
Zeiss LSM 510 Confocal Microscope using Ar and HeNe lasers and a 5x objective lens.   
 
Cell Seeding Efficiency and DNA Content 
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 Samples were harvested 24-hours post-seeding, rinsed with PBS, and frozen at -
80°C.  Scaffolds and serially diluted cell standards were thawed, lyophilized, and 
digested at 55°C in 500 µl of 0.25 mg/ml proteinase K (Fisher Scientific, Pittsburgh, PA) 
in 100 mM ammonium acetate (pH 7.0) for 24 hours.  Digested samples were assessed 
for DNA content via the PicoGreen dsDNA Quantitation Kit (Molecular Probes, Eugene, 
OR).  DNA data was converted to cell numbers using a linear standard curve and 
normalized by original seeding density (500,000 cells/scaffold) to determine cell seeding 
efficiency.     
 
Real Time RT-PCR 
 Total RNA was isolated at 7 and 21 days post-seeding using the RNeasy RNA 
isolation kit with RNAlater stabilization reagent (Qiagen).  cDNA synthesis was 
performed on DNaseI-treated (27 Kunitz units/sample) total RNA (0.25 µg) by oligo(dT) 
priming using the Superscript™ First Strand Synthesis System for RT-PCR (Invitrogen, 
Carlsbad, CA).  Gene expression was assessed by quantitative RT-PCR using SYBR 
Green intercalating dye (Molecular Probes) and rat-specific primers 66, 137.  Primer 
specificity was confirmed by ABI Prism 7700 Dissociation Curve Software. Standards 
for each gene were amplified from cDNA using real-time oligonucleotides, purified using 
a Qiagen PCR Purification kit, and diluted over a functional range of concentrations.  
Transcript concentration in template cDNA solutions was quantified from a linear 
standard curve, normalized to total RNA (0.25 µg), and expressed as nanomoles of 
transcripts per µg of total RNA.  Detection limits for each gene were determined by 




 High resolution X-ray microcomputed tomography (micro-CT) with a Scanco 
µCT Medical CT 40 imaging system (Bassersdorf, Switzerland) was used to quantify in 
vitro mineralization of 3-D scaffolds.  Formalin-fixed specimens were scanned in 70% 
ethanol at 16 µm voxel resolution and evaluated at a threshold corresponding to a linear 
attenuation of 0.96 cm-1, filter width of 1.2, and filter support of 2.0.  Reconstructed and 
thresholded images were evaluated using direct distance transformation methods to 
calculate mineralized matrix volume within each construct 288.     
 
FTIR Spectroscopy 
 Scaffolds at 42 days post-seeding were fixed in 100% ethanol and dried at 50ºC 
overnight.  Bone samples were scraped from a lyophilized rat cranium and used as a 
positive control.  Bulk samples were mixed with KBr (Sigma) and pressed into pellets 
with a custom built apparatus.  Samples were analyzed with a Nicolet Nexus 470 FTIR 
spectrometer (ThermoNicolet, Madison, WI) equipped with a DTGS detector.  Sixty-four 
scans were acquired at 4 cm-1 resolution under N2 purge.  
 
Histology  
 Formalin-fixed constructs were paraffin embedded and sectioned at 5 µm 
thickness.  Sections were stained with hematoxylin-eosin and von Kossa to observe 




All experiments were performed three times in triplicate, each with unique Runx2 
retroviral supernatant preparations, and two independent isolates of primary dermal 
fibroblasts.  Data are reported as mean ± standard error of the mean (SEM), and statistical 
comparisons using SYSTAT 8.0 were based on an analysis of variance (ANOVA) and 
Tukey’s test for pairwise comparisons, with a p-value < 0.05 considered significant.  In 
order to make the variance independent of the mean, statistical analysis of real-time PCR 
data was performed following logarithmic transformation of the raw data 66.     
 
Results 
Cellular Viability  
Runx2-expressing and unmodified fibroblasts were seeded on collagen, PCL, and 
PLGA scaffolds at a density of 500,000 cells/construct and cultured in vitro under static 
conditions in osteogenic differentiation media.  Scaffold colonization and cellular 
viability were assessed at 1, 21, and 42 days post-seeding by confocal microscopy and 
Live/Dead staining (Fig. 6.1).   After 1 day in culture, cells displayed a fibroblastic 
morphology and were evenly distributed throughout all three scaffolds.  Marked increases 
in green fluorescent intensity were observed at 21 and 42 days, indicating that cells 
remained viable and exhibited a time-dependent increase in construct colonization 
throughout the culture period.  After 42 days in culture, confluent populations of viable 
cells and minimal necrotic regions (<5%) were observed at the periphery of all 
constructs.  Cell viability did not appear to be dependent on scaffold properties.  















Figure 6.1.  Runx2-transduced fibroblasts remain viable and populate polymeric 
scaffolds in vitro.   Fibroblasts were transduced with Runx2 retrovirus, seeded on 
collagen, PLGA, or PCL scaffolds and cultured in vitro with osteogenic media.  Cellular 
viability was assessed at 1, 21, and 42 days post-seeding by confocal microscopy and 















PLGA, and PCL matrices, with construct colonization directed along the structural 
architecture of each scaffold.   
 
Scaffold Colonization and Seeding Efficiency 
Scaffold seeding efficiency and changes in cell number during in vitro culture 
were evaluated by quantification of DNA content at 1, 21, and 42 days post-seeding (Fig. 
6.2A+B).  After 1 day in culture, collagen scaffolds contained the greatest number of 
Runx2-expresing fibroblasts, corresponding to a seeding efficiency of 43.9 ± 6.5%, while 
PCL and PLGA exhibited significantly lower seeding efficiencies of 11.1 ± 1.9% and 
23.6 ± 2.1%, respectively.  After 21 days in culture, collagen and PLGA scaffolds 
showed a significant decrease in cell number, which leveled off at 42 days post-seeding.  
In contrast, Runx2-expressing fibroblasts seeded on PCL scaffolds exhibited a marked 
increase in cell number at 21 days post-seeding, which also leveled off at day 42.  
Because these trends are inconsistent with the increase in cell colonization observed at 
the periphery of fibrous collagen/PLGA sponges by fluorescence microscopy (Figure 1), 
we attribute the time-dependent reduction in DNA content to cell necrosis or lack of 
colonization within the inner core of these constructs.  No differences in cell viability or 
colonization patterns were detected between Runx2-expressing and unmodified control 
cells at any time point (data not shown).   
  
Osteoblastic Gene Expression 
 Osteogenic gene expression was investigated at 7 days post-seeding by 













Figure 6.2.  Tissue-engineered constructs are differentially colonized by Runx2-
expressing fibroblasts.  Fibroblasts were transduced with Runx2 retrovirus, seeded on 
collagen, PLGA, or PCL scaffolds and cultured in vitro with osteogenic media.  (A) Cell 
seeding efficiency was determined by quantification of DNA content and cell number 
present in scaffolds at 1 day post-seeding (Mean ± SEM, n=6; ANOVA: p<0.002; 
*different from Runx2-PCL (p<0.05); § different from Runx2-PLGA (p<0.05)).  (B)  
Cell numbers throughout culture period were evaluated by quantification of DNA content 






















































































Figure 6.3.  Runx2 upregulates osteoblastic gene expression in fibroblasts seeded on 
polymeric scaffolds.   Fibroblasts were transduced with Runx2 retrovirus or left 
unmodified for controls, seeded on collagen, PLGA, or PCL scaffolds, and cultured in 
vitro with osteogenic media.  mRNA transcript levels were investigated by quantitative 
RT-PCR at 7 days post-seeding (Mean + SEM, n=3; ANOVA: p<1E-3; * different from 
control-PCL only (p<0.05); **different from control-collagen and control-PCL (p< 0.05); 














































































well-documented role during the osteoblastic differentiation program, including: Runx2, 
alkaline phosphatase (ALP), osteocalcin (OCN), and bone sialoprotein (BSP) 224.  Runx2 
mRNA was upregulated by at least one order-of-magnitude in Runx2-transduced 
fibroblasts seeded on all three scaffolds compared to unmodified control cells seeded on 
the same scaffolds (data not shown).  Sustained expression of Runx2 significantly 
enhanced ALP and BSP expression in fibroblasts seeded on collagen, PLGA, and PCL 
scaffolds.  Moreover, BSP gene expression was significantly higher on Runx2-engineered 
collagen and PCL constructs than on Runx2-engineered PLGA foams.  OCN mRNA was 
upregulated in Runx2-engineered fibroblasts relative to unmodified control cells when 
seeded on fibrous collagen disks, but not when seeded on PCL or PLGA synthetic 
matrices.  18S gene expression was used as a loading control and remained unchanged 
for all treatment groups.     
 
Mineral Deposition and Characterization 
Mineralization within tissue-engineered constructs was quantified by micro-CT 
imaging at 28 and 42 days post-seeding (Fig. 6.4A+B).  Runx2-expressing fibroblasts 
deposited significantly higher levels of mineralized matrix on collagen scaffolds cultured 
in vitro for 28 and 42 days compared to unmodified cells.  Mineral deposition was also 
increased on Runx2-engineered PLGA foams relative to constructs containing control 
cells at 42 days post-seeding only.  In contrast, Runx2-expressing fibroblasts seeded on 
PCL scaffolds showed no significant difference in mineral deposition compared to 
control cells at all time points.  Importantly, genetically engineered cells displayed a 



















Figure 6.4.  Mineralization capacity of Runx2-engineered fibroblasts is scaffold-
dependent.  (A) Representative micro-CT images of Runx2-expressing and unmodified 
fibroblasts seeded on collagen, PCL, and PLGA scaffolds and cultured in osteogenic 
media for 42 days.  Scale bar indicates 1 mm. (B) Quantification of mineral volume by 
micro-CT image analysis of constructs after 28 and 42 days in vitro culture in osteogenic 
media (Mean + SEM, n=6; ANOVA: p<1E-11; *different from control-PCL, Runx2-
PCL, and control-PLGA (p<1E-5); § different from Runx2-PLGA (p<1E-5); ‡ different 































































to PCL and PLGA synthetic matrices.  A low level of radiopaque material was detected 
on all scaffolds seeded with unmodified control cells, with collagen showing significantly 
more background than PCL and PLGA.    The presence of this radiodense material was 
dependent on the lot of serum (data not shown) and did not significantly increase with 
time in culture, suggesting that in vitro culture conditions may have led to amorphous 
calcium phosphate or non-biological mineral precipitation.   
Fourier Transform Infrared spectroscopy (FTIR) was used to characterize the 
chemical composition of the mineral phase deposited within tissue-engineered constructs 
(Fig. 6.5).  Constructs containing Runx2-engineered cells displayed amide I/II peaks at 
1655 cm-1 and 1550 cm-1, an enhanced phosphate peak at 1100 cm-1, a doublet split 
phosphate peak at 560 and 605 cm-1, and a carbonate peak at 870 cm-1.  This chemical 
signature is similar to the profile for cranial bone (positive control) and represents the 
characteristic bands of a carbonate-containing, poorly crystalline hydroxyapatite 227.  
Deposition of biological mineral was observed on Runx2-engineered collagen, PCL and 
PLGA constructs.  Importantly, the carbonate and phosphate doublet bands were absent 
in all three scaffolds seeded with control cells, suggesting that the radiopaque regions 
detected by micro-CT corresponded to non-biological mineral deposits.  These 
observations are corroborated by reports from several other research groups that in vitro 
culture conditions can lead to non-biologic mineral precipitation 225, 289, 296, 297. 
 
Cell and Mineral Distribution 
The distribution of mineral within Runx2-engineered constructs was visualized by 



















Figure 6.5.  Runx2-engineered constructs display FTIR bands characteristic of 
carbonate-containing, poorly crystalline hydroxyapatite.  Chemical composition of 
the mineral phase deposited on (A) collagen, (B) PCL, and (C) PLGA scaffolds was 
analyzed by Fourier transform infrared spectroscopy (FTIR) at 42 days post-seeding.  All 
Runx2-engineered constructs and cranial bone samples displayed amide I and II peaks 
indicative of proteins, an enhanced phosphate peak at 1100 cm-1, a doublet split 
phosphate peak at 560 and 605 cm-1, and a carbonate peak at 870 cm-1, which represent 
the characteristic bands of a carbonate-containing, poorly crystalline hydroxyapatite.  
Carbonate and phosphate doublet peaks were absent in all control constructs, indicating 
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confined to the outer 800 µm and 400 µm periphery of Runx2-engineered collagen and 
PLGA scaffolds, respectively.  In contrast, mineral deposits were distributed throughout 
the interior of Runx2-engineered PCL scaffolds and remained confined to a 50-200 µm 
circumference surrounding polymeric struts.  Cell and mineral distribution within tissue-
engineered constructs was also examined by histological analyses (Fig. 6.6B).  von Kossa 
staining for phosphate deposits confirmed the presence and orientation of mineral 
deposits observed by micro-CT imaging.  All control scaffolds showed a low level of 
background von Kossa staining, likely caused by detection of the phosphate component 
within non-biological mineral deposits. Hematoxylin-eosin (H&E) staining revealed that 
cellular distribution was highly dependent on scaffold properties.  Dense cell populations 
were confined to the outer face and edges of matrices with highly porous, sponge-like 
morphology (collagen and PLGA).  Among these, a markedly thicker layer of cell growth 
was observed at the periphery of collagen compared to PLGA, and minimal cell growth 
was observed in the interior of both constructs.  In contrast, a thin layer of cells were 
observed around all PCL microfilaments, including those within the construct interior.  
Notably, mineralization was co-localized with and adjacent to cell growth on all three 
scaffolds.  No difference in cell distribution was detected in scaffolds seeded with control 
cells relative to Runx2 cells.   
 
Discussion 
We demonstrate that the osteogenic potential of Runx2-expressing fibroblasts is 
highly dependent on the architecture and surface properties of polymeric scaffolds.  


















Figure 6.6.  Scaffolds differentially modulate distribution of fibroblasts and matrix 
mineralization. (A)  Cross-sectional micro-CT images depicting the distribution of 
mineralized matrix within Runx2-engineered constructs 42 days post-seeding.  Scale bar 
indicates 1 mm.  (B)  Cellular distribution and mineral deposition within tissue-
engineered constructs was visualized by staining histological sections with hematoxylin-



























higher levels of mineral on fibrous collagen disks relative to constructs based on PCL and 
PLGA.  The chemical composition of the mineral phase on all three Runx2-engineered 
scaffolds was verified by FTIR spectroscopy to display the characteristic bands of 
carbonate-containing, poorly crystalline hydroxyapatite.  This chemical signature was 
absent in control samples seeded with unmodified fibroblasts.  Moreover, differential 
patterns of cell proliferation and gene expression were observed on tissue-engineered 
constructs, but these trends did not correlate with scaffold-directed mineral deposition.  
Histological analyses revealed that matrix mineralization co-localized with cellular 
distribution, which was confined to the periphery of fibrous collagen and PLGA sponges 
and around the circumference of PCL microfilaments.  Collectively, this work 
underscores the importance of scaffold parameters on the capacity of Runx2-engineered 
primary dermal fibroblasts to differentiate into a mineralizing osteoblastic phenotype for 
bone tissue engineering applications.   
 An ideal biomaterial scaffold for bone grafting applications would satisfy several 
essential design criteria, including: (1) highly porous architecture to ensure cell survival 
and rapid vascular infiltration, (2) easily processed into anatomically-relevant shapes, (3) 
biocompatible to minimize host inflammatory response, (4) well-characterized 
biodegradation profile to enable persistence of bioactive factors at the implantation site, 
(5) surface chemistry/topography which promotes cell adhesion, proliferation, 
differentiation, and (6) mechanical properties which approximate native skeletal tissue 
and are tailored to  the specific load-bearing application 313, 314.   A wide variety of 
polymers have been explored for their ability to satisfy these material requirements.  
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Among these, scaffolds manufactured from naturally-derived collagen and synthetic 
polymers, such as PLGA and PCL, have shown significant promise in numerous grafting 
and cell-transplantation applications 315.  Collagen is biodegradable, osteoconductive, and 
contains biological recognition sequences which may specifically influence cell behavior 
316.  Yet, scaffolds produced with this natural polymer are limited by inadequate 
mechanical properties and batch-to-batch inconsistency.  PCL and PLGA are aliphatic 
polyester polymers used to reproducibly manufacture scaffolds in large-scale with a 
highly controlled degradation profile and architecture 307, 317.  Despite these advantages, 
the hydrophobic surface chemistry and acidic by-products from the degradation of these 
synthetic polymers may create a microenvironment which is suboptimal for cell 
growth/differentiation.  In addition, selection of a fabrication technique also plays an 
important role in defining the biological and mechanical properties of polymeric 
scaffolds.  Conventional fabrication methods (solvent casting, melt molding, gas 
foaming) yield foam-like structures with variable control of pore size, distribution, and 
interconnectivity 314.   More recently, highly reproducible scaffolds with an 
interconnected network of honeycomb-like pores have been fabricated by fused 
deposition modeling 309, 310, 318-320.  Overall, it is clear that many of the specified design 
requirements for scaffold optimization are contradictory, making 
prioritization/reconciliation of these components a challenging step in the development of 
tissue-engineered bone grafts.     
In the present work, we investigated the ability of three polymeric matrices with 
highly divergent properties to support osteoblastic differentiation and mineral deposition.  
The biological response of cells seeded within these matrices may be influenced by 
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scaffold architecture, surface properties (e.g. chemistry, roughness/topography), and/or 
surface chemistry-dependent differences in protein adsorption 311.  Numerous studies 
have shown that biomaterial surface properties, including chemistry and hydrophobicity, 
will modulate the type, quantity, conformation, and activity of adsorbed serum-derived 
proteins 321-325.  These substrate-dependent differences in protein adsorption have distinct 
effects on cellular adhesion and phenotype expression directed by biomaterial substrates 
325-330.  All constructs in this study were pre-coated with the adhesive glycoprotein 
fibronectin and cultured for 42 days in osteogenic media containing serum.  Thus, it is 
possible that scaffold surface chemistry modulated the conformation/activity of adsorbed 
fibronectin or other serum-derived proteins, which in turn may have regulated 
osteoblastic differentiation and mineralization 331, 332.  Furthermore, scaffold architecture 
(porosity, pore size, interconnectivity) has also shown a marked effect on bone formation 
and tissue in growth in vivo 333-336.  However, the effect of pore size on osteoblastic 
proliferation and function in vitro is highly variable depending on the substrate material, 
fabrication method, and the seeded osteogenic cell-type 309, 337-340.  Finally, biomaterial 
surface roughness has been reported to have a marked effect on proliferation, 
metabolism, and differentiation of osteoblastic cell-types 341, 342.  Overall, it is important 
to note that the optimization of scaffold architecture and surface properties would require 
the systematic isolation of each design parameter and the correlation of these parameters 
to osteogenic outcome variables.  This work was intended to serve as a global assessment 
of the osteogenic capacity of Runx2-expressing fibroblasts when seeded on various 
scaffolds and cannot be used to draw direct correlations between individual construct 
parameters and osteogenic differentiation.   
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Scaffold-dependent modulation of cell numbers and colonization patterns within 
tissue-engineered constructs was observed in the present study.  Runx2-expressing 
fibroblasts showed significantly higher seeding efficiency on fibrous collagen disks 
relative to PLGA and PCL matrices.  Notably, this initial cell adhesion showed a strong 
inverse correlation with scaffold pore size (collagen (61.7um) > PLGA (100 um) > PCL 
(500um)), suggesting that a microporous architecture promotes better cell retention than 
an open macroporous network.  Nevertheless, after 42 days in culture, DNA content 
decreased on collagen/PLGA foams and increased on PCL networks.  We speculate that 
the time-dependent reduction in DNA content is due to cell necrosis within the inner core 
of constructs as a result of mass transport limitations associated with the porous, sponge-
like architecture of collagen and PLGA foams 290, 291, 298.  This hypothesis is supported by 
the enhanced cell numbers observed on PCL, where the scaffold’s macroporous, fully 
interconnected channel network may have led to improved diffusion of nutrients/oxygen 
and removal of waste products.  Furthermore, histological analyses revealed that cell 
infiltration and mineral deposition was limited to the outer periphery of scaffolds with a 
fibrous foam-like geometry (collagen, PLGA).  Despite similarities in geometry, collagen 
disks contained a markedly thicker cell layer than PLGA foams at the construct 
periphery, possibly because naturally-derived polymers more closely resemble the 
chemical composition of the cells’ native environment.  In contrast, tissue growth was 
directed along the circumference of interconnected microfilaments of PCL and 
distributed throughout the construct interior.  Collectively, these results suggest that cell 
distribution is predominantly guided by scaffold architecture.   
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Runx2-expressing fibroblasts show the highest capacity for mineralization in vitro 
when seeded on fibrous collagen sponges.  This enhanced cellular phenotype is likely a 
function of the porous scaffold architecture and the biological recognition sequences 
found within type I collagen, which are known to induce osteoblastic differentiation via 
α2β1 integrin-mediated signaling cascades 80, 252, 343, 344.  Overall, trends in mineral density 
did not correlate with scaffold-dependent changes in DNA content, suggesting that 
enhanced mineral deposition is not a simple function of increased cell numbers.  Indeed, 
minimal deposition of mineral was detected on PCL, despite the significant cell numbers 
within these scaffolds, highlighting the importance of the construct’s material properties 
during osteoblastic differentiation. Runx2-engineered PLGA constructs showed 
significantly enhanced mineral deposition compared to PCL scaffolds containing Runx2-
engineered fibroblasts, corroborating reports that PLGA-coated surfaces are more 
osteoconductive than those coated with PCL 345.  Finally, all constructs showed 
upregulation of osteoblastic genes when seeded with Runx2-transduced fibroblasts 
compared to unmodified control cells, but the magnitude of this expression was only 
slightly modulated by scaffold properties.  Trends in gene expression also did not mirror 
mineral deposition, showing that cell function can be differentially modulated by scaffold 
properties despite minimal changes in early phenotypic markers.  Further insights into the 
relative contributions of scaffold architecture and surface chemistry toward osteogenic 
differentiation would be obtained by culturing Runx2-expressing cells on collagen-, 
PLGA-, and PCL-coated two-dimensional surfaces.    
In conclusion, we have demonstrated that the osteogenic potential of Runx2-
expressing fibroblasts is highly dependent on scaffold properties, with fibrous collagen 
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disks exhibiting significantly higher mineral deposition than gas-foamed PLGA sponges 
and fused deposition modeled PCL.  These results highlight the importance of scaffold 
optimization in the development of tissue engineered bone constructs.   
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CHAPTER 7 
ENGINEERING HETEROGENEOUS BONE-LIGAMENT 
INTERFACES WITH A THREE-DIMENSIONAL SPATIAL 




Interfacial zones between tissues provide specialized, transitional junctions 
central to normal tissue function.  These interfaces usually consist of multiple cell-types 
and spatially-graded matrix components arranged in a complex hierarchical structure to 
fulfill specific functional roles.  One example in human anatomy of this important 
structure-function relationship is found in the bone-soft tissue interfaces of the 
musculoskeletal system 346, 347.  In particular, the insertion site between the anterior 
cruciate ligament and the tibia consists of a heterogeneous interface with four distinct 
regions, including: ligament, fibrocartilage, calcified fibrocartilage, and bone 348-350. This 
graded transitional zone facilitates the transmission of complex mechanical loads across 
the knee joint by minimizing stress concentrations at the junction of two tissue types 155, 
351.  Conventional soft tissue autografts typically fail at this insertion site due to 
inadequate tissue integration, further highlighting the physiologic importance of these 
heterogeneous structures 149, 352, 353.  
The lack of robust, functional interfaces between bone and soft tissues severely 
limits the functional integration and biological performance of conventional orthopaedic 
grafting strategies 156.  Tissue engineering principles have been pursued to create these 
heterogeneous interfaces 218.  The general paradigm for this approach, in which 
phenotype-specific cells and/or bioactive growth factors are integrated into polymeric 
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matrices, has been successfully applied in recent years toward the development of bone, 
ligament, and cartilage tissues in vitro and in vivo 142, 148, 156, 354.  Yet, beyond the basic 
evidence of tissue formation, the regeneration of complex tissue structures which 
recapitulate the microarchitecture and function of native tissue has not been realized.  
Overall, the development of graded/transitional interfacial tissue zones represents a 
significant challenge in current tissue engineering and regenerative medicine strategies.   
Emerging themes in early embryonic development provide insights into natural 
biological mechanisms for complex tissue formation 355, 356.  One widely-accepted 
concept is that diffusion of small signaling molecules (i.e. morphogens) from a source to 
a sink leads to concentration gradients which specify spatial cues to specific cells 357.  
Extracellular morphogen gradients often direct cell fate by activating intracellular 
transcription factors via concentration thresholds 358, 359.  Furthermore, the extracellular 
matrix has been found to aid in gradient formation by presenting binding sites for soluble 
morphogens via heparin sulfate proteoglycans 360.  Alternatively, morphogens can also be 
transcription factors with an intracellular mode of action 361-363.  Taken together, these 
principles suggest that the recapitulation of nature-inspired gradients may enable the 
organization of cell fates into specific three-dimensional patterns.   
Current technologies to create gradients of bioactive molecules in vitro involve 
the encapsulation of growth factors within 3-D polymeric matrices or covalent/non-
covalent immobilization of peptide sequences to patterned biomaterial surfaces 364-368.  
These protein-based approaches are limited by suboptimal delivery vehicles, poor 
spatiotemporal dosage control, short protein half-life, and the cost-prohibitive 
supraphysiologic concentrations required to initiate a cellular response 369, 370.  In order to 
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circumvent these issues, we leveraged biomaterial-mediated retroviral gene transfer as a 
novel strategy to create a spatial distribution of genetic material encoding for a tissue-
specific transcription factor within 3-D polymeric networks.  We have previously 
reported that retroviral overexpression of the osteogenic transcription factor Runx2 using 
conventional ex vivo gene transfer techniques in fibroblasts will reprogram this non-
osteoblastic cell into a mineralizing, osteoblastic phenotype in vitro and in vivo 131, 132, 136.  
In the present study, we demonstrate that zonal organization of bone and soft tissue-
mimetic tissue can be engineered by a simple, one step seeding of autologous fibroblasts 
onto polymeric scaffolds containing spatially-defined regions of the Runx2 retroviral 
vector.  This approach is fundamentally different from current strategies used to create 
heterogeneous tissues, which use co-culture of multiple cellular phenotypes and/or multi-
phase scaffolds with pore-size or compositional gradients 217, 371-373.  Overall, this 
research is significant toward the regeneration of transitional interfacial zones which 
mimic the cellular and micro-structural characteristics of native tissue. These strategies 
were developed in the context of the bone-ligament enthesis as a model system, but are 
broadly applicable to a wide variety of heterogeneous biological tissues. 
 
Materials and Methods 
Cell Culture and Reagents 
Primary fibroblasts were harvested from 8- to 16-week-old male Wistar rats by 
enzymatic digestion of the dermal skin layer 220.  Cells were expanded in growth media 
consisting of DMEM, 10% fetal bovine serum, and 1% penicillin-streptomycin.  
Antibiotics and cell culture media were obtained from Invitrogen (Carlsbad, CA), fetal 
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bovine serum was purchased from Hyclone (Logan, UT), and all other cell culture 
supplements and reagents were acquired from Sigma (St. Louis, MO).   
 
Retrovirus Production 
The Runx2 retroviral vector utilizes the promoter activity of a 5’ long terminal 
repeat to express a single, bicistronic mRNA encoding the murine cDNA for the type II 
MASNSLF Runx2 isoform,221, 222 followed by an internal ribosomal entry site and a 
Zeocin resistance-enhanced green fluorescent fusion protein (Fig. 7.1A) 66.  Empty vector 
control plasmid lacked the Runx2 insert.  Plasmid DNA was purified from transformed E. 
coli using Megaprep kits from Qiagen (Valencia, CA).  Retroviruses were packaged by 
transient transfection of helper-virus free ΦNX amphotropic producer cells with plasmid 
DNA as described elsewhere 66.  
 
Scaffold Coating and Seeding 
Scaffolds were coated with 0.01% poly-L-lysine (70,000-150,000 MW), as this 
concentration and charge/molecule ratio has been shown to yield high levels of virus 
particle adsorption and transduction efficiency 374.  In order to test the feasibility of 
biomaterial-mediated retroviral gene transfer, rectangular fibrous collagen scaffolds (3 
mm wide x 8 mm long x 2 mm thick, average pore size 61.7 µm, 93.7% pore volume, 
Kensey Nash, Exton, PA) were uniformly coated with poly-L-lysine (PLL) for 30 
minutes followed by incubation in Runx2 or empty vector retroviral supernatant for 4.5 
hours in a humidified 5% CO2 atmosphere at 32 °C.   Virus-only control scaffolds were 
uniformly coated with water followed by incubation in Runx2 retrovirus, while PLL-only 
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control scaffolds were uniformly coated with PLL followed by incubation in PBS 
supplemented with 10% fetal bovine serum.  All constructs were washed 1-2x with PBS 
and seeded at a density of 2x105 cells/scaffold in osteogenic growth media.   
 In order to generate constructs with a spatial distribution of retrovirus,  collagen 
scaffolds (5 mm wide x 20 mm long x 2 mm thick) were partially coated on the proximal 
end with 0.01% PLL for 30 minutes and incubated in Runx2 or empty vector retroviral 
supernatant for 4.5 hours.   Virus-only control scaffolds were partially coated with water 
followed by incubation in Runx2 retrovirus, while PLL-only control scaffolds were 
partially coated with PLL followed by incubation in PBS supplemented with 10% fetal 
bovine serum.  These gradient constructs were washed 1-2x with PBS and seeded at a 
density of 1x106 cells/scaffold in osteogenic growth media.   
All constructs were transferred twenty-four hours post-seeding to osteogenic 
differentiation media consisting of DMEM, 10% fetal bovine serum, 100 U/ml penicillin 
G sodium, 100 µg/ml streptomycin sulfate, 50 µg/ml L-ascorbic acid, 2.1 mM sodium β-
glycerophosphate, and 10 nM dexamethasone.  Culture media was changed every 3 days 
until end-point assay.  No differences were observed between empty vector retrovirus 
(negative control) and unmodified cells in all experiments.   
 
Cell Viability  
 Scaffolds were harvested at 21 and 42 days post-seeding, rinsed in complete 
Dulbecco’s phosphate buffered saline (PBS), and incubated in 4 µM calcein-AM and 4 
µM ethidium homodimer-1 (Molecular Probes, Eugene, OR) in PBS for 30 minutes under 
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gentle agitation. Constructs were then rinsed (3 x 10 minutes) in PBS and analyzed with a 
Zeiss LSM 510 Confocal Microscope using Ar and HeNe lasers and a 5x objective lens.   
 
DNA Content 
 Samples were harvested at 1, 21, and 42 days post-seeding, rinsed with PBS, and 
frozen at -80°C.  Scaffolds and serially diluted cell standards were thawed, lyophilized, 
and digested at 55°C in 500 µl of 0.25 mg/ml proteinase K (Fisher Scientific, Pittsburgh, 
PA) in 100 mM ammonium acetate (pH 7.0) for 24 hours.  Digested samples were 
assessed for DNA content via the PicoGreen dsDNA Quantitation Kit (Molecular Probes, 
Eugene, OR).  Raw DNA data was converted to cell numbers using a linear standard 
curve. 
 
Real time RT-PCR 
 Total RNA was isolated at 7 days post-seeding using the RNeasy RNA isolation 
kit with RNAlater stabilization reagent (Qiagen).  cDNA synthesis was performed on 
DNaseI-treated (27 Kunitz units/sample) total RNA (0.25 µg) by oligo(dT) priming using 
the Superscript™ First Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA).  
Gene expression was assessed by quantitative RT-PCR using SYBR Green intercalating 
dye (Molecular Probes) and rat-specific primers as previously described 66, 137.  Primer 
specificity was confirmed by ABI Prism 7700 Dissociation Curve Software. Standards 
for each gene were amplified from cDNA using real-time oligonucleotides, purified using 
a Qiagen PCR Purification kit, and diluted over a functional range of concentrations.  
Transcript concentration in template cDNA solutions was quantified from a linear 
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standard curve, normalized to 0.25 µg of total RNA, and expressed as nanomoles of 
transcripts per µg of total RNA.  Detection limits for each gene were determined by 
reactions without cDNA and fall below the y-axis minimum. 
 
Microcomputed Tomography 
 High resolution X-ray microcomputed tomography (micro-CT) with a Scanco 
µCT Medical CT 40 imaging system (Bassersdorf, Switzerland) was used to quantify in 
vitro and in vivo mineralization of 3-D scaffolds.  Formalin-fixed specimens were 
scanned at a 16 µm voxel resolution.  Uniformly coated scaffolds cultured in vitro were 
evaluated at a threshold corresponding to a linear attenuation of 1.04 cm-1, Gauss filter 
sigma of 1.2, and filter support of 2.  The inner volume of partially coated scaffolds 
cultured in vitro was manually segmented to eliminate edge effects and evaluated 
between lower and upper thresholds corresponding to linear attenuations of 2.08 cm-1 and   
3.2 cm-1, respectively.  Partially coated scaffolds implanted in vivo were evaluated at a 
threshold corresponding to a linear attenuation of 1.20 cm-1.   Reconstructed and 
thresholded images were evaluated using direct distance transformation methods to 
calculate mineralized matrix volume within each construct.   
 
Mechanical Testing 
  Fresh specimens were washed in PBS, cut in half (gauge length and width of 10-
mm and 5-mm, respectively), placed into soft-tissue clamps of an ELF 3200 mechanical 
testing system (EnduraTEC / Bose, Eden Prairie, MN), and pulled to failure at a rate of 
0.2 mm/sec. Force was recorded using a 11-lb load cell (Interface, Scotsdale, AZ) and 
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displacement recorded via computer acquisition interface (WinTest, EnduraTEC).  Stress 
and strain were calculated from the force and displacement data by adjusting for the 
tissue’s cross-sectional area and gauge length, respectively.  
 
Subcutaneous Implantation 
 Heterogeneous constructs were subcutaneously implanted into the backs of 7-
week-old syngeneic rats after 24 hours culture in osteogenic growth media (n=3 for each 
treatment group).  Two implants were placed in each animal, one on each side of a 
midline incision into subcutaneous pockets made by blunt dissection.  Constructs were 
explanted after 2 weeks of implantation following euthanasia by CO2 inhalation.  All 
procedures were carried out according to an IACUC-approved protocol as previously 
described 131, 138.   
 
Histology and Immunohistochemistry 
 Formalin-fixed constructs were paraffin embedded and sectioned at 5 µm 
thickness.  Sections were stained with hematoxylin-eosin and von Kossa to observe 
cellular distribution and matrix mineralization within 3-D constructs, respectively.  eGFP 
expression was observed by immunostaining using a colorimetric avidin-biotin kit 
(Vector Labs, Burlingame, CA).  Sections were deparaffinized, rehydrated, and then 
pretreated using protease-induced antigen retrieval in 1 µg/mL proteinase K.  After 
pretreatment, slides were incubated in a rabbit polyclonal primary antibody against eGFP 
(Molecular Probes) followed by sequential incubation in biotinylated anti-rabbit 
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secondary antibody and avidin-biotin linked alkaline phosphatase.  Slides were then 
incubated in Vector Red substrate and counterstained with hematoxylin. 
 
Data Analysis 
Unless otherwise stated, all in vitro experiments were performed two times in 
triplicate, each with unique Runx2 retroviral supernatant preparations, and two 
independent isolates of primary dermal fibroblasts.  Data are reported as mean ± standard 
error of the mean (SEM), and statistical comparisons using SYSTAT 8.0 were based on 
an analysis of variance (ANOVA) and Tukey’s test for pairwise comparisons, with a p-
value < 0.05 considered significant.  In order to make the variance independent of the 
mean, statistical analysis of real-time PCR data was performed following logarithmic 
transformation of the raw data 66. 
 
Results 
Biomaterial-mediated retroviral gene transfer approach 
  As a first step toward creating a heterogeneous interface, we explored the 
feasibility of delivering genetic material to fibroblasts via a biomaterial-mediated 
retroviral gene transfer approach.  We exploited the ability of cationic polymers (e.g. 
poly-L-lysine (PLL), polybrene) to neutralize charge and aggregate retroviral particles in 
order to immobilize retrovirus onto collagen scaffolds 374, 375.  Scaffolds were uniformly 
coated with 0.01% PLL incubated for 4.5 hours in retroviral supernatant, and seeded with 
primary dermal fibroblasts.  Cells were enzymatically digested from collagen scaffolds 
and analyzed for transduction efficiency by quantification of eGFP expression via flow 
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cytometry with a Vantage SE cell sorter (Becton-Dickinson, San Jose, CA).  eGFP 
expression was detected in ≥ 20% of primary dermal fibroblasts after 14 days in culture 
in osteogenic growth media, demonstrating sustained and integrated transgene expression 
by the retroviral vector (Fig. 7.1B).  Quantitative RT-PCR analysis revealed that viral 
uptake of virus is dependent on pre-treating scaffolds with PLL, as eGFP gene expression 
was upregulated on PLL+R2RV-coated scaffolds compared to virus-only controls (Fig. 
7.1C).  These results were corroborated by immunohistochemical staining for eGFP 
expression. eGFP co-localized with fibroblasts only on scaffolds co-treated with 
PLL+R2RV (Fig. 7.1D, E).  Finally, confocal image analysis of live/dead fluorescent 
staining (Fig. 7.1F) and quantification of DNA content (Fig. 7.1G) indicated that 
fibroblasts remain viable throughout the 42 day culture period and equivalently colonize 
collagen scaffolds independent of treatment group.  
 
Biomaterial-mediated gene transfer of Runx2 retrovirus promotes osteogenesis in 
fibroblasts 
 Osteogenic gene expression within uniformly coated constructs was quantified by 
real time RT-PCR after 7 days culture in osteogenic differentiation media (Fig. 7.2A).  
Biomaterial-mediated delivery of the Runx2 retroviral vector upregulated osteoblastic 
gene expression compared to PLL-only and virus-only control constructs.   This response 
was specific to osteogenic markers, as type II collagen expression remained unchanged.  
Mineral deposition within uniformly coated scaffolds was analyzed after 49 days culture 
in osteogenic differentiation media (Fig. 7.2B,C).  Fibroblasts deposited a significant 















Figure 7.1:  Biomaterial-mediated retroviral gene transfer results in efficient transduction 
and sustained transgene expression in fibroblasts. Negatively-charged Runx2 retrovirus 
(R2RV) was immobilized onto fibrous collagen scaffolds uniformly coated with the cationic 
poly-L-lysine (PLL).  Primary dermal fibroblasts were then seeded onto these scaffolds and 
statically cultured in vitro.   (A) The Runx2 retroviral vector expresses the type II Runx2 isoform 
and a Zeocin:eGFP selectable marker from a single bicistronic mRNA.   (B) Detection of GFP 
expression by flow cytometry after enzymatic digestion of cells from collagen scaffolds 
demonstrated efficient fibroblast transduction at 14 days post-seeding.   (C) eGFP mRNA levels 
were upregulated in PLL+R2RV-coated scaffolds compared to controls at 7 days post-seeding, 
demonstrating that viral uptake by fibroblasts is dependent on pre-coating scaffolds with poly-L-
lysine (Mean + SEM, n=3; ANOVA: p<0.05; * different from R2RV only control (p=0.05)). (D) 
The spatial localization of eGFP expression and cell distribution was qualitatively observed 
within histological sections by immunohistochemical staining for eGFP (pink, arrow) and 
hematoxylin and eosin counterstain (blue), respectively.  10x micrographs.  Scale bar=500 µm.  
(E) 20x micrograph of eGFP expression (pink) co-localizing with fibroblasts (blue) within a 
scaffold uniformly coated with PLL+R2RV after 21 days in culture.  Scale bar=250 µm. (F) 
Uniform cellular colonization and viability throughout the 42 day culture period was confirmed 
by confocal microscopy image analysis of live (green)/dead (red) fluorescence staining and (G) 




only controls showed negligible mineral deposits.  Notably, an unexpected low level of 
radiodense material was observed on PLL-only controls, suggesting that in vitro culture 
conditions may lead to precipitation of non-biological mineral.  This possibility was 
further supported by FTIR analysis of the chemical composition of the mineral phase. 
Retrovirus-coated scaffolds and cranial bone samples displayed the characteristic bands 
of carbonate-containing, poorly crystalline hydroxyapatite, while this chemical signature 
was absent in control samples.  In addition, immunohistochemical staining for eGFP 
expression was performed to assess the spatial distribution of transduced fibroblasts 
within uniformly coated constructs (Fig. 7.2D).  eGFP-positive cells co-localized with 
von Kossa-positive mineral deposits, indicating that mineral deposition was primarily 
originated by fibroblasts which were susceptible to biomaterial-mediated viral gene 
delivery.   
 Importantly, histological and micro-CT analyses of cross-sectional images 
revealed that cell colonization and mineral deposition patterns are differentially 
modulated by the virus delivery strategy (Fig. 7.3A,B).  Mineral deposits displayed a 
dense morphology and were confined to the periphery of scaffolds seeded with 
fibroblasts engineered with Runx2 retrovirus by conventional gene transfer techniques.  
In contrast, discrete mineralized nodules corresponding to transduced cell colonies were 
distributed throughout the interior of scaffolds that had been coated with PLL+R2RV 
prior to cell seeding.  These results are important because the clinical application of 
current tissue engineering strategies to critical-sized bone defects is significantly limited 
by the formation of a mineralized shell around the scaffold periphery which, 













Figure 7.2:  Biomaterial-mediated gene delivery of Runx2 retrovirus promotes 
osteoblastic differentiation in fibroblasts.  Scaffolds were uniformly coated with poly-
L-lysine (PLL) and incubated in retroviral supernatant (R2RV) prior to seeding with 
primary dermal fibroblasts. (A)  Osteogenic gene expression was upregulated within 
constructs uniformly coated with PLL+R2RV compared to virus-only and PLL-only 
controls after 7 days in vitro culture in osteogenic media. (Mean + SEM, n=3;  Runx2: 
ANOVA: p=0.002, ** different from both R2RV only (p=0.01) and PLL only (p=0.002) 
controls;  BSP: ANOVA:  p= 0.000066, ** different from both R2RV only (p=0.00009) 
and PLL only (p=0.00023) controls;  CollagenI:  ANOVA: p=0.017, * different from 
PLL only control (p=0.015). (B)  Micro-CT images showing enhanced mineral deposition 
on scaffolds uniformly coated with PLL+R2RV compared to virus-only and PLL-only 
controls. Scale bar=1 mm.   (C)  Mineral deposition within uniformly coated scaffolds 
was quantified by micro-CT image analysis after 49 days in osteogenic media. (Mean + 
SEM, n≥4; ANOVA: p<0.0001; ** different from both R2RV only (p=0.00018) and PLL 
only (p=0.05) controls).    (D) Histological analyses revealed that genetically-engineered 
eGFP-positive fibroblasts co-localized with mineral deposits, indicating that mineral 
deposition was primarily originated by fibroblasts which were susceptible to biomaterial-
mediated viral gene delivery.  Cell and mineralized matrix distribution was visualized by 
staining serial histological sections for eGFP expression (eGFP immunohistochemistry, 
pink), fibroblasts (H&E, blue), and phosphate deposits typically present within 



























Figure 7.3.  Fibroblast colonization and mineral deposition patterns are 
differentially modulated by virus delivery strategy.  (A)  Cross-sectional micro-CT 
images depicting the distribution of mineralized matrix within Runx2-engineered 
constructs.  Scale bar indicates=1 mm.   (B)  Cell and mineral distribution within collagen 
disks was visualized by hematoxylin-eosin (H&E) and von Kossa staining, respectively.  
Scale bar=250 µm.   Mineral deposits displayed a dense morphology and were confined 
to the periphery of scaffolds seeded with fibroblasts engineered by conventional ex vivo 
gene transfer techniques.  In contrast, discrete mineralized nodules corresponding to 
individual transduced cells were distributed throughout the interior of scaffolds that had 



















these results indicate that biomaterial-mediated retroviral gene delivery is a feasible 
strategy for the genetic modification and differentiation of fibroblasts into a mineralizing 
osteoblastic phenotype within 3-D matrices. 
 
Spatially-regulated genetic modification of fibroblasts in 3-D matrices  
 A spatial distribution of Runx2 retrovirus was created by partially coating the 
proximal end of scaffolds with PLL prior to incubation in retroviral supernatant (Fig. 
7.4).  These constructs were then seeded with primary dermal fibroblasts and cultured in 
vitro under static conditions in osteogenic media until endpoint assay.  
Immunohistochemical staining revealed the presence of a retrovirus-induced graded 
distribution of genetically engineered cells, with eGFP-expressing cells distributed 
throughout the scaffold interior on the proximal, PLL+R2RV-coated portion of constructs 
(Fig. 7.5B).  These Runx2-expressing cells co-localized with a graded distribution of 
mineral deposition, further demonstrating that cellular uptake of the Runx2 retroviral 
vector is highly dependent on the adsorption of the retrovirus to positively-charged PLL 
prior to cell seeding (Fig. 7.5C).  Confocal microscopy image analysis of live/dead 
fluorescent staining showed that cell distribution and viability were uniform throughout 
the scaffold, confirming that the spatial distribution of mineral was not due to differences 




























Figure 7.4.  Biomaterial-mediated gene transfer approach used to spatially control 
genetic modification and differentiation of fibroblasts within 3-D matrices.  (A) A 
spatial distribution of Runx2 retrovirus was created in 3-D by coating the proximal 
portion of fibrous collagen scaffolds with positively-charged poly-L-lysine prior to 
incubation in retroviral supernatant.  These constructs were then seeded with primary 
dermal fibroblasts and cultured in vitro in osteogenic media or implanted in vivo into a 
subcutaneous, ectopic site until characterization with end point assays.  (B)  Schematic 
representation of cell-seeded constructs containing a spatial distribution of non-




























Figure 7.5.   Spatially regulated genetic modification of fibroblasts in 3-D matrices 
containing a graded distribution of Runx2 retrovirus. A spatial distribution of Runx2 
retrovirus was created by partially coating the proximal portion (left side) of fibrous 
collagen scaffolds with poly-L-lysine prior to incubation in retroviral supernatant.  These 
constructs were then seeded with primary dermal fibroblasts and cultured in vitro in 
osteogenic media.  (A) Confocal microscopy image of live (green)/dead (red) 
fluorescently-stained cells showing uniform fibroblast distribution.  Scale bar=4 mm.  (B) 
Immunohistochemical staining for eGFP counterstained with hematoxylin (blue) showing 
elevated eGFP expression (pink) on the region with immobilized Runx2 retrovirus. (C) 
Cross-sectional micro-CT image of mineral deposits showing transitional mineralized 
zone co-localizing with eGFP expression. Scaffold is outlined in dashed box. 
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Zonal organization of osteoblastic and fibroblastic phenotypes within 3-D matrices in 
vitro and in vivo 
Gene expression within partially coated constructs was quantified by real time 
RT-PCR after 7 days in osteogenic differentiation media.  Fibroblasts seeded on the 
proximal, PLL+R2RV-coated portion of collagen scaffolds (sideA) exhibited significant 
upregulation of osteoblastic genes, while cells seeded on the distal scaffold portion 
(sideB) incubated in retrovirus alone expressed background levels of these osteoblastic 
markers (Fig. 7.6A). This induction in osteoblastic differentiation was due the presence 
of immobilized Runx2 retrovirus as PLL-only treated scaffolds displayed background 
levels of osteoblastic markers. 
Mineral deposition within partially coated constructs was evaluated with micro-
CT image analysis after 42 days culture in osteogenic differentiation media.  Remarkably, 
scaffolds containing a spatial distribution of immobilized retrovirus (PLL+R2RV) 
showed zonal organization of both mineral deposition and non-mineralized, fibroblastic 
extracellular matrix (Fig. 7.6B).  The magnitude of the mineral volume fraction was 
highest on the proximal end of the scaffold and decreased gradually along the length of 
the construct toward the distal end (Fig. 7.6C).  This mineral gradient was not detected on 
PLL-only and R2RV-only control constructs.    
The biomechanical properties of these heterogeneous constructs were 
characterized with tensile testing at a strain rate of 0.2 mm/s (Fig. 7.6D).  Construct 
stiffness (0.198 ± 0.038 N) and maximum force at failure (0.277 ± 0.04 N/mm) were 
significantly enhanced on the proximal, PLL-coated portion (side A) of R2RV-coated 
scaffolds when compared to control specimens.  Furthermore, the material properties of 
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R2RV-coated constructs (Young’s Modulus (0.16 ± 0.024) and maximum stress (0.03 ± 
0.004)) were also significantly upregulated compared to control samples.  Taken together, 
this data demonstrates that increases in both the structural and material mechanical 
properties of heterogeneous bone-ligament tissue constructs are localized to scaffold 
regions containing the highest amount of mineralized tissue.   
Finally, engineered scaffolds were implanted into an ectopic, subcutaneous site in 
order to assess the capacity of these constructs to mature into a bone-ligament-mimetic 
tissue in vivo in the absence of osteoinductive cues and cell-types typically present in 
orthotopic defects.   Micro-CT image analysis revealed spatial patterning of mineral 
deposition within constructs containing a graded distribution of the Runx2 retroviral 
vector after 14 days in vivo (Fig. 7.7A,B).  Negligible mineral deposits were detected on 
control constructs coated with empty vector retrovirus.  
 
Discussion   
The ultimate goal of tissue engineering is the regeneration of complex tissues 
which mimic the cellular and micro-structural characteristics of native tissue to restore 
normal function. The objective of the present study was to engineer a heterogeneous 
bone-soft tissue interface by spatially regulating the expression of a tissue-specific 
transcription factor in fibroblasts within 3-D matrices.  Toward this end, we first 
demonstrate that biomaterial-mediated retroviral gene transfer is a feasible strategy for 
the genetic modification and differentiation of fibroblasts into a mineralizing osteoblastic 
phenotype.  We then leveraged the observation that retroviral uptake from tissue 












Figure 7.6.  Zonal organization of osteoblastic and fibroblastic phenotypes created 
by 3-D retroviral gradients in vitro.  A spatial distribution of Runx2 retrovirus was 
created by partially coating the proximal (left half, side A) portion of scaffolds with poly-
L-lysine (PLL) prior to incubation in retroviral supernatant and cell seeding.  (A) 
Osteogenic gene expression, including Runx2, osteocalcin, and bone sialoprotein, was 
upregulated by at least 2 orders-of-magnitude compared to controls on the proximal, 
PLL+R2RV-coated portion (side A) of a representative scaffold containing a virus 
gradient. (B)  Micro-CT images showing spatial patterning of both mineral deposition 
and non-mineralized, fibroblastic extracellular matrix in tissue engineered constructs 
containing a spatial distribution of immobilized Runx2 retrovirus. This graded mineral 
distribution was not observed on virus-only or PLL-only controls.  Scale bar=3.5mm. (C) 
Quantification of mineral volume in 2 mm segments moving lengthwise down the z-axis 
of representative constructs with micro-CT image analysis. (D) Tensile testing at a strain 
rate of 0.2 mm/s indicated that the structural and material mechanical properties were 
significantly enhanced on the proximal, PLL-coated portion (side A) of R2RV-coated 
scaffolds compared to control specimens.  Notably, this increase in mechanical properties 
corresponding to the region of these constructs containing the highest content of mineral 
deposition.  (Mean + SEM, n>10; Max Force at Failure: ANOVA: p=0.00012; *** ≠ 
EVRV sideB (p=0.000079), EVRV sideA (p=0.0437), and R2RV sideB  (p=0.0089). 
Stiffness: ANOVA: p=0.0004; *** ≠ EVRV sideB (p=0.00034), EVRV sideA (p=0.035), 
and R2RV sideB  (p=0.0122).  Young’s Modulus: ANOVA: p=0.000067; ** ≠ EVRV 
sideB (p=0.000047) and R2RV sideB  (p=0.005).  Maximum stress: ANOVA: 
p=0.000069; *** ≠ EVRV sideB (p=0.000044), EVRV sideA (p=0.049), and R2RV 















Figure 7.7.  Runx2-induced spatial patterning of mineral deposition in vivo.  Dermal 
fibroblasts were uniformly seeded on collagen scaffolds containing a spatial distribution 
of immobilized Runx2 retrovirus (left half of scaffold was coated with poly-L-
lysine/Runx2 retrovirus).  These heterogeneous tissue engineered constructs were 
implanted into a subcutaneous, ectopic site in order to  assess the ability of these 
constructs to create a graded interface in the absence of an osteogenic environment.   (A) 
Micro-CT images of explanted constructs after 14 days in vivo showing a spatial 
organization of mineral deposition. Scale bar=3mm.  (B) Quantification of bone volume 
in 1 mm segments moving lengthwise down the z-axis of representative constructs by 
micro-CT image analysis. The magnitude of the mineral volume was highest on the 
proximal, PLL-coated portion of the scaffold and decreased gradually moving lengthwise 
down the z-axis of the construct toward the distal end. This positional mineral 
















































retrovirus within tissue engineered constructs.  These 3-D retroviral gradients resulted in 
spatially regulated genetic modification of fibroblasts and, consequently, zonal 
organization of osteoblastic and fibroblastic cellular phenotypes in vitro.  Furthermore, 
spatial patterns of mineral deposition and non-mineralized fibroblastic extracellular 
matrix were also observed after subcutaneous in vivo implantation.  Taken together, these 
results indicate that a continuous, biphasic bone-soft tissue interface can be developed by 
a simple, one step seeding of fibroblasts into polymeric scaffolds containing a graded 
distribution of the Runx2 retroviral vector.  Notably, the proposed work focuses on a 
single cell type to generate these heterogeneous tissue constructs; this aspect is 
fundamentally different from current approaches dealing with creating bi/tri-layered 
scaffolds via multiple steps and combining different cellular phenotypes (e.g., osteoblasts 
and fibroblasts) 217, 371, 372.   
Concentration gradients of extracellular and intracellular morphogens play a 
central role in directing cell fate and establishing tissue axes during embryonic pattern 
formation 355, 356.  Remarkably, embryonic positional fields less than 30 cells wide can be 
organized into discrete domains of gene expression with crisp borders 376.  Mechanisms 
by which these gradients are translated into precise spatial control over cellular response 
are not fully understood.  Yet, one predominant theme is that morphogen diffusion leads 
to the activation of downstream transcription factors via differential cell sensitivity to 
concentration thresholds 356, 358 .  We hypothesize that precise and robust control over 
spatial patterns of tissue-specific transcription factor expression would be amenable to 
complex tissue formation.  In support of this hypothesis, we provide evidence that a 
continuous, biphasic bone-soft tissue interface can be engineered with a 3-D gradient of 
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genetic material encoding for the osteogenic transcription factor Runx2.   This result 
represents an important step toward the development of enabling technologies for precise 
and robust control over 3-D spatial cues.  The degree to which a tissue engineered 
substitute must resemble native tissue in order to induce functional integration and 
regeneration has not been defined, but is likely dependent on the anatomic location of the 
defect.  Ultimately, spatial control at the single-cell length scale (100 µm) may be 
required to engineer complex structures which recapitulate the precise architecture and 
biochemical properties of native tissue 359.   
A central issue toward the creation of heterogeneous tissues is the development of 
technologies for spatiotemporal control over signaling molecule(s) to control cell 
phenotype.   Attempts to create morphogen gradients in vitro have predominantly relied 
on the immobilization of growth factors within 3-D polymeric matrices or covalent/non-
covalent tethering of peptide sequences to patterned biomaterial surfaces 365-368, 377.  
These protein-based approaches are limited by suboptimal delivery vehicles, poor 
spatiotemporal dosage control, short protein half-life, and the cost-prohibitive 
supraphysiologic concentrations required to initiate a cellular response 370.  In addition, it 
is exceedingly difficult to engineer precise gradients of soluble bioactive factors in vivo 
due to the complex milieu 369.  Ultimately, it is unlikely that bolus delivery of a single 
protein gradient will supply sufficiently robust/precise spatiotemporal control to induce 
the formation of complex tissues which mimic native organ function.  In this study, we 
explore the feasibility of biomaterial-mediated gene transfer to spatially pattern the 
genetic modification and subsequent differentiation of cells seeded within these 
constructs.  In contrast to conventional gene therapy techniques, this approach promotes 
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gene delivery by co-localizing the cell adhesion substrate and gene delivery vehicle 378, 
379.  This approach is more cost-effective than protein-based therapies and may allow for 
finer control over individual cell fate by providing graded positional cues within a 3-D 
substrate 380.  Furthermore, the selection of genetic material encoding for a tissue-specific 
transcription factor instead of a secreted, soluble factor, may offer more precise control 
over single-cell differentiation without dramatic consequences to the surrounding cells.  
Indeed, delivery of genes encoding for soluble factors has been problematic because 
cellular secretion of these proteins is poorly controlled and paracrine signaling to 
neighboring cells may induce undesired cellular effects7, 8.   
Gene carriers have been tethered to or encapsulated within biomaterial supports 
with a wide range of immobilization schemes 381.  These technologies have successfully 
facilitated the localized delivery of nonviral and viral vectors to cells seeded on 2-D 
biomaterial surfaces 379, 382, 383.   Furthermore, transient transfection of host cells in vivo 
was reported from 3-D scaffolds containing naked DNA plasmid and adenovirus 380, 384, 
385.  More recently, the immobilization of adeno-associated virus to allogenic bone grafts 
has shown utility in bone healing 386.  Despite these advances, these technologies are 
limited in applications that require long-term transgene expression or spatial gradients of 
factor delivery.  We expand upon these concepts with this work to create spatial gradients 
of retrovirus within three-dimensional polymeric networks. We develop a novel 
biomaterial-mediated method for retroviral gene delivery to fibroblasts by exploiting the 
ability of cationic polymers (e.g. PLL) to charge neutralize and aggregate retroviral 
particles 374, 375. Importantly, retroviral particles immobilized within 3-D scaffolds retain 
the ability to transduce cells cultured on these matrices.  Using this technique, we show 
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that a homogeneous population of fibroblasts can be locally patterned into two different 
cell fates by seeding them on three-dimensional matrices containing defined spatial 
domains of immobilized retrovirus encoding for the osteogenic transcription factor 
Runx2.   
Retroviral transduction of mammalian cells is a highly complex process which 
remains poorly understood.  The general mechanism for viral attachment involves a three 
steps, including:  (1) virus diffusion to the cell surface, (2) non-specific binding to the 
cell membrane, and (3) specific binding of viral envelope protein gp70 to its cognate 
cellular receptor 374.  Slow diffusion and rapid decay of retroviral particles have been 
identified as the primary factors limiting the efficiency of retroviral gene transfer 387.    
Cationic polymers, such as polybrene and PLL, have been shown to enhance transduction 
efficiency by altering viral adsorption kinetics 374, 388.  These positively-charged polymers 
neutralize the negatively-charged retrovirus, thereby enhancing non-specific adsorption 
to target cell surface by reducing virus-cell electrostatic repulsion and enhancing viral 
aggregation 374.   In this study, we observed that biomaterial-mediated transduction is 
highly dependent on pre-coating these scaffolds with PLL prior to incubation in retroviral 
supernatant.  We hypothesize that our approach may promote non-specific adsorption to 
target cell surface by overcoming diffusion limitations from conventional ex vivo 
techniques in suspension, enhancing virus aggregation, reducing viral degradation rate, 
and reducing cell-virus electrostatic repulsion.   
Heterogeneous zones of ligament, fibrocartilage, mineralized fibrocartilage, and 
bone are found at the transitionary region between the anterior cruciate ligament and 
bone 348, 350, 389.  In the present work, we engineer a biphasic construct containing a 
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continuous interface of osteoblastic and fibroblastic tissue by using the bone-soft tissue 
interface as a model system.   It is unlikely that static culture of these constructs in vitro 
will lead to the development of tissue that fully recapitulates the structure of this 
interface.  However, we suggest that the interplay of these heterogeneous constructs with 
the mechanical forces and biochemical cues in an orthotopic in vivo environment may 
lead higher-order tissue organization 149, 352, 353.  More specifically, we hypothesize that 
the continuous interface between fibroblasts and mineralizing Runx2-expressing 
fibroblasts may lead to a cartilage intermediate.  This hypothesis was formulated based 
on the fact that mesenchymal progenitor cells go through a highly complex, intermediate 
cartilaginous phase prior to mineralized matrix deposition during long-bone development 
and fracture healing in a process termed endochondral ossification 30, 31.  Further support 
for this idea is gathered by studies that provide evidence for a cartilage intermediate 
phase using fibroblast/osteoblast co-cultures 371. 
In summary, we demonstrate that a biphasic construct containing a continuous 
interface of osteoblastic and fibroblastic tissue can be developed by a simple, one step 
seeding of autologous fibroblasts into polymeric scaffolds containing a graded 
distribution of the Runx2 retroviral vector.  The concept of controlling expression of 
tissue-specific transcription factors to create spatial gradients of differential cell function 
within 3-D matrices may be applicable to the development of interfacial zones for a large 
number of tissue engineering applications.  Overall, these results are significant toward 
the development of autologous grafting templates containing transitional interfacial zones 







Significant progress has been attained toward the development of retroviral, 
adenoviral, and adeno-associated viral vectors for musculoskeletal tissue repair and 
regeneration.  Recent studies in preclinical animal models suggest that virus-based 
genetic engineering strategies may provide enhanced in vivo bone formation compared to 
direct implantation of either osteogenic cells or recombinant protein therapy alone.  
Moreover, limitations associated with the administration of supraphysiologic 
recombinant protein doses may be circumvented by cells engineered to produce these 
factors in a continuous manner via natural cellular mechanisms.  These advantages 
suggest that the additional complexity associated with genetic engineering strategies may 
be warranted for bone repair applications.  However, before clinical application is 
realized, extensive preclinical studies, including experiments in larger animal models, 
will be necessary to address concerns that the therapeutic potential of targeted gene 
delivery will be counteracted by the safety risks associated with administration of viral 
vectors.  Characterization of the safety profile of these vectors is particularly important 
for non-lethal bone repair applications that are meant to improve quality of life for the 
patient.   
The optimal combination of gene transfer vector, regenerative molecule(s), and 
cell source for robust, yet highly controlled bone formation in immunocompetent patients 
has not been identified. Despite observed efficacy in animal models, the therapeutic 
dosage necessary to induce bone healing in humans without a significant humoral/cellular 
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immune response is still unknown.  Characterization of the protein release profile and the 
threshold of factor delivery necessary to achieve efficacy will be necessary for each 
individual approach based on a different regenerative molecule or combination of 
molecules.  Additional comparative studies will also be necessary to determine the 
relative potency as well as applicability of osteoblastic and nonosteoblastic cell-types in 
bone regeneration in order to select the appropriate cell source.  Moreover, studies 
characterizing cell fate after implantation and the cellular origin of bone formation will 
become increasingly important in the clinical application of these strategies to human 
bone defects.  A comparative analysis of the relative therapeutic merit of each genetic 
engineering strategy is challenging because independent investigators use a diverse range 
of vectors, cell-types, therapeutic transgenes, and in vivo animal models.  Furthermore, it 
is difficult to draw conclusions even from studies which do attempt this comparison 390 
because the mechanism of viral gene transfer is highly dependent on a number of 
variables which are difficult to control (e.g. transfection/transduction efficiency, vector 
exposure time during infection, virus titer, cell confluence, serum lot, cell proliferation 
rate, vector pseudotype, and/or infection procedure).  Overall, the pursuit of many of 
these options in parallel is important because it is unlikely that one single strategy will be 
universally appropriate for the treatment of the diverse orthopaedic conditions requiring 
grafting procedures.   
Significant progress has also been made in recent years toward the development 
of gene therapy-based strategies to improve the biochemical, mechanical, and 
histomorphological properties of healing ligament tissue.  Nevertheless, this particular 
field is still in its infancy, largely because an incomplete understanding of the molecular 
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pathways involved in ligament development/healing has significantly hindered the 
development of novel strategies for ligament repair.  The spatial and temporal cascade of 
factors that is necessary for the differentiation of stem cells into a ligament fibroblast-
specific cellular phenotype has not been identified.  In addition, no unique biochemical 
markers exist to distinguish ligament tissue from other fibroblastic tissue-types, making 
characterization difficult.  Thus, future advances in ligament cell biology will likely 
enable development of genetic engineering strategies based on novel therapeutic 
molecules alone or in combination.  Many more in vitro and in vivo studies will be 
necessary before a grafting template will be realized which recapitulates the precise 
architecture, biochemical composition, and mechanical properties of the native ligament 
tissue.   
Numerous gene therapy strategies have successfully enhanced mineral deposition 
or soft tissue repair in vivo, but the development of grafts which fully recapitulate the 
three-dimensional structure and functional characteristics of bone and/or ligament tissue 
has not been realized.  It is not currently well understood whether the optimal orthopaedic 
regenerative strategy must perfectly mimic the precise architecture and biochemical 
properties of native bone.  Indeed, it is likely that the degree of native tissue 
recapitulation will be dependent on the anatomic location of the defect, the level of 
damage to vasculature and progenitor cell populations within the host tissue bed 
surrounding the repair site, and general health/age of the patient.  Nevertheless, it is likely 
that the complex biomolecular organization of endogenous skeletal tissue cannot be 
achieved by the delivery of a single dose of recombinant protein to the repair site in a 
poorly-controlled manner.  Future studies should aim to clarify how close to native tissue 
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is “close enough” to ubiquitously induce healing in variety of bone defects with varying 
severity.  Current and emerging gene transfer technologies focusing on regulated 
expression systems (including inducible and tissue-specific systems) as well as 
combinatorial strategies may enable the design of therapies which more closely mimic 
the complex spatial and temporal cascade of proteins involved in bone formation.  These 
strategies in combination with appropriate cell sources and engineered biomaterial 
matrices represent promising avenues to the generation of structural and functional 
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